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ABSTRACT 
 
The 2A peptide is a short viral peptide of 18-23 amino acids, present in some 
picornaviruses. These RNA viruses encode a polyprotein that is late-processed to 
produce all viral proteins. 2A allows the primary cleavage between the capsidic and the 
replicative proteins. It works as an autonomous element during translation, capable of 
mediating self-processing at its C-terminus. It modifies the ribosome activity, 
promoting hydrolysis of the ester bond between the nascent peptide and the tRNA rather 
than the formation of the peptide linkage, resulting in a premature release of the 
upstream protein and continuation of translation from the in-frame downstream Pro 
codon. We call this property “non-conventional translation termination”, in contrast to 
the “conventional translation termination” occurring at a STOP codon site and mediated 
by the Release Factors 1 and 3. For its activity both the amino acids Asn-Pro-Gly at the 
C-terminus of the 2A peptide, and the Pro at the N-terminus of the downstream protein 
are essential. Due to its property of self-processing at the C-terminus, in mammalian 
cells it can be used to produce two proteins from a single open reading frame (ORF). 
In the first part of the work we tested two different 2A peptides (one derived from 
the Foot-and-Mouth Disease Virus (F2A) and one from the Porcine Teschovirus (T2A)) 
in order to see possible differences between their activity in term of non-conventional 
translation termination and re-initiation of translation from the 2A downstream Pro. We 
found that both these peptides were very efficient in terminating translation, in fact we 
observed only a very little amount of fusion protein. However, re-initiation from the 2A 
downstream Pro was not complete, in fact we observed that the downstream protein 
was produced in a lower amount than the upstream one. We also determined that F2A 
worked better than T2A, allowing synthesis of the downstream protein with higher 
efficiency. These results indicate that F2A peptide is a powerful system for the co-
expression of proteins in vivo. We exploited this technology for the production of 
recombinant antibodies. We found that both in vitro and in vivo antibody’s light and 
heavy chains were produced, and the complete antibody was properly folded. 
In the second part of the work we investigated a particular feature of the 2A 
peptide: when it was positioned immediately upstream of a STOP-codon, expression of 
the upstream protein was heavily impaired. We found that the compromised expression 
was due to the amino acidic and not to the nucleotidic sequence of the peptide. We 
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found also that it was a consequence of a strong ribosome stalling at the Gly-STOP-
codon boundary, totally dependent on the last thirteen 2A residues and on the presence 
of Asn-Pro-Gly as C-terminal amino acids. As a consequence of the stalling, a 
ribosome-mediated quality control is activated, inducing ubiquitination and proteasome 
degradation of the small amount of protein produced. This 2A regulatory activity on 
translation was effective on both membrane-bound and free ribosomes. We found that, 
for membrane-bound ribosomes, members of the retrotranslocation pathway such as the 
AAA-ATPase p97 and the deubiquitinase YOD1 were involved, thus suggesting a 
quality control mechanism that senses the presence of stalled ribosomes on the ER 
membrane cytosolic side and signals to effectors present in the luminal side to induce 
ERAD (Endoplasmic Reticulum Associated Degradation). 
 
It is widely known that one of the main players in ER Associated Degradation is 
the AAA-ATPase p97/VCP. It is generally thought that p97 ATPase activity is required 
for retro-translocation and proteasomal degradation, and that its loss causes retention of 
ERAD substrates in the ER lumen. As a consequence, p97 ATPase activity is 
considered essential for extraction of proteins from the ER membranes. 
To study the role of p97 in ERAD, we used a method recently developed in our 
laboratory (Petris et al., 2011), which is based in the specific in vivo mono-biotinylation 
by the cytosolic biotin ligase BirA of protein substrates tagged with the 15 amino acids-
long Biotin Acceptor Peptide BAP (GLNDIFEAQKIEWH). This method allows a 
precise discrimination between the proteins located in the Endoplasmic Reticulum (non 
biotinylated) or in the cytoplasm (biotinylated). 
We analysed the effect of: 1) a dominant negative form of p97 (p97QQ), 2) a p97 
specific siRNA, and 3) the p97 chemical inhibitor DBeQ, on the three different ERAD 
model substrates NS1, Null Hong Kong mutant of !1 anti-trypsin (NHK-!1AT), and 
Tetherin. Our results clearly challenge the predominant view of p97 as energy provider 
for the extraction of unfolded proteins from a putative retrotranslocon in an ATP-
dependent manner. We found that p97 activity is not involved in the retrotranslocation 
of these proteins from ER to cytosol, but rather in the segregation of proteins already in 
the cytosolic side and in the recruitment of PNGase. Similar results were obtained 
analysing the effect of a dominant negative form of the p97-associated deubiquitinase 
YOD1 (YOD1 C160S). 
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1. INTRODUCTION 
 
1.1 The eukaryotic ribosome 
 
1.1.1 Structure of the eukaryotic ribosome 
The ribosome is a large cellular ribonucleoprotein, responsible for the translation 
of the genetic material into polypeptide sequences. It selects the correct cognate 
aminoacyl-tRNA, based on the complementarity of its anti-codon with the mRNA 
codon, and extends the polypeptide chain by one amino acid until it encounters a stop 
codon. In growing cells, most ribosomes are active in translation and they synthesize 
new polypeptides incorporating 5-9 amino acids per second (Kramer et al., 2009). 
The eukaryotic ribosome is composed of a small subunit and a large subunit, 
called 40S and 60S respectively (“S” stands for the rate of sedimentation in 
centrifugation in Svedbergs. One S is a measure of time, and is defined as exactly 10"13 
seconds), with a total molecular mass of about 4 MDa. 40S has the decoding function, 
whereas 60S the catalytic function. 
The 40S subunit is composed by 18S RNA (1870 nucleotides long) and 33 
proteins; it is generally divided into several regions: head, neck, body, platform, beak, 
shoulder and foots. It contains three functional sites: the mRNA path, that conducts 
mRNA during translation; the decoding center, where the codon-anticodon interaction 
takes place and the translation fidelity is ensured; the three tRNA-binding sites, called 
amino-acyl (A) site, peptidyl (P) site, and exit (E) site. The A site is where the 
aminoacyl-tRNA binds as it enters the ribosome, the P site binds the tRNA carrying the 
nascent peptide (peptidyl-tRNA), and the E site is the place where tRNA dissociates 
from the ribosome (Figure 1.1) (Melnikov et al., 2012; Rabl et al., 2011; Steitz, 2008). 
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Figure 1.1 Structure of eukaryotic small ribosomal subunit 40S. (A) Views of the solvent-exposed 
and 60S binding site showing the 18S rRNA as spheres and colored according to each domain, and 
the proteins as grey cartoons (abbreviations: H, head; Be, beak; N, neck; P, platform; Sh, shoulder; 
Bo, body; RF, right foot; LF, left foot). (B) Views of the solvent-exposed and 60S binding site 
showing the ribosomal proteins as cartoons in individual colours; rRNA is shown as grey surface 
(Rabl et al., 2011). 
 
The 60S subunit is composed by 5S RNA, 5.8S RNA, 28S RNA (121, 156, and 
5034 bases respectively) and 47 proteins; its main regions are the central protuberance, 
the L1 stalk and the P stalk. It contains two main structures: the Peptidyl Transferase 
Center (PTC) and the Ribosomal Exit Tunnel (RET). PTC is the active site where two 
fundamental events take place: a) the formation of the peptide bond between the nascent 
peptide and the next adjacent amino acid catalysed by the peptidyl transferase, and b) 
the hydrolysis of the ester bond in peptidyl-tRNA and the release of the complete 
!"
!"
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polypeptide chain. RET is a structure from which the newly synthesised peptide exits 
from the ribosome on the solvent side (Figure 1.2) (Klinge et al., 2011; Kramer et al., 
2009; Melnikov et al., 2012). 
During translation the two subunits interact to form a unique complex, the 80S 
ribosome. Interactions are established at the interface between the subunits, with several 
contact point called bridges. In eukaryotic ribosome there are 10 bridges, formed by 
proteins of the large subunit that bind the small subunit with a large part of their 
structure (Melnikov et al., 2012; Zaher and Green, 2009). 
 
Figure 1.2. Structure of the large ribosomal subunit 60S. (A) Views of the solvent-exposed and 40S 
binding side with color-coded RNA expansion segments. (B) Views of the solvent-exposed and 40S 
binding side with color-coded ribosomal proteins shown as ribbons (Klinge et al., 2011). 
 
!"
#"
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1.1.2 The ribosomal exit tunnel 
The Ribosomal Exit Tunnel is a structure starting at the PTC and spanning the 
body of the large ribosomal subunit; it has a length of 80-100 Å with an average 
diameter of 15 Å (10 Å at its narrowest and 20 Å at its widest point). Its shape 
resembles a tube, capable of accommodating peptides of 30 amino acids in an extended 
conformation, or up to 60 amino acids in a !-helical conformation. The tunnel’s inner 
surface is negatively charged and constituted mainly of 28S rRNA, whit some 
protruding loops constituted by the ribosomal proteins L4, L22 and L23. In particular, at 
a distance of 30 Å from the PTC there is a marked constriction of the tunnel due to a #-
hairpin loop of L22 in close proximity to a loop of L4. At its end, the ribosomal exit 
tunnel enlarges and it is composed of RNA, a ring of four conserved ribosomal proteins 
(L25, L26, L35 and L39e) and some other proteins specific for the different kingdoms 
(L19e and L31e in eukaryotes) (Figure 1.3) (Ban et al., 2000; Kramer et al., 2009; 
Nissen et al., 2000; Ramu et al., 2011; Wilson and Beckmann, 2011; Yap and Bernstein, 
2009). 
Figure 1.3. Structure of the eukaryotic ribosomal exit tunnel. Transverse sections through the 
eukaryotic large ribosomal subunit to reveal the tunnel components. Peptidyl-tRNA (orange), RNA 
(grey) and ribosomal proteins (blue), except ribosomal proteins L4 (red), L17 (blue), L25 (yellow), 
L35 (purple), L26 (green) and L39e (cyan) (Wilson and Beckmann, 2011). 
Introduction 
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Until recently, it was a general thought that the ribosome did not take notice of the 
polypeptide it was making. Evidences show that the peptidyl transfer reaction, as well 
as the termination of translation, is affected by the nature of the side-chains of the 
amino acids located in the ribosome exit tunnel. This implies that the ribosome is not a 
neutral and passive conduit in respect to peptide sequences, but it can recognize cis-
acting signals in the nascent peptide and use them to control translation. Often the 
signals serve as regulator of the expression of downstream genes, and require a 
threshold concentration of a small molecule such as an amino acid or an antibiotic to be 
active (Yap and Bernstein, 2009). There are several examples, both in prokaryotes and 
eukaryotes, of special effector sequences that affect translation elongation or 
termination (described in paragraphs 1.2.2 and 1.2.3, respectively) when located in 
ribosomal exit tunnel (Tenson and Ehrenberg, 2002). It has been proposed that the exit 
tunnel, and in particular its constricted part, acts as a discriminating exit gate by 
interacting with nascent chains, and that this interaction can pause or attenuate the rate 
of translation. Some mutations in both rRNA and ribosomal protein capable of reducing 
or abolishing this property have been identified, suggesting that the interactions 
triggering this mechanism are specific (Nakatogawa and Ito, 2002). The result of these 
specific interactions is a structural rearrangement of the ribosome, and the formation of 
a Stalled Ribosome Complex (SRC) (Ramu et al., 2011). One of the well studied 
examples of translational control mediated by amino acidic sequences are the upstream 
Open Reading Frames (uORFs), very short ORFs within the 5'-untranslated region of an 
mRNA that interfere with the expression of a downstream primary ORF. A scanning 
ribosome that recognizes and translates an uORF can do different things: it can remain 
associated with the mRNA and reinitiates the translation at the next start codon; it can 
stall during the elongation or the termination, blocking the scanning of the other 
ribosomes; it can alter mRNA stability by triggering nonsense-mediated mRNA decay. 
There are several examples of regulation through uORF in eukaryotic cells: 
surprisingly, if compared, this sequences show a very little similarity between them 
(Morris and Geballe, 2000). 
S-Adenosylmethionine decarboxylase (AdoMetDC) is an enzyme involved in the 
polyamine biosynthesis. Polyamines cellular levels regulate the expression of 
AdoMetDC through its mRNA, which contains a short uORF encoding for the amino 
Introduction 
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acids MAGDIS and located 14 nucleotides from the 5’ cap. In response to low levels of 
polyamine, AdoMetDC mRNA becomes highly loaded with ribosomes, causing an 
increase in protein levels. Presence of polyamines, instead, increase the interaction 
between uORF-encoded peptide and the downstream mRNA, leading to arrest of the 
ribosome at the termination site (Ruan et al., 1996). 
arg-2 in the fungus Neurospora crassa encodes the small subunit of the arginine-
specific carbamoyl phosphate synthetase, an enzyme involved in fungal arginine 
biosynthesis; its expression is negatively regulated by arginine levels in the culture 
medium. Responsible for this regulation is a uORF located in the leader of the mRNA, 
encoding for the so called Arginine Attenuator Peptide (AAP), 24 amino acids long 
(MNGRPSVFTSQDYLSDHLWRALNA). A similar uORF encoding for an AAP is found 
also in S. cerevisiae, A. nidulans and C. neoformans. In presence of high concentration 
of arginine, the rate of synthesis of ARG-2 is reduced because of the arrest of the 
translating ribosomes on AAP; ribosome stalling prevents the ribosome to reach the 
downstream start codon of the enzyme coding sequence, reducing gene expression 
(Ruan et al., 1996; Wang and Sachs, 1997). Moreover, it triggers the degradation of 
uORF containing mRNA by the nonsense-mediated mRNA decay pathway. It has been 
demonstrated that some of the residues of the AAP are critical for its function: the 
residues 9-20 are the minimal domain sufficient to confer regulatory function; Aspartic 
acid in position 12, Tyrosine-13, Leucine-14 and Triptofane-19 can not be changed to 
Alanine or Proline without loosing AAP function; in these position also a conservative 
substitution reduced the function (Spevak et al., 2010). 
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1.2. Eukaryotic translation 
Translation is the final step of the gene-expression pathway and consists in the 
“conversion” of the message in the mRNA into a protein. This process can be divided 
into four different steps: translation initiation, elongation, termination, and ribosome 
recycling. 
 
1.2.1 Translation initiation 
Translation initiation in eukaryotes is a very complex event, in which more than 
25 polypeptides participate. Initiation starts with the assembly of the 43S pre-initiation 
complex: it contains the eIF2!GTP!Met-tRNAi (eIF: eukaryotic Initiation Factor) 
ternary complex, that after its formation binds to another complex formed by the small 
ribosomal subunit (40S) and the eIFs 3, 1, 1A and 5. eIF4F complex (constituted by 
eIF4A, eIF4E and eIF4G) binds the mRNA 5’-cap and unwinds structures of the 5’-
UTR; then, together with eIF3 and the poly(A) binding protein, it loads the mRNA onto 
the 43S complex. The 43S complex begins to scan the mRNA until it finds the initiation 
codon AUG and the codon-anticodon base pairing between the AUG and the initiation 
tRNA takes place. This event triggers eIF2-bound GTP hydrolysis and the dissociation 
between eIF2!GDP and Met-tRNAi,: this reaction stimulates the exit of most of the 
initiation factor from the 40S subunit; only Met-tRNAi base-paired with AUG remains 
into the P site of the 40S. The final step of the initiation is performed by eIF5B!GTP, 
which facilitate the joining of the large ribosomal subunit (60S) to the 40S!Met-
tRNAi!mRNA complex. After GTP hydrolysis, also eIF5B!GDP dissociates from the 
complex and the ribosome is competent for polypeptide synthesis (Figure 1.4) (Gebauer 
and Hentze, 2004; Jackson et al., 2010; Kapp and Lorsch, 2004). 
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Figure 1.4. Mechanism of eukaryotic translation initiation (Gebauer and Hentze, 2004; Jackson et 
al., 2010). 
 
1.2.2 Translation elongation 
Translation elongation begins with a peptidyl-tRNA in the P site of the ribosome 
next to a free A site. An amynoacil-tRNA!GTP!eEF1A complex (eEF: eukaryotic 
Elongation Factor) is carried to the A site; here a series of events ensures that only the 
pairing with correct cognate tRNA allows the continuation of elongation. Codon-
anticodon base pairing causes the movement of three bases in the small ribosomal 
subunit’s rRNA and the interaction between them and the mRNA-tRNA duplex. This 
interaction causes the hydrolysis of GTP and then eEF1A!GDP releases the aminoacyl-
tRNA into the A site. The ribosomal peptidyl transferase center catalyses the formation 
of a peptide linkage between the peptidyl-tRNA in the P site and the next amino acid in 
Introduction 
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the A site: the nascent peptide is transferred from the tRNA present in the P site to that 
present in the A site. The result is a deacylated-tRNA that has to be translocated from 
the P to the E site, and the new peptidyl-tRNA from the A to the P site; this task is 
performed by eEF2. This cycle is repeated until a stop codon enters the P site (Figure 
1.5) (Gebauer and Hentze, 2004; Kapp and Lorsch, 2004). 
Figure 1.5. Mechanism of eukaryotic translation elongation (Schneider-Poetsch et al., 2010). 
 
1.2.3 Translation termination 
Translation termination is the final step of protein synthesis and occurs when one 
of the three stop codons (UAA, UGA or UAG) enters the ribosomal A site. Termination 
is mediated by two classes of Release Factors (RFs): class I RFs recognize and bind to 
the termination codons in the small ribosomal subunit A site, and trigger the hydrolysis 
of the ester bond between the nascent peptide and the tRNA in the P site, a process that 
takes place in the PTC of the large ribosomal subunit. Class II RFs enhance the activity 
of class I RF by their GTPase activity, and confer GTP dependency to the termination 
process. In eukaryotes there is only one protein per class: eRF1 (class I), that recognizes 
all three stop codons, and eRF3 (class II) (Figure 1.6) (Alkalaeva et al., 2006; Baierlein 
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and Krebber, 2010; Jacobson, 2005; Kisselev et al., 2003; Korostelev, 2011; Nakamura 
and Ito, 2003). 
 
Figure 1.6. Mechanism of translation termination in eukaryotes (Alkalaeva et al., 2006). 
 
eRF1 consists of three domains, each one deputy to one of the three different 
functions of the protein: domain N contains the conserved NIKS and YxCxxxF domains 
that are involved in STOP-codon recognition at the decoding center of the small 
subunit; how the recognition takes place is still largely unknown, it seems that eRF1 
recognizes the STOP codon through a complex three-dimensional network formed by 
conserved residues. Domain M contains the universally conserved domain GGQ that 
triggers peptidyl-tRNA hydrolysis and it is also involved in the stimulation of eRF3 
GTPase activity. Domain C mediates the interaction with eRF3 (Alkalaeva et al., 2006; 
Cheng et al., 2009; Song et al., 2000). As mentioned before, the main domain of eRF3 
is the GTPase, whose function is to couple eRF1-mediated codon recognition and 
peptidyl-tRNA hydrolysis, and efficient peptide release. 
eRF1 interacts with eRF3 in a highly specific manner through their C-terminal 
domain. In presence of GTP eRF1 M domain provides an additional affinity between 
the proteins (Figure 1.7) (Kononenko et al., 2008). An important feature of eukaryotic 
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RFs is that they form a relatively stable long-lived complex and show a mutual 
interdependence. Despite the complex connections between eRF1 and eRF3 are not 
completely clarified, it has been suggested that: eRF1 promotes GTP but not GDP 
binding to eRF3; eRF1 induces eRF3’s GTPase activity on the ribosome; eRF3 
stimulates peptide release by eRF1 (Cheng et al., 2009). 
 
 
 
 
 
 
 
Figure 1.7. Model of the 
eRF1/eRF3/GTP complex (Loh 
and Song, 2010). 
 
 
1.2.4 Ribosome Recycling 
The last stage of translation does not involve the production of a protein; it 
consists in the recycling of the ribosomal subunits in order to use them in another round 
of translation. During prokaryotic translation termination, ribosome recycling is carried 
on by Elongation Factor-G, Initiation Factor-3 and mainly by Ribosome Recycling 
Factor (RRF); eukaryotes do not encode an RRF homolog and the mechanism of 
recycling is very different, as well as the termination stage. 
Eukaryotic ribosome recycling is promoted by the combination of eIFs 3, 1, 1A 
and 3j. eIF3 plays the main role, because it is the only factor that can dissociate post-
termination ribosomes on its own and start in this way the recycling process; its 
function is enhanced by the three other participating factors. After the dissociation 60S 
leaves the complex while eIF3 remains attached to the 40S subunit, together with 
mRNA and tRNA, preventing its re-association. eIF1 promotes the dissociation of the 
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deacylated tRNA from the P site, and eIF3j the release of mRNA. Probably the complex 
40S!eIF3!eIF1!eIF1A does not dissociate but it is the starting point for the assembly of 
the pre-initiation complex 43S (Figure 1.8) (Kapp and Lorsch, 2004; Pisarev et al., 
2007) 
Figure 1.8. Mechanism of eukaryotic ribosome recycling (Pisarev et al., 2007). 
 
1.2.5 Co-translational quality control 
Maintenance of proteome homeostasis is crucial for all cellular processes but it is 
also challenging, because proteins are continuously made by the 106-107 ribosomes 
present in eukaryotic cells. De novo protein folding is delicate and error-prone, and the 
cellular strategy to safeguard this process involves a set of molecular chaperones. 
Chaperones involved in de novo folding assistance can be dived into two groups: the 
first comprises chaperones binding both the ribosome and the nascent peptide 
controlling the earlier folding steps, collectively called CLIPS (Chaperones Linked to 
Protein Synthesis), the second comprises cytosolic chaperones not bound to the 
ribosome of the Hsp70/40 and Hsp60/10 families (Figure 1.9). 
The main members of CLIPS are the nascent polypeptide-associated complex 
(NAC) and the Ribosome-associated complex (RAC), (Pechmann et al., 2013; Preissler 
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and Deuerling, 2012). NAC is a widely conserved heterodimeric protein that associates 
with ribosomes in 1:1 stoichiometry. It is composed by an !-NAC (NACA) and a #-
NAC (BTF3b) subunit, and it has been characterized as the first cytosolic factor that 
binds nascent polypeptides emerging from the ribosome, preventing incorrect 
interactions with other factors (Wiedmann et al., 1994). Dimerization occurs through 
their homologous six-stranded #-barrel-like NAC domains, one in each subunit; in 
addition NACA contains also a C-terminal ubiquitin-associated domain, suggesting 
different functions for the two subunits (Liu et al., 2010; Spreter et al., 2005). Among 
the subunits BTF3b directly binds both the nascent polypeptide and the ribosome near 
the exit site of RET through its N-terminal ribosome-binding domain, whereas NACA 
binds weakly the nascent peptide and does not bind the ribosome. Ribosome binding 
seems to be a prerequisite for NAC interaction with the nascent polypeptide (Beatrix et 
al., 2000). It has recently been discovered that NAC interacts with the Signal 
Recognition Particle (SRP, described in paragraph 1.3.2): in particular it seems that the 
presence of SRP is sensed from within RET to pre-emptively recruit SRP to the 
ribosome in a manner modulated by NAC, that thus controls the fidelity of protein 
translocation to the ER by increasing SRP specificity (Zhang et al., 2012). RAC is a 
heterodimeric complex composed by a chaperone belonging to the Hsp40 and one to the 
Hsp70 family, in mammals Mpp11 and Hsp70L1 respectively. Mpp11 binds to the 
ribosome through its J-domain, while the function of Hsp70L1 is still poorly 
understood. Mammalian RAC cooperates with the cytosolic Hsp70, stimulating its ATP 
hydrolysis (Jaiswal et al., 2011; Otto et al., 2005) 
 
 
 
 
 
 
 
 
. 
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Figure 1.9. Chaperone networks involved in de novo protein folding. The ribosome-associated 
chaperones comprise the nascent polypeptide-associated complex (NAC) and RAC; in addition, RAC 
recruits cytosolic Hsp70 to nascent polypeptides. Hsp70-Hsp40 and TRiC/CCT chaperones act 
downstream of ribosome-associated chaperones on a subset of newly synthesized proteins that 
require further folding assistance (Preissler and Deuerling, 2012). 
 
Another type of co-translational quality control occurs at the mRNA level, 
preventing the translation of truncated or nonfunctional transcripts, which may generate 
proteins with deleterious effects; translational stalling is the signal that causes the 
triggering of these quality control pathways. These pathways are classically divided in 
nonsense-mediated decay (NMD), targeting mRNAs containing a premature STOP 
codon, nonstop decay (NSD), targeting mRNAs lacking a STOP codon, and no-go 
decay (NGD), targeting mRNAs containing various potential stalling sequences (Lykke-
Andersen and Bennett, 2014; Shoemaker and Green, 2012). 
NMD has been the first pathway to be identified and the most studied. The core 
NMD machinery is composed by three highly conserved trans-acting factors, called UP-
Frameshift proteins (UPF); UPF1 is a helicase essential to NMD, recruited to mRNA 
upon recognition of a STOP codon. In addition NMD requires also factor regulating 
UPF1 phosphorylation status, represented by the proteins of the SMG family (Chang et 
characterized. This chaperone is only found in bacteria and
chloroplasts. It consists of three domains: an N domain, a
peptidyl-prolyl cis–trans isomerase (PPIase) domain and a
C domain. TF adopts an extended three-dimensional con-
formation with the C domain positioned in the center of the
molecule (Figure 2a,b) [16,17]. The N domain uses a con-
served signature motif to mediate binding to the ribosome
via ribosomal protein (r-protein) L23 at the rim of the
ribosomal tunnel exit (Figure 2b,d). The TF N domain,
together with the C domain, forms an open cavity with two
protruding arms [16–18]. The PPIase domain is located at
the distal end of TF. It has been suggested that this domain
prolongs the residence time of TF on nascent chains and
thereby may contribute to delay cotranslational folding
(discussed later). However, the PPIase activity of TF is
not essential in vivo and TF variants lacking the isomerase
function show a chaperone activity that is comparable to
wild type TF [15,19,20].
TF exists in a monomer–dimer equilibrium. In its mo-
nomeric state, TF associates transiently with ribosomes
and hunches over the ribosomal tunnel, facing its central
cavity towards the tunnel exit. Therefore, TF is ideally
positioned to capture emerging chains (Figure 2d). TF has
multiple binding sites for substrates throughout its inter-
ior, which is lined by several hydrophobic side chains that
can provide multiple hydrophobic contact sites for an
unfolded polypeptide chain (Figure 2c) [16,21,22]. Indeed,
the residence time of TF on translating ribosomes (between
10 and 50 s) correlates with the hydrophobicity of the
nascent polypeptide [23]. In addition to the hydrophobic
contacts, the cavity also exposes hydrophilic side chains;
thes  might be involved in electrostatic cont cts to sub-
strates. Accordingly, it has been shown that TF binds to the
folded and positively charged r-protein S7 [24,25]. Thus,
the substrate interface of TF is versatile, using different
types of interactio s, which could explain its bro d sub-
strate spectrum (discussed later).
TF accommodates the substrate in its interior, which
provides a protective environment to prevent proteins from
aggregating or being degraded (Figure 2d) [26,27]. In
addition, ribosome-bound TF can prevent premature and
incorrect folding of proteins during synthesis. For example,
it retards cotranslational folding of recombinantly
expressed firefly luciferase in E. coli cells, thereby enhanc-
ing the total yield of active luciferase [23,28]. By contrast, it
is unclear whether TF can also promote cotranslational
folding processes. The local accumulation of folding-
competent polypeptide segments within the TF cavity
may favor the formation of key contacts in the nascent
chain and thus drive initial folding steps. On the basis of its
crystal structure, TF can accommodate entire protein
domains or even small proteins (with a size up to 130
aa) in its central cavity [16]. Indeed, it has been shown
that purified TF stimulates the refolding of denatured
glyceraldehyde 3-phosphate dehydrogenase to its native
state in the absence of ribosomes [29]. However, whether
this also holds true for the folding of nascent polypeptide
chains awaits experimental proof.
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Figure 1. Chaperone networks involved in de novo protein folding. The concept of chaperone systems that assist de novo protein folding is conserved across all kingdoms
of life. In (a) Escherichia coli, (b) Saccharomyces cerevisiae and (c) mammals, chaperones bind directly to ribosomes (grey) to act on nascent polypeptides (orange). These
ribosome-associated chaperones comprise trigger factor in bacteria and the eukaryotic a–b heterodimer nascent polypeptid -ass ciat d complex (NAC). In addition, the
heat shock protein (Hsp)70/40-based systems Zuo/Ssz/Ssb and MPP11/Hsp70L1 localize to ribosomes in yeast and mammals, respectively. The ribosome-associated
complex (RAC) consists of Ssz and zuotin (Zuo) in yeast [48]. MPP11 and Hsp70L1 form mammalian RAC (mRAC). Ssb homologs are restricted to fungi, whereas
mammalian RAC recruits cytosolic Hsp70 to nascent polypeptides [10]. Members of the Hsp70/40 and Hsp60/10 ch perone famili s act downstr am of ribosome-associated
chaperones on a subset of newly synthesized proteins that require further folding assistance. These include the DnaK/DnaJ and GroEL/GroES chaperone systems in
bacteria, and Ssa-Ydj1/Sis1 and the chaperonin TRiC/CCT in yeast [4,11,13,30,64]. Hsp70–Hsp40 chaperones and TRiC/CCT also interact with newly synthesized proteins in
mammalian cells. Specialized chaperones, such as prefoldin, participate in de novo folding of certain substrates [65,66].
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al., 2007). It is not yet completely clear which are the STOP codon features that allow 
UPF/SMG to distinguish between a premature STOP codon from a normal one. A first 
indication is that a premature STOP codon is far from the 3’ UTR, and in particular the 
absence of the poly(A)-binding protein could not allow an efficient termination (Amrani 
et al., 2004). Second, if the premature STOP codon arises before an exon junction, the 
ribosome could not remove it from the mRNA, and its presence could results in a signal 
for NMD (Chang et al., 2007). NDM has different outcomes: aberrant mRNA is 
degraded by endonuclease, the recruitment of ribosomes to this mRNA is actively 
repressed, and the native polypeptide produced is subjected to proteolysis (Figure 1.10). 
 
Figure 1.10. Nonsense-mediated mRNA decay (NMD) models. In presence of a premature STOP 
codon, lack of proximity with the 3’UTR is proposed to disrupt interaction between eRF3 and PABP. 
In the EJC model this results from encountering a stop codon upstream of an EJC (Shoemaker and 
Green, 2012). 
 
NSD occurs when a translating ribosome reaches the mRNA 3’ end without 
encountering a termination codon. In yeast the most important factors involved in NSD 
are Ski7, that acts first “tagging” mRNA for being degraded by the exosome (van Hoof 
et al., 2002), and the complex Hbs1-Dom34, that promotes the disassembly of the 
ribosomes and the degradation of the nascent peptide (Pisareva et al., 2011; Tsuboi et 
al., 2012). NGD is triggered by different kinds of defects such as RNA structural 
elements, rare codons, and mRNA depurination by viral enzymes. Also in this pathway 
the complex Hbs1-Dom34 play an essential role, in this case by stimulating an initial 
endonucleolytic cleavage on the substrate mRNA near the ribosome stalling site, and a 
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As a technical note, although the term ‘stalling’ is broadly used 
in the literature, kinetically distinguishing between transient pauses 
and stable stalls is difficult with currently available techniques 
(for example, toeprinting and ribosomal profiling). So, for example, 
although these techniques identify high ribosome density at certain 
proline-rich sequence motifs16,17, the duration of such a pause in 
the cell remains to be determined. To maintain consistency with the 
literature, translational pauses that are sufficient to induce NGD 
will be referred to as stalls throughout this article. Implicit in this 
characterization, however, is the understanding that in most cases, 
the kinetic features of these stalling determinants remain to be 
thoroughly evaluated.
NSD was similarly discovered as a mechanism to resolve ribosome 
complexes stalled on defective mRNA. As the name implies, nonstop 
decay is broadly interpreted as a process for eliminating mRNAs that 
lack a stop codon18,19. mRNAs not carrying an in-frame stop signal 
can be of two types: the first class includes truncated mRNAs (Fig. 2a, 
bottom), in which the ribosome simply runs to the end of the tem-
plate; the second class includes mRNAs lacking a stop codon but with 
a poly(A) tail (Fig. 2c). In the latter case, it was initially assumed that 
ribosomes would translate through the poly(A) tail, reach the 3` end of 
the mRNA and stall at the end of the template. If this were true, NGD 
and NSD substrates would differ according to whether the inducing 
stall occurs mid-message (NGD) or at the end of the mRNA (NSD).
Recently, however, these distinctions between NGD and NSD have 
become blurred. It is now thought that translation of poly(A) sequences 
into polylysine can cause ribosome stalling through interactions 
between the positively charged peptide and the overwhelmingly nega-
tively charged exit channel of the ribosome20,21. The potency of these 
stalls increases with length but can be observed after incorporating as 
few as six lysine residues (corresponding to the translation of as few 
as 18 adenosine nucleotides)20. As the typical length of a poly(A) tail 
is ~70 nucleotides in yeast and ~200 in human cells22, a ribosome that 
translates into the poly(A) region is likely to stall long before reach-
ing the 3` end of the mRNA. Therefore, poly(A) read-through, which 
was previously referred to as an end-of-message stall, or NSD, may 
also involve peptide-mediated internal stalling, reminiscent of NGD. 
Regardless of how they are classified, what ultimately appears to unify 
all NGD and NSD substrates is the formati , following endonucleo-
lytic cleavage, f a secondary stall formed by the upstream tr nslating 
ribosome reaching the cleavage site (Fig. 2d). This secondary stall is a 
clear target for additional rounds of NGD and NSD.
Independent of the cause, all stalls require similar resolution of the 
ribosome complex. In the end, ‘unnatural’ stalls and stochastic trans-
lational pausing must be distinguished from one another. Although 
the mechanism of this discriminati n is unknow , it s ems prob-
able that the kinetics of these events play a critical role such that the 
surveillance machinery efficiently recognizes only sufficiently long-
 lasting stalls. Such models have been well supported in other systems; 
for ex mple, in protein quality control, specifically during pr t in 
folding, cells rely on the length of time a misfolded species exists to 
distinguish between transient folding intermediates and terminally 
misfolded protein p oducts23.
Ribosome recognition by key mRNA surveillance factors
If a stalled ribosome complex is a substrate for surveillance, what 
are the specialized cellular factors that recognize these ribosome 
complexes and target them for resolution?
NMD. Some of the key factors involved in NMD—the UPF 
(for ‘upstream frameshifting’) genes Upf1, Upf2 and Upf3—were iden-
tified in early genetic screens in yeast24–27. Each of the three factors 
is highly conserved in eukaryotes and implicated in NMD in a broad 
range of organisms28. Upf1 is an enzyme containing both ATPase and 
helicase activities29; inhibition of either of these activities impedes 
NMD30. Upf1 interacts with both eRF1 and eRF3 and is probably 
present during initial recognition of a premature stop codon31,32  
(Fig. 1b). Upf1 also interacts directly with Upf2 and Upf3 (ref. 33). 
Upf2 and Upf3 modulate Upf1 activity and are thought to function as 
protein scaffolds34–36; any direct catalytic function for Upf2 and Upf3 
is unknown. Further studies in higher eukaryotes have implicated 
numerous other critical and conserved factors involved in NMD37. 
Several of these factors will be discussed in this Perspective, in partic-
ular those that directly engage the translational machinery. However, 
for a more extensive review of the role of these other factors in NMD, 
we direct the reader to ref. 28.
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Figure 1 Recognition of NMD surveillance 
targets. (a) Canonical termination. Capped and 
polyadenylated mRNAs are translated through 
the ORF until recognition of a stop codon by 
the eukaryotic release factors, eRF1 and eRF3. 
Close proximity of authentic stop codons with the 
poly(A) tail is proposed to facilitate interactions 
between eRF3 and PABP that positively 
contribute to peptide release. (b) Nonsense-
mediated decay. In the case of a PTC, lack of 
proximity is proposed to disrupt interaction 
between eRF3 and PABP. Canonical termination is 
further modified by the presence of NMD factors. 
In the EJC model of higher eukaryotes, this results 
from encountering a stop codon upstream of an 
EJC. In this model, communication between the 
termination factors and the EJC is effectively 
bridged by Upf1 in coordination with Upf2 and 
Upf3. In the 3` UTR model, a PTC effectively 
extends the de facto 3` UTR of the mRNA. This 
provides a larger binding platform for Upf1, which 
drives the termination event toward NMD rather 
than classical termination. Gray rectangle, ORF; 
thick black line, 5` and 3` UTRs.
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subsequent mRNA degradation by the exosome. Hbs1-Dom34 are also involved is 
ribosome recycling. Hbs1 and Dom34 are structurally related to the canonical 
termination factor eRF1 and eRF3, interact directly with the A site of the ribosome, but 
instead of promoting translation termination, they promote subunit dissociation and 
recycling, and peptydil-tRNA drop-off (Figure 1.11) (Shoemaker et al., 2010). 
Figure 1.11. Non-stop decay and No-go decay mechanisms (Graille and Seraphin, 2012). 
 
To be degraded, the nascent peptide must be ubiquitinated; until now, two are the E3 
ligases associated to these pathways: Not4 component of the Ccr4-Not deadenylase, 
associated both with NGD and NSD (Dimitrova et al., 2009), and Ltn1, mainly 
associated to NSD (Bengtson and Joazeiro, 2010). Ltn1, interestingly, has been found as 
part of a complex, called Ribosome-bound Quality Control complex (RQC), responsible 
for the disposal of stalled nascent peptide via the ubiquitin-proteasome system. RQC 
comprises also Rqc1 (Ribosome Quality Control 1), Tae2 (Translation-Associated 
Element 2) and Cdc48/p97 (described in paragraph 1.3.7.1) (Brandman et al., 2012; 
Defenouillere et al., 2013) 
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1.3 Endoplasmic Reticulum (ER) 
 
1.3.1 General aspects 
The endoplasmic reticulum (ER) is the largest organelle in the eukaryotic cell, 
spreading in cytoplasm from the nuclear membrane to the Golgi apparatus. The 
environment in the ER lumen is very different from other cell compartment; in fact it is 
characterized by a high Ca2+ concentration and a more positive redox potential. 
It is usually divided in subdomains: the nuclear envelope (NE), the rough ER 
(rER), the smooth ER (sER), and the ER-Golgi intermediate compartment (ERGIC). 
rER is characterized by a sheet-like morphology and by the presence of membrane-
associated ribosomes responsible for the synthesis of secretory and membrane proteins. 
sER is formed by tubular structure devoid of ribosomes, and it is the site of lipid and 
steroid synthesis, carbohydrate metabolism, regulation of calcium levels and drug 
detoxification. Each subdomain is in communication with the others, forming an 
interconnected network of tubules, cisternae and vesicles delineated by membranes, in 
which approximately one third of the proteins encoded by the genome are synthesised, 
processed and transported (Chen et al., 2013; Lavoie and Paiement, 2008). 
 
1.3.2 Protein synthesis and translocation 
Synthesis of all proteins begins on ribosomes free in the cytosol, but translation of 
secretory and type I membrane proteins must continue on ribosomes bound to the ER, 
where the proteins must enter to acquire their final conformation and to be transported 
to their destination. The signal recognition particle (SRP) and its receptor (SR) are the 
universally conserved molecular machinery able of performing this function. 
SRP is a ribonucleoprotein complex composed of a 7SL RNA of about 300 
nucleotides in complex with six protein subunits, among which SRP54 is the most 
important for its function. SRP54, in fact, participates in the interaction with the 
ribosome, in the recognition of the signal sequence, and in the GTP-dependent 
interaction between SRP and SR. All these processes are essential for a proper transfer 
of the ribosome-nascent chain complex (RNC) to the translocon (Nyathi et al., 2013). 
Transfer mechanism is tightly coordinated: SRP recognizes and binds the signal peptide 
(SP, a short hydrophobic sequence of about 20 amino acids) as the nascent polypeptide 
emerges from the ribosome. SRP binds to ribosomes with low affinity independently 
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from the presence of a SP, but binding with SP dramatically increases affinity for 
ribosome. GDP associated with SRP is replaced by GTP, and the RNC is delivered to 
the ER membrane. Here SRP interacts with SR, causing conformational rearrangements 
that reduce the affinity of SRP for RNC, facilitating the transfer of RNC to the 
translocon. After this, SRP and SR dissociate and are recycled, while the protein starts 
to get translocated (Figure 1.12) (Nyathi et al., 2013; Rapoport et al., 1996; Shan and 
Walter, 2005). 
Figure 1.12. Signal Recognition Particle cycle. When the signal sequence of a growing polypeptide 
chain has emerged from the ribosome (1) it is recognized by the SRP (2). SRP binds its receptor (3) 
and, after GTP hydrolysis, it releases the nascent chain and is recycled (4). Signal sequence is 
cleaved by a peptidase (5), the nascent chain continue to grow (6) until translation termination, 
when the ribosome subunits are recycled (7) and the new protein can reach its folded conformation 
(8) (Berg et al., 2012). 
 
The translocon, called Sec61 in eukaryotes and SecY in prokaryotes, is an 
evolutionary conserved heterotrimetric membrane protein complex, composed by two 
essential and highly conserved subunits named ! and $, and a less well conserved and 
non essential subunit #. !, the subunit that forms the channel pore, contains ten 
transmembrane domains, with N- and C-terminus in the cytosol. It is divided into two 
halves (TM1-5 and TM6-10), each one consisting of three outer and two inner TMs. # is 
composed by a single TM domain that begins with a disordered cytoplasmic segment 
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and crosses over the !-subunit N-terminus. $ has one TM domain divided into two 
helices, its main role is to clamps together the two halves of the !-subunit. The cytosolic 
side of the channel inner part has a funnel-like shape, with a diameter of 20-25Å at the 
cytosolic side and a constriction in the membrane middle. This structure corresponds to 
a closed, impermeable pore, blocked at the bottom of the funnel by the so-called “plug”, 
a portion of TM2 that separates the cytoplasmic site of the channel from the aqueous 
space. When plug is displaced the channel assumes an hourglass-shaped structure and 
becomes open for polypeptide translocation; one of the signal triggering this process is 
the binding between the signal sequence and the translocon. In the narrowest point the 
channel displays a “pore ring” of hydrophobic residues; the pore has diameter of about 
5-8Å, but it can widen to 20Å allowing the translocation of the polypeptide but not the 
passage of other small molecules; interactions between translocon and polypeptide 
occur almost only at this site (Figure 1.13). 
 
Figure 1.13. General architecture of the SecY complex. Left, view from the cytosol. The !-subunit 
is coloured blue to red from the N to the C terminus with the TM segments numbered; the "-subunit 
is shown in pink and the #-subunit in magenta. Right, view from the back, with the phospholipid head 
group and hydrocarbon regions of the membrane shown in blue and grey in the background. 
Cytosolic loops probably involved in ribosome and SecA binding are indicated (adapted from (Van 
den Berg et al., 2004). 
 
The model for translocation of a soluble protein starts with the plug closing the 
channel; after the binding of a partner (i.e. the ribosome), the channel undergoes a 
also be identified from a comparison with the M. jannaschii
complex. The bacterial b-subunit (SecG) comprises two TMs, the
second of which has the same position and orientation as the TMof
Secb of M. jannaschii25 (Fig. 2a), suggesting that they may have
analogous functions. The N-terminal TM of the bacterial b-subunit
(SecG) has no correspondence in archaea and eukaryotes. The
g-subunit (SecE) of E. coli has two non-essential TMs at its N
terminus23, which correspond to the two helices that are far apart
from the others in the 2D crystal structure of the E. coli protein
(Fig. 2a). These helices are in approximately the same location as the
N terminus of the M. jannaschii g-subunit in the X-ray structure
(Fig. 2b).
Translocation pore and plug
Experiments in different systems have shown that the SecY/Sec61p
complex forms oligomers during translocation, but as we will argue
later, our structure suggests that a single copy of the SecY/Sec61p
complex serves as a functional channel. A large, funnel-like cavity
with a diameter of 20–25 A˚ at the cytoplasmic side of the SecY
complex could serve as a channel entrance (Fig. 3a, b). It contains
many conserved residues (Supplementary Fig. S6), suggesting that it
has an important function. The funnel tapers to a close in the
middle of the membrane (Fig. 3b), indicating that the structure
corresponds to a closed channel, impermeabl to polypeptid s or
even small molecules.
How might the channel open and how could it recognize signals?
A large body of data in the literature allows us to propose specific
models for these and other properties. TM2a, which we call the
‘plug’, blocks the bottom of the funnel about halfway across the
membrane, and separates the cytoplasmic side from the external
aqueous space (Fig. 3a). We propose that the channel opens for
polypeptide translocation by displacement of the plug. Consistent
with this hypothesis, a cysteine introduced into the plug at residue
67 of the E. coli a-subunit (SecY; corresponding to M. jannaschii
Thr 61) can form a disulphide bridge in vivo with a cysteine
introduced at residue 120 of the E. coli g-subunit (SecE;
M. jannaschii residue 64)26. These residues are more than 20 A˚
apart in the closed state of the channel (Fig. 3a). Disulphide bridge
formation results in a dominant-negative phenotype, as would be
expected if the channel were locked into a permanently open state.
Another combination of cysteines (E. coli residue 64 in the a-sub-
unit (SecY) and 124 in the g-subunit (SecE)) is also lethal, whereas
combinations of neighbouring residues are not26, suggesting that
the helical structures of the plug and the g-subunit are maintained
during movement. Given that the TM of the g-subunit is a
continuous helix with one hydrophobic side, we assume that it
remains stationary while the plugmoves as a rigid body into a cavity
on the external side of the channel next to the C terminus of the
g-subunit (Fig. 3b, c). This displacement requires a translation of
,22 A˚ towards the back of the molecule, as well as a shift of about
12 A˚ towards the external side of the membrane. The hinges for the
motion could be the Gly residues at positions 49 and 68. Although
not universally conserved, all species have small residues in this
region that could serve this function. Movement of the plug would
ope the pore (Fig. 3b, c), resulting in a hourglass-shaped channel
with aqueous funnels that taper to a constriction in the middle of
the membrane (Fig. 3b).
The funnel-like cavities on both sides of the constriction would
create an aqueous channel across the membrane (Fig. 4a, b). This
feature is consistent with fluorescence life-time measurements3,
which suggest that a translocating polypeptide is in an aqueous
environment. The walls of both funnel-like cavities contain hydro-
Figure 1 General architecture of the SecY complex. a, Stereo view from the cytosol (top).
The a-subunit is coloured blue to red from the N to the C terminus with the TM segments
numbered; the b-subunit is shown in pink and the g-subunit in magenta. b, View from the
back, with the phospholipid head group and hydrocarbon regions of the membrane
shown in blue and grey in the background. Cytosolic loops probably involved in ribosome
and SecA binding are indicated. c, Top view with the N- and C-terminal halves of the
a-subunit in blue and red, respectively. d, Top view sliced through the middle of the
membrane. The solid lines connect the TMs from the N to the C terminus in the two halves;
the dotted arrow shows the axis of internal symmetry. e, Slab views from the front and
back, with the foreground removed and TM1 (dark blue), TM2a and TM2b (sky blue)
highlighted.
articles
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conformational change that removes the plug and allows the insertion of the nascent 
peptide. Peptide inserts in the channel as a loop, whit its mature region in the pore and 
the signal sequence intercalated at its beginning. When the polypeptide is transported 
through the pore the signal sequence is cleaved and the ring forms a seal around the 
peptide to avoid the entrance of other molecules. At the end of the translocation, plug 
returns to block the channel. Translocation of a membrane protein (Figure 1.14) is a 
little bit different since the hydrophobic regions have to be inserted in the membrane; to 
do so, the transmembrane segments move through a lateral gate into the lipid phase, 
while the hydrophilic ones move alternately from the ribosomes to the ER lumen, or 
emerge between the ribosome and the translocon in the cytosol (Nyathi et al., 2013; 
Rapoport, 2007; Van den Berg et al., 2004) 
 
Figure 1.14. General model for transmembrane protein translocation across ER membrane 
(Rapoport, 2007). 
 
1.3.3 Protein folding and glycosylation 
Once they have reached the ER lumen, soluble and membrane proteins are 
subjected to several co- and post-translational modifications, aimed at the achievement 
of a proper folding. The main modifications are: the removal of the signal peptide, the 
glycosylation, the oxidation and, in some proteins, the addition of a 
glycosylphosphatidylinositol (GPI) anchor. 
Signal Peptide Peptidase (SPP) and the homologous SPP-like (SPPL) protease 
constitute, in mammals, a family of five peptidases belonging to the wider class of 
GxGD protease. SPP/SPPLs are responsible for the cleavage of the signal peptide from 
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the nascent protein and for its subsequent degradation (Voss et al., 2013; Weihofen et 
al., 2002) 
Glycosylation is the transfer of an oligosaccharyl moiety (Glc3Man9GlcNAc2, 
Figure 1.15) from the lipid carrier dolichylpyrophosphate to the amide group of a Asn 
residue in the sequence context Asn-X-Ser/Thr, where X can be any amino acid other 
than Pro (Bause, 1979). 
Figure 1.15. Structure of the preformed Glc3Man9GlcNAc2 sugar moiety (Caramelo and Parodi, 
2008). 
 
This reaction is accomplished by the oligosaccharyltransferase (OST), a 
heteromeric multisubunit complex in the ER membrane, found to be in close proximity 
to the translocon. Mammalian OST is composed by several membrane proteins, among 
which the well characterized are ribophorin I and II, OST48 and DAD1. Two OST 
isoforms are known: STT3A OST isoform glycosylates polypeptide chains co-
translationally, while STT3B isoform can glycosylates post-translationally sites skipped 
by STT3A (Aebi, 2013; Yan and Lennarz, 2005). It has been shown that glycosylation 
occurs when the distance from the translated NXS/T sequence and the PTC is 65-75 
amino acids, depending on the tendency of the nascent chain to adopt an ! helix 
conformation inside the RET (Whitley et al., 1996). It is important to note that not all 
the potential N-glycosylation consensus sequences are effectively glycosylated: amino 
acids adjacent to the sequence have a role in the binding of the polypeptide substrate 
with OST, suggesting that the enzyme could recognize a particular conformation 
formed by several amino acids (Petrescu et al., 2004). 
Immediately after the addition to a protein, the N-glycosylation tree is rearranged 
by the enzymes glucosidase I (GI) and II (GII). GI is a type II membrane glycoprotein 
that removes the outermost glucose residue; this reaction occurs almost simultaneously 
with glycan transfer, suggesting the close proximity of this enzyme to OST. GII is a 
cells) affected the process and outcome of glycoprotein produc-
tion as well as the fidelity of quality control in a variety of ways.
Effects were seen on the folding rate (which was accelerated
particularly when CRT was absent), in the folding efficiency
(which was generally reduced), and in the retention of incom-
pletely folded glycoproteins in the ER (which was affected only
whenassociationwithboth lectinswas bolished).CNXseemedto
bemore important thanCRTas foldingassistant.LossofCRThad,
in fact, onlymarginal consequences,whereas loss ofCNXresulted
in a dramatic impairment of influenza viru HA folding and in a
more substantial elevation of other alternative ER resident chap-
erones, a symptom of ongoing ER stress.
Totally unexpected resul s were obtained upon studying th
interaction of CNX/CRT and other chaperones with cellular
and viral glycoproteins expressed in cells lacking functional
CNX (22). Thre variants of the same cellular glycoprotein dif-
fering in folding competence, number of glycans, and solubility
status, which were CNX substrates in wild-type cells, failed to
interact with CRT when xpressed in CNX-null fibroblasts.
Instead, they interacted more strongly with BiP. In contrast,
four viral glycoproteins (Semliki Forest virus E1 and p62, vesic-
ular st matitis virus G, and influenza virus HA) gav different
results. The first two glycoproteins normally interact with both
CNX and CRT, but in CNX-minus cells, they interacted more
bundantly with CRT, and their aturation proceed d nor-
mally. In the case of HA, a glycoprotein that is deeply depend-
ent on CNX for successful maturation and that normally inter-
acts with both CNX and CRT, the absence of the former lectin
resulted in a persistent interactionwithCRT.Themost surpris-
ing result was obtained with G protein that normally interacts
only with CNX. Infection of CNX-deficient fibroblasts with
vesicular stomatitis virus (viral infection was also used to
express E1, p62, and HA) resulted in the interaction of G pro-
tein with CRT. As transfection of G protein failed to trigger its
interaction with CRT, it was suggested that viral infection
somehow subverted the normal glycoprotein recognition by
the ER lectins. This result may explain why total inactivation of
CNX/CRT cycles affects viral replication and infectivity but not
viability of mammalian cells. Additional expression of individ-
ual glycoproteins, both of cellular and viral origin and in this
last case as a result of both viral infection and transfection,must
be studied to substantiate this very interesting finding.
Getting Out: ER-associated Degradation Components
That Recognize Glycoproteins
Exit of properly folded glycoproteins from CNX/CRT cycles
poses no conceptual problems, as their conformations do not
allow GT-mediated reglucosylation. But, how do cells recognize
that glycoproteins are irreparably misfolded or that multimeric
complexes are definitively unable to complete their oligomeric
structures andpull themout from futileCNX/CRTcycles to allow
proteasomaldegradationtoproceed?Although intensiveworkhas
been dedicated to this issue in recent years and substantial pro-
gress has beenmade, the picture that now emerges is rather com-
plex, and no clear answer to the question is yet available.
The observation that addition to mammalian cells of man-
nose analogs (behaving as ER mannosidase I and/or as polym-
annose lectin inhibitors) delayed degradation of misfolded gly-
coproteins prompted the suggestion that a “mannose removal
time clock” regulated disposal. As removal ofmannose is slower
than that of glucose by GI and GII, it was proposed that deman-
nosylation of glycoproteins staying in the ER for relatively long
periods, as happens with irreparablymisfolded glycoproteins, was
tag identifyingmolecules to be driven to degradation.
There are at least two proteins in ER-associated degradation
that may interact with polymannose chains for pulling mis-
folded glycoproteins out from CNX/CRT cycles: ER !-manno-
sidase I and EDEM. Bothmammalian and yeast cell ERmanno-
sidases I are membrane proteins that convert Man9GlcNAc2 to
Man8GlcNAc2 isomerB (M8B) (Fig. 2), but they are not as specific
as initially thought because the recombinant species were able to
further degrade M8B to smaller glycans. However, high enzyme
concentrations not thought to occur in vivowere employed in the
assays (23). Nevertheless, glycans smaller than M8B have been
detected in glycoproteins forced to stay in the ER for rather long
time periods as happens with irreparably misfolded and ER resi-
dent glycoproteins (24–26). The enzymatic activities responsible
for further degradation of Man8GlcNAc2 glycans in the ER have
not been unequivocally identified yet, and theymight not even be
ER resident proteins. It is known that irreparablymisfolded glyco-
proteins may cycle between the ER and Golgi before being driven
to degradation in both yeast andmammalian cells (27–32). Unlike
the S. cerevisiae Golgi, which is devoid of mannosidase activities,
mammalian cell cis-Golgi cisternae display three !-mannosi-
dase activities able to degradeMan9GlcNAc2 toMan5GlcNAc2
(Fig. 2, residues a–e, h, and j) (33, 34). Furthermore, mamma-
lian (but not yeast) cells have an ERGIC/cis-Golgi endomanno-
sidase that yields M8A (Fig. 2) and Glc-Man as degradation
products of Glc1Man9GlcNAc2.
Genome analysis revealed that there are three ER !-manno-
sidase I homologs in mice and only one in either S. pombe or
S. cerevisiae (35–40). They are called EDEM in mammalian
cells and Htm1p or Man1p in yeast. EDEMs were first thought
to be membrane-bound, but recent work showed them to be
soluble proteins (41, 42). EDEMs display a 450-residue domain
that shares 35% sequence identity with the catalytic domain of
ER!-mannosidase I. It was first proposed that EDEMs behaved
as lectins and not as enzymes, as they lack a particular disulfide
bond thought to be required for hydrolytic activity, but further
sequencing work detected several active fungal mannosidases
FIGURE 2. Structure of glycans. The lettering (a–n) follows the order of addi-
tion of monosaccharides in the synthesis of Gl 3Man9GlcNAc2-P-P-dolicho .
GI removes residue n, and GII removes residues l andm. GT adds residue l to
residue g. M8A lacks residues g and l–n; M8B formed by mammalian or yeast
cell ER !-mannosidase I lacks residues i and l–n; and Man8GlcNAc2 isomer C
lacks residues k and l–n. The smallest glycan formed in the S. pombe ER
(Man7GlcNAc2) lacks residues i, k, and l–n.
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soluble luminal enzyme composed of two domains: !, containing the catalytic site, and 
#, containing a KDEL domain that retains the protein in the ER; GII removes a second 
glucose, generating a monoglucosylated protein. This structure is recognized by 
Calnexin (CNX) and Calreticulin (CRT), two ER resident lectins that favour the folding 
process, and then subjected again to the removal of the last glucose by GII, thus 
releasing the glycoprotein from the lectins. CNX is type I transmembrane protein, while 
CRT is a soluble luminal ER protein. After being released from CNX/CRT, the protein 
may have two fates: if it is correctly folded, it can exit the ER; if it is incompletely 
folded, it is recognized and reglucosylated by UDP-Glc:glycoprotein 
glucosyltransferase (GT), causing the return in the CNX/CRT cycle. Permanently 
misfolded glycoproteins may be transported to the cytosol for proteasomal degradation 
(Figure 1.16) (Caramelo and Parodi, 2008; Helenius and Aebi, 2004; Parodi, 2000; 
Trombetta, 2003). Transport of a luminal protein to the cytosol is a process known as 
retrotranslocation or dislocation. 
Figure 1.16. Schematic representation of the Calnexin/Calreticulin cycle. Newly synthesized N-
glycoproteins are deglucosylated by GI and GII. The resulting monoglucosylated protein is 
recognized by the chaperone CNX that, with the assistance of the oxidoreductase ERp57, attempts to 
fold the substrate. The substrate is release by GII that cleaves the last glucose: if it is folded it is 
released into the secretory pathway, otherwise it is reglucosylated by GT and retargeted to CNX or 
CRT (Helenius and Aebi, 2004). 
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Formation of intra-molecular and inter-molecular disulphide bonds (oxidation) is 
the third modification that proteins undergo in the ER, essential for protein function and 
stability. This reaction, that causes the oxidation of reduced cysteine (-SH) to oxidized 
cysteine (S-S), is accomplished mainly by the proteins ER oxidoreductin 1 (Ero1) and 
protein disulphide isomerase (PDI). Ero1 is a disulphide oxidase characterized by seven 
conserved cysteine residues, involved in catalysing electron transfer. PDI family 
members are characterized by the presence of at least one thioredoxin-like domain 
containing Cys-X-X-Cys (CXXC) motifs in the active site, and are involved in the 
disulphide bond formation, isomerization and reduction (Frand and Kaiser, 1998; 
Pollard et al., 1998; Tu and Weissman, 2004). Ero1 oxidizes PDI through the reduction 
of molecular oxygen with the help of a bound FAD cofactor; PDI then catalyses the 
formation of disulphide bonds in folding proteins. This process is independent from the 
presence of glutathione. PDI, in addition to being an oxidizing enzyme, is an isomerase 
that shuffles non-native disulphide bond, and acts also as a chaperone preventing 
protein aggregation (Gruber et al., 2006; Tu et al., 2000; Tu and Weissman, 2004). The 
oxidation process actually begins when the proteins are still in the CNX/CRT cycle; 
here, in fact, they are exposed to the thiol-disulfide oxidoreductase ERp57, a close 
homologue of PDI, that has been shown to form mixed disulphides with incompletely 
folded glycoproteins (Appenzeller-Herzog and Ellgaard, 2008; Araki and Nagata, 2011; 
Helenius and Aebi, 2004). 
One of the main chaperones assisting protein folding in the ER is the Hsp70 
chaperone BiP, also known as grp-78 or HSPA5. 
 
1.3.4 Unfolded Protein Response 
As described, ER is the site where the folding of secretory and membrane proteins 
takes place; however, a large accumulation of aberrant proteins can occur and be fatal 
for the cell. Cells have evolved some conserved signalling pathway, able to monitor and 
to overcome alterations in the ER’s protein-folding capacity, that collectively are named 
Unfolded Protein Response (UPR). Briefly, UPR reduces the protein loading into the 
ER, increases the ER capacity to manage unfolded proteins and, if homeostasis can not 
be re-established, trigger cell death. Three UPR stress branches have been identified, 
each one defined by a sensor: the Inositol-Requiring Protein-1 (IRE1), the Activating 
Transcription Factor-6 (ATF6), and the Protein kinase RNA-like ER Kinase (PERK) 
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(Figure 1.17). All these proteins are characterized by being transmembrane ER-resident 
proteins, with a sensor for the protein-folding environment in the ER portion, and an 
effector in the cytosolic part (Ron and Walter, 2007; Walter and Ron, 2011). 
 
Figure 1.17 Schematic representation of the three main UPR pathways (Cyr and Hebert, 2009). 
 
The IRE1 branch is the most conserved and the only one present in lower 
eukaryotes. IRE1 is a type I transmembrane protein that has, in the cytoplasmic portion, 
both a protein kinase and a ribonuclease domain. IRE1 is activated by binding of 
unfolded proteins or by release of BiP, then it oligomerizes and trans-
autophosphorylates. In this form it uses a unique mechanism of non-conventional 
splicing, cleaving its substrate, an mRNA encoding for XBP1, generating a spliced 
version able to activate the UPR target genes (Calfon et al., 2002; Ron and Walter, 
2007). 
ATF6 is a type II transmembrane protein encoding a transcription factor in its 
cytosolic domain. It is synthesized as an inactive precursor that, under ER stress 
conditions it is transported to the Golgi, where the proteases S1P and S2P remove the 
luminal and the transmembrane domain, respectively. The resulting N-terminal 
fragment (ATF6f) is a DNA-binding portion (ATF6f) that, transported in the nucleus, 
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activates UPR target genes. The main targets of ATF6 are ER-resident proteins involved 
in protein folding, such as the chaperone BiP, PDI and the chaperone GRP94 (Haze et 
al., 1999; Walter and Ron, 2011). 
PERK is a type I transmembrane protein with a kinase domain in the cytosolic 
portion; it oligomerizes and undergoes activating trans-autophosphorylation. In this 
form it phosphorylates the translation initiation factor eIF!, inhibiting translation 
initiation and so reducing the loading of new proteins in the ER (Harding et al., 1999). 
Interestingly, some mRNA containing short open reading frames in the 5’UTR are 
preferentially translated when eIF2 is phosphorylated; the most important in UPR is the 
transcription factor ATF4, involved in the integrated stress response, which controls the 
levels of pro-survival genes related to redox balance, amino acid metabolism, protein 
folding and autophagy (Hetz, 2012; Lu et al., 2004). 
The ER chaperone BiP plays an important role in the activation of these branches. 
Its binding to the luminal portions of IRE1 and PERK, in fact, inhibits their spontaneous 
oligomerization and subsequent phosphorylation. When the levels of unfolded proteins 
increase, BiP binds preferentially to misfolded proteins, releasing IRE1 And PERK that 
can trigger UPR (Bertolotti et al., 2000; Ron and Walter, 2007). BiP binds also ATF6, 
masking its Golgi-localization signal, and release it only under stress conditions, 
allowing its transport (Hetz, 2012; Shen et al., 2002). 
 
1.3.5 Endoplasmic Reticulum Associated Degradation: substrate recognition 
When a secretory or membrane protein definitively fails in reaching its proper 
folding status, it must be degraded through a pathway called Endoplasmic Reticulum 
Associated Degradation (ERAD). How a potential ERAD substrate is selected is still 
not fully clear, but some features of the nascent polypeptide have been linked to its 
degradation. 
When a protein has a folded conformation, hydrophobic regions are usually 
masked in the interior of the protein; these regions, however, might be exposed in an 
unfolded or misfolded protein, potentially leading to aggregation. In these cases 
solubility is maintained by the chaperones belonging to the 70kDa heat-shock protein 
(Hsp70) family, the most important of which is BiP. Prolonged interaction between an 
ERAD substrate and a chaperon might be a sufficient signal to trigger ERAD (Denic et 
al., 2006; Vembar and Brodsky, 2008). 
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As described in paragraph 1.3.3, after glycosylation by OST and removal of two 
glucose residues by GI and GII, a nascent glycoprotein is bound by the lectins CNX and 
CRT that help it to reach a folded conformation and prevent aggregation. Removal of 
the last glucose residue by GII releases the protein; however, if it is still misfolded, GT 
reglucosylates the polypeptide leading to a rebind by CNX/CRT. This cycle ends when 
are involved the ER mannosidades, the enzymes responsible for the recognition and 
labelling of terminally misfolded proteins. Removal of three or four mannoses (creating 
M6 and M5 structures) from the deglucosylated precursor, in fact, irreversibly prevents 
reglucosylation by GT and so the return in the CNX/CRT cycle (Lederkremer, 2009; 
Nakatsukasa and Brodsky, 2008). Enzymes responsible for demmanosylation, also 
called trimming, belong to the glycosyl-hydrolase 47 family, which includes the ER !1-
2 mannosidase I (ERManI), the three ER degradation-enhancing ! mannosidase-like 
proteins (EDEM), and the Golgi resident Man IA, IB and IC. Among them, ERManI 
seems to be the most active in the production of M6-5 sugar moieties, while it is still not 
clear if EDEMs are co-factor of ERManI or if they are true mannosidase (Avezov et al., 
2008; Lederkremer, 2009; Molinari, 2007). Trimmed oligosaccharides are then 
recognized by the ER-resident lectins OS-9 and XTP3-B through a mannose-6-
phosphate receptor homology (MRH) domain and sent to degradation. Interestingly, 
OS-9 and XTP3-B are found also involved in ERAD of non-glycosylated proteins; 
however the events that initiate their degradation are still poorly understood (Bernasconi 
et al., 2008; Christianson et al., 2008). 
 
1.3.6 ERAD: dislocation 
After the engagement by OS-9/XTP3-B, ERAD substrates must be transported 
from ER to the cytosol, in a process called dislocation or retrotranslocation. The ER-
resident glycoprotein Suppressor/Enhancer of Lin-12-like (SEL1L) plays an essential 
role in coordinating substrate recruitment, ubiquitination and dislocation. SEL1L is 
characterized by a large region exposed into the ER lumen, containing several TRP-type 
domains implicated in protein-protein interaction. It forms a complex with OS-9/XTP3-
B (Bernasconi et al., 2008; Christianson et al., 2008; Hosokawa et al., 2008), with the 
E3 ligase Hydroxymethylglutaryl reductase degradation protein 1 (Hrd1), with one of 
the three Derlin proteins (Lilley and Ploegh, 2005) and with several co-factors whose 
role is to adapt the different substrates to the complex (Christianson et al., 2012). In 
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addition to Hrd1, the other E3 ubiquitin ligase strongly associated with ERAD is gp78 
(Fang et al., 2001). Both these E3s are characterized by having the catalytic RING 
domain exposed to the cytosolic side of the ER membrane, thus ubiquitination of ERAD 
substrates take place on the cytosolic side. 
How the proteins are extracted from the ER and translocated to the cytosol is still 
not known. The involvement of ER-resident proteins such as sec61, Derlin, or Hrd1 
have been postulated, based on their membrane-spanning topology, their proximity to 
other membrane-associated components of the ERAD system, and on the ability to co-
precipitate or be cross- linked to putative dislocation intermediates. Sec61 was found 
associated with the Major Histocompatibility Complex class I molecule (MHC-I) in 
cells expressing the hCMV immunoevasins US2 and US11, that trigger MHC-I 
degradation (Wiertz et al., 1996). Moreover, sec61 was implicated also in the export of 
cholera toxin from ER (Schmitz et al., 2000). However, several data argue against a 
general involvement of sec61 in retrotranslocation; first, it is still unclear if aberrant 
proteins completely dissociate from the translocon after their import: their binding to 
sec61 may be the consequence of a prolonged interaction rather than a retargeting to the 
channel. Second, as described in paragraph 1.3.2, sec61 has a diameter of 20Å in its 
narrowest point: this size is not compatible with the passage of partially folded and 
glycosylated proteins (Bagola et al., 2011). We have recently demonstrated that 
Tetherin and CD4 are retrotranslocated as partially folded and multimeric proteins, 
further suggesting that Sec61 can not be the retrotranslocon (Petris et al., 2014). 
Another transmembrane protein proposed as retrotranslocating channel is Derlin, 
present in mammals in three homologous proteins required for distinct degradation 
pathway. Derlin-1 was described to be involved in US11 induced MHC-I degradation, 
in fact it was found associated both with the glycosylated and the deglycosylated MHC-
I forms. Moreover, it was identified as an interactor of the ATPase p97 (described later 
in paragraph 1.3.7.1), indicated as the major source of ATP energy during dislocation, 
and of the ubiquitin ligases Hrd1 and gp78 (Lilley and Ploegh, 2004, 2005; Ye et al., 
2004). Also Hrd1 oligomers have been proposed as retrotranslocation channel; in 
particular its transmembrane segment is involved in the dislocation of Parkin-associated 
endothelin receptor-like receptor (Pael-R) (Omura et al., 2008) and of other proteins in 
yeast (Carvalho et al., 2010). 
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1.3.7 ERAD: Cytosolic Steps  
Addition of ubiquitin molecules on ERAD substrates is next step. This labelling is 
necessary not only for proteasomal degradation; probably it serves also to prevent the 
substrates from moving back into the ER lumen, and it has been proposed to be 
necessary for the dislocation from the ER, constituting a recognition signal for 
downstream components. Polyubiquitination, however, has been proposed to be 
necessary but not sufficient for retrotranslocation: this is not, in fact, a passive process 
such as the translocation from cytosol to ER, but it requires ATP hydrolysis (Flierman 
et al., 2003; Shamu et al., 2001; Tsai et al., 2002). The driving force for dislocation has 
been proposed to be supplied by the ATPase p97/VCP (described in detail in paragraph 
1.3.7.1), that binds the ubiquitin through its co-factors Ufd1 and Npl4, two proteins 
containing many ubiquitin-binding domains (Meyer et al., 2000). 
The last cytosolic step prior to proteasomal degradation is optional, and consists 
in the removal of N-linked glycans by the action of peptide N-glycanase (PNGase). 
PNGase hydrolyzes the #-glycoamide bond between the asparagine residue and the 
GlcNAc group at the reducing end of the oligosaccharide, resulting in the release of a 
free glycan with the concomitant conversion of the asparagine to aspartic acid 
(Plummer et al., 1984). It was shown that PNGase could act both upstream and 
downstream to proteasomal degradation, as its activity is not essential for substrate 
degradation (Kario et al., 2008). However in most cases ERAD retrotranslocated 
substrates become first deglycosylated and then degraded, as revealed by proteasome 
inhibition, that causes accumulation of deglycosylated molecules. PNGase interacts 
indirectly with the proteasome through RAD23 (Suzuki et al., 2001) and directly with 
p97 (Zhao et al., 2007); RAD23 interacts with the proteasome through its Ubiquitin-like 
Domain (UBL), with ubiquitin through an Ubiquitin-associated domain (UBA), and 
indirectly with p97; p97, as mentioned before, interacts directly and indirectly with 
ubiquitin and proteasome. These interactions highlighted the presence of a relevant and 
complex network linking in many ways the main cytosolic ERAD players. 
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1.3.7.1 AAA ATPase p97/VCP 
p97/VCP (Valosin-Containing Protein, Cdc48 in yeast) is a highly conserved 
ATPase belonging to the type II AAA family (ATPases Associated with various cellular 
Activity). Structurally it is a homohexameric complex composed of six protomers 
arranged in a ring around a central pore. Each protomer contains three domains joined 
by conserved linkers: a flexible N-terminal substrate/adaptor molecule recognition 
domain, and two AAA domains called D1 and D2; the C-terminal region is disordered 
and not structurally characterized. The six D1 and D2 domains forms the hexameric 
double-ring structure packed in a head-to-tail arrangement. Each AAA domain contains 
the signature nucleotide binding motif (Walker A or P-loop), the hydrolysis motif 
(Walker B or DEXX box), and a Second Region of Homology (SRH) necessary for 
efficient hydrolysis (Davies et al., 2008; Zhang et al., 2000). D2 domains have the 
major ATPase activity as they work under physiological temperatures, while D1 
domains work under heat shock conditions (Song et al., 2003). ATP hydrolysis causes 
huge conformational changes, resulting in open and closed configuration of the D1 and 
D2 domains. D2 domain has two loops in the pore: one contains Trp552 and Phe551 
and is involved in substrate interaction, the other one contains Arg586 and Arg599 and 
is essential for ATPase activity; in the hexamer, the presence of a “ring” of twelve Arg 
suggests a role in protein unfolding. D1 domain has a loop, in the narrowest region of 
the pore, in which His317 is found to be essential for p97 function; in the hexamer the 
ring of six His constitutes the closest common point of contact for the protomers, 
suggesting that this amino acid could be the interaction nexus for the six protomers 
(Figure 1.18) (DeLaBarre and Brunger, 2005; DeLaBarre et al., 2006). 
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Figure 1.18. p97 structure. (left) Ribbon representations of full-length p97 (pdb code: 1R7R) and 
(right) p97 ND1 complexed with p47 UBX (pdb code: 1S3S) are shown in top and side views 
(Dreveny et al., 2004). 
 
p97 is very abundant, accounting for about 1% of total cellular protein; this 
abundance reflects the wide variety of roles that it plays inside the cell, for which 
viability it is essential. p97 activity has been linked with Golgi, ER and nuclear 
membrane reassembly; ERAD; lysosomal degradation through autophagy and 
endolysosomal sorting; protein quality control on the outer mitochondrial membrane; 
chromatin-associated functions; signalling and cell cycle regulation (Meyer et al., 2012; 
Yamanaka et al., 2012). The ability to perform such a great variety of functions resides 
in its N-terminal domain, through which it associates with a large number of partners 
and cofactors (Figure 1.19). p97-interacting proteins were shown to have one of the 
following domains: UBX/UBX-like domain (i.e. Ubxd2, Ubxd8, p47, Ufd1, YOD1), 
UBD domain (i.e. Npl4), PUB domain (i.e. PNGase), SHP box (i.e. derlin), VCP-
interacting motif (i.e. gp78) and VCP-binding motif (i.e. ataxin-3) (Madsen et al., 2009; 
Yeung et al., 2008). Interestingly, the various functions of p97 are all connected to the 
ubiquitin pathway: the N-domain contains itself a low affinity ubiquitin-binding site (Ye 
716 Biochemical Society Transactions (2004) Volume 32, part 5
Figure 1 Compilation of structures, p97 and p97-interacting proteins
(A) Ribbon representations of full-length p97 (pdb code, 1R7R) and p97 ND1 complexed with p47 UBX (pdb code, 1S3S)
are shown in top and side views. (B) A gallery of protein structures that have been reported to interact with p97: ubiquitin
(pdb code, 1UBI), SYT I C2A domain (pdb code, 1BYN), TB-RBP (pdb code, 1KEY) and clathrin heavy chain (Clathc) N-terminal
domain and proximal leg (pdb codes, 1BPO and 1B89).
Another essential protein involved in the fusion events
of organelles is VCIP135 (valosin-containing protein [VCP]
[p97]–p47 complex-interacting protein, p135), this is believed
to help disassemble the p97–p47–syntaxinV complex [19].
VCIP135 binds to p97 and syntaxinV and its activity was
shown to be crucial for the reassembly of Golgi stacks after
mitosis, which was independent of proteasome involvement
[20]. It is a member of the otubain family of cysteine pep-
tidases and acts as a deubiquitinating enzyme [20]. Sequence
analysis predicts that it contains a UBX, which is suggested
to be the main binding site or p97 [19].
Recently, four other proteins have been shown to interact
with p97/Cdc48, representing examples from other UBX
protein subfamilies. The yeast Cui (Cdc48p UBX-containing
interactor) proteins, Cui1p, Cui2p and Cui3p, have been
reported to interact with Cdc48 [21]. Cui2p and Cui3p are
rather Y33K than p47-related. These proteins also interact
with Ufd3 [21], a WD repeat protein associated with Cdc48p
[22]. Diploid cells lacking these Cui proteins are defective in
tetrad formation but their detailed function remains elusive.
Lastly, Ubx2, found in yeast an humans, was identified to
interact with Cdc48/p97 [18]. Cells lacking Ubx2 did not dis-
play any specific phenotype. Ubx2 displays some similarities
wi h Fas-associated factor 1, as it is predicted to contain an
N-terminal UBA, C-terminal UBX and a thioredoxin-like
domain [18].
C©2004 Biochemical Society
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et al., 2003), many p97 co-factors bears ubiquitin-binding domains and, since p97 is 
made of six protomers, co-factors that don’t have ubiquitin-binding activity may 
collaborates with those that have it (Ye, 2006). p97 has been shown to associates with 
E3 ubiquitin ligases such as Hrd1 and gp78 (Lilley and Ploegh, 2005); with the E4 
ubiquitin extending enzyme Ufd2 (Richly et al., 2005); with deubiquitinating enzymes 
such as ataxin-3 (Wang et al., 2006) and YOD1 (Ernst et al., 2009). 
 
Figure 1.19. Schematic molecular organization of p97/VCP. The binding domains of the different 
co-factors of Cdc48/p97 are indicated (Dargemont and Ossareh-Nazari, 2012). 
 
For the purpose of this thesis, the most relevant role of p97 is in ERAD. In most 
cases p97 participates to this pathway in complex with the heterodimeric co-factor 
composed by Ufd1 (Ubiquitin Fusion Degradating protein 1) and Npl4 (Nuclear protein 
localization protein 4 homolog) (Meyer et al., 2000; Ye et al., 2001). The common view 
is that p97-Ufd1-Npl4 is recruited to the ER membrane, where there are at least seven 
different membrane-embedded ERAD components carrying a p97-binding motif. Here 
the precise function of p97 complex is not clear, but it seems it binds ubiquitinated 
ERAD substrates and supply the energy for dislocation or for the release from the 
membrane of substrates already retrotranslocated. Moreover, p97 serves as a scaffold 
that links dislocated substrates to cytoplasmic co-factors involved in substrates 
modifications, especially those related to ubiquitination status. 
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1.3.8 Ubiquitin-Proteasome System 
 
1.3.8.1 Ubiquitin: structure and conjugation 
Ubiquitin is the prototype of a family of proteins that share a remarkable structure 
despite their variable sequences. These proteins, involved in several cellular processes, 
share also the peculiar feature to be covalently attached to an amino group of the target 
protein through their C-terminal glycine motif. In addition to ubiquitin, other members 
of this family are Sumo (Small ubiquitin-like modifier), Nedd8 (Neuronal-precursor 
cell-expressed developmentally down-regulated protein 8), Fat10 (F-adjacent transcript-
10), ISG15 (IFN-stimulated gene 15), Ufm1 (Ubiquitin-fold modifier 1), Urm1 
(Ubiquitin-related modifier 1), Hub1 (Homologous to ubiquitin 1), Atg8 (Autophagy), 
Atg12; these proteins are collectively called Ubiquitin-like proteins (Ubl) (Hochstrasser, 
2009; Pickart and Eddins, 2004). 
Ubiquitin (Figure 1.20) is a highly conserved small protein of 76 amino acids (8.5 
kDa), encoded by the four different genes: UBB and UBC encode polyubiquitin chains 
of four and nine tandem repeats, respectively, while UBA52 and RPS27A encode for a 
ubiquitin monomer fused to the ribosomal proteins L40 and S27A, respectively. Single 
ubiquitin subunits are generated by proteases by post-translational cleavage (Baker and 
Board, 1987; Jonnalagadda et al., 1989). Ubiquitination, that is the linkage of a single 
ubiquitin molecule to proteins, occurs mainly on the amino groups of Lys and on the N-
terminal free amino group; however, the mechanism underlying Lys ubiquitination may 
also be applied to other amino acids: Cys, Ser, Thr and Tyr could also be ubiquitin 
linkage sites (McDowell and Philpott, 2013). After the addition on the protein of the 
first ubiquitin molecule, the polyubiquitin chain can be created: ubiquitin, in fact, 
possesses seven Lys (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63), which are 
the attachment sites for chain assembly. The particular lysine used for the development 
of the polyubiquitin chain leads to the creation of diverse structures, which in turn have 
a different biological significance and are related to different cellular processes. 
Ubiquitination through Lys11, Lys29, Lys48 and Lys63 have been linked to 
proteasomal degradation; between them, the K48 linkage is the most prevalent 
(Baboshina and Haas, 1996; Chau et al., 1989; Komander and Rape, 2012). 
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Figure 1.20 Ubiquitin structure. Ribbon representation of 
an ubiquitin monomer, with indicated the Lys (K) (Randles 
and Walters, 2012) 
 
Ubiquitination is the result of the activity of three type of enzymes: an E1 
ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin 
ligase (Figure 1.21) (Pickart and Eddins, 2004). 
 
Figure 1.21. Schematic representation of the ubiquitination steps (Hochstrasser, 2009). 
 
E1 activates ubiquitin C-terminus by binding it to MgATP; ATP hydrolysis 
provides the energy for the production of an acyl-adenylate intermediate, that reacts 
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with a Cys of E1 to generate an E1~Ubiquitin thiol ester (~ represents a high energy 
covalent complex). In general, each ubiquitin-like molecule has a single dedicated E1 
(Schulman and Harper, 2009). Ubiquitin is then transferred from E1 Cys to an E2 Cys 
via a thioesterification reaction. In humans around 40 active E2 enzymes have been 
identified. They are directly involved in the selection of the Lys on which to construct 
ubiquitin chain; moreover they can influence the specificity of the ubiquitination, and 
consequently the cellular fate of the substrate, because individual E2 interacts with 
specific E3 enzymes (van Wijk and Timmers, 2010). The last step is performed by an 
E3 enzyme, which creates an isopeptide bond between a Lys %-amino group of the 
target protein and the ubiquitin. In eukaryotic cells are present more than six hundreds 
of E3: based on their structure they belong to the HECT (Homologous to E6AP 
Carboxy Terminus), or to the RING (Really Interesting New Gene), or to the U-box 
(UFD2 homology) E3 ligases (Pickart and Eddins, 2004). RING E3 ligases are 
characterized by a RING domain consisting of a series of specifically spaced Cys and 
His residues buried within the domain’s core, where they help maintain the overall 
structure through binding of two Zn atoms. They induce the transfer of ubiquitin first by 
inducing proximity between E2-ubiquitin and the substrate: RING domain active site, in 
fact, remains too far from the E2 active site to play a “true” catalytic role. Second, 
several evidences suggest that E2-ubiquitin undergoes a conformational change upon 
binding to RING, thus releasing ubiquitin. In ERAD the best known RING E3 ligases 
are Hrd1 and gp78 (Deshaies and Joazeiro, 2009; Metzger et al., 2012). U-box E3 
ligases are characterized by the U-box domain, a derived version of the RING domain 
that lacks the metal-chelating residues Cys and His, but contains stabilizing hydrogen 
bond and salt bridges. Except for this feature, U-box retains the same pattern of amino 
acid residue conservation, suggesting a similar structural arrangement. They function 
similarly to the RING E3s in mediating ubiquitin-conjugation of protein substrates 
(Aravind and Koonin, 2000; Hatakeyama and Nakayama, 2003). HECT E3 ligases 
represent the minority part (around 5%) of the E3s and employ a mechanism unique 
among E3s: they form a trans-thiol bond with ubiquitin before conjugation with the 
substrate; in their case, therefore, the E3 Cys and not the E2 Cys is the last stop for 
activated ubiquitin. They are characterized by a HECT domain at the C-terminus, while 
at the N-terminus they have diverse domains that mediate substrate targeting. HECT 
domain itself is divided in a N-terminal lobe that interacts with E2, and a C-terminal 
lobe containing the active-site Cys for the binding to ubiquitin (Metzger et al., 2012; 
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Rotin and Kumar, 2009). After the addition of the first ubiquitin, the substrate is 
released or the ubiquitination steps can be repeated to elongate the ubiquitin chain: this 
activity is performed by the same E3 ligase that performed the first conjugation, or by a 
different one (Metzger et al., 2012). 
 
1.3.8.2 Deubiquitination 
Deubiquitinating enzymes (DUBs) are proteases responsible for the production of 
ubiquitin from the inactive precursors and for its removal from the substrates; they do 
this by cleaving and so exposing the Gly residue at ubiquitin C-terminal. Until now 
around a hundred of DUBs have been identified and classified into five major classes: 
four of them belongs to the cysteine proteases (Ubiquitin-specific protease (USP), 
Otubain protease (OTU), Machado-Joseph disease protease (MJD), and Ubiquitin C-
terminal hydrolases (UCH)), and one to the metalloproteases (Ubiquitin-specific JAMM 
domain containing metalloprotease) (Ha and Kim, 2008). USP is the largest and most 
diverse class of DUBs: they have a size that ranges from 300 to 800 amino acids and a 
catalytic site of 40 kDa, containing two short and well-conserved Cys and His boxes 
which include the residues critical for catalysis. UCHs are small protease of 20-30 kDa 
that cleaves ubiquitin from very short substrates of 20-30 amino acids; this restriction is 
due to a loop that partially occludes their active site (Amerik and Hochstrasser, 2004; 
Ha and Kim, 2008; Nijman et al., 2005). OTUs belong to the ovarian tumor proteins 
superfamily and are characterized by a highly conserved deubiquitinating domain of 
around 130 amino acids, with Cys and His catalytic residues. Different members of this 
family bind and cleave ubiquitin from different chains: Otu1, for example, binds 
preferentially K48 chains, while A20 hydrolyzes K63 chains (Messick et al., 2008). 
This domain has been found not only in all eukaryotes, but also in proteins of virus 
infecting eukaryotic cells, probably constituting a mechanism to evade the immune 
system. Crimean Congo Haemorrhagic Fever Virus-L protein contains a 169 amino 
acids long OTU domain able to cleave ubiquitin from K48 and K63 polyubiquitin chain 
(Frias-Staheli et al., 2007). MJDs comprise ataxin-3 and some other ataxin-like proteins. 
Ubiquitin-specific JAMM domain containing metalloproteases, unlike the other DUBs, 
bind Zn2+ through two His and one Asp; the main member of this family is Rpn11, a 
subunit of the 19S proteasomal lid subcomplex (Ha and Kim, 2008). 
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1.3.8.3 Proteasome: structure and function 
The proteasomal complex 26S is the main ATPase dependent protease in the cell 
and it is the main responsible for protein degradation. In eukaryotic cells it is localized 
both in the nucleus and in the cytosol, with a very little exchange between these two 
populations (Reits et al., 1997). Degradation occurs with high specificity, achieved in 
part by the tagging system constituted by ubiquitin (Komander and Rape, 2012), in part 
by the requirement of unstructured region at which the proteasome can initiate 
degradation (Prakash et al., 2004), in part by the structure of the proteasome (Pickart 
and Cohen, 2004). The 26S proteasome is composed of a core particle, also known as 
20S, and a regulatory particle, also known as 19S (Figure 1.22). 
 
 
 
 
 
 
 
 
Figure 1.22 Subunit composition of the 26S 
proteasome (Pickart and Cohen, 2004). 
 
20S is composed by 28 subunits arranged into four seven-subunit rings stacked on 
top of each other to form a compact cylinder. The inner rings consist of related #-
subunits, three of which contain proteolytic active sites: #1 prefers to cleave on the C-
terminal side of acidic residues (caspase-like), #2 after tryptic residues (trypsin-like), 
and #5 after hydrophobic residues (chymotrypsin-like). The presence of a wide array of 
protease activities makes the proteasome virtually able to degrade every kind of 
polypeptide (Borissenko and Groll, 2007; Finley, 2009). The outer rings consist of 
related !-subunits: when the core particle is in a closed state the N-terminal of !-
subunits converge closing the entrance to the channel, while holoenzyme formation by 
binding of 19S to 20S open the channel. Catalytic site can be accessed only through 
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axial pores, with a diameter of up to 2nM and so too narrow to allow the entering of 
folded polypeptide, even in an open state (Groll et al., 2000; Pickart and Cohen, 2004; 
Smith et al., 2007). Presence of !-rings, moreover, creates two interior compartments, 
also called “antechamber” (size of 59 nm3), additional to the catalytic one forms by #-
rings, called “catalytic chamber” (size of 84 nm3). Functions of the antechambers are 
believed to be the holding of a considerable mass of substrate or partial digestion 
products, and the regulation of the entry in the catalytic chamber (Figure 1.23) (Pickart 
and Cohen, 2004). 
 
Figure 1.23. Molecular structures of eukaryotic 20S proteasomes. (a) side views of the 20S 
proteasome, the !-subunits are located at the ends, whereas the "-subunits form the two inner rings. 
(b) Top views of the !-ring (upper panel) and the "-ring (lower panel). "-ring has an open space in 
its centre, whereas the !-ring is closed by the amino-terminal extensions of the !-subunits (Murata 
et al., 2009). 
 
19S is composed by at least 19 subunits and two catalytic activities: ATP 
hydrolysis and ubiquitin proteolytic cleavage. 19S is divided into two subcomplexes: 
the base and the lid. The base consists of six ATPases (Rpt1-6) critical for 26S 
formation, two large organizing subunits (Rpn 1 and 2) that work as scaffolds to 
mediate proteasome binding to a variety of factors, and two ubiquitin receptors (Rpn10 
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and 13). The lid is composed by the deubiquitinating enzyme Rpn11, whose activity is 
critical for proteasome function, its inactive binding partner Rpn8, and seven 
scaffolding subunits (Rpn3, 5, 6, 7, 9, 12, 15); moreover, also Rpn10 can associate with 
the lid (Finley, 2009; Glickman et al., 1998). Rpn11 is a Zn2+-dependent DUB, able to 
cleave both K48- and K63-linked polyubiquitin chains from substrates targeted to 
proteasomal degradation (Yao and Cohen, 2002). In addition a large number of proteins 
associate with the 19S to modulate degradation: among them there are proteins 
containing ubiquitin-like and ubiquitin-associated domains and other DUBs (Finley, 
2009). 
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1.5. Picornaviruses 
Picornaviruses are non-enveloped viruses containing a positive-sense single-
stranded RNA genome that belong to the Picornaviridae family. The family 
Picornaviridae consists of 12 genera and comprises several human and animal 
pathogens, as well as some viruses that infect plants and insects. From a structural point 
of view, the virions are spherical with a diameter of about 30nm. Virus particles capsid 
has an icosahedral symmetry: it contains 60 protomers, each formed by one copy of the 
four VP (Viral Protein) 1, 2, 3 and 4 (Fields et al., 2001). 
 
1.5.1 Genome organization 
The genome of picornaviruses is organized in a single-stranded RNA molecule of 
positive polarity that varies in length from 7.2 to 8.8 kb and works as an mRNA. It is 
composed of a single ORF (Open Reading Frame) encoding a polyprotein, which after 
translation is then cleaved by viral elements into mature proteins. The genome is 
infectious itself: indeed it is translated on entry into the cell and produces all the viral 
proteins required for viral replication. 
Since the genome has a positive polarity, it is read as a mammalian mRNA from 
5’ to 3’ end; like an mRNA, it has a poly(A) tail at the 3’ end, but it shows a unique 
feature at the 5’ end: instead of a cap, it has a virally encoded protein knows as VPg 
(Virion Protein genome linked) covalently linked. The 5’-UTR (UnTranslated Region) 
is long and contains sequences involved in genome replication and translation; one of its 
most important features is the presence of an IRES (Internal Ribosome Entry Site) that 
directs translation of the mRNA by internal ribosome binding. The 3’-UTR is very short 
and has a role in the synthesis of the negative strand during the viral cycle. 
Picornaviral ORF is generally divided into three consecutive parts: P1 that 
encodes for the structural proteins of the capsid; P2 and P3, encoding the non-structural 
replication proteins. Picornavirus proteins are synthesized as a polyprotein subsequently 
processed in the single components during three consecutive steps. Except for entero- 
and hepatoviruses, the first cleavage is co-translational and causes the release of the N-
terminal portion of the polyprotein (P1 or P1-2A); for enteroviruses the primary 
cleavage is mediated by the viral protease 2Apro. The second cleavage requires the 
synthesis of viral protease 3Cpro; this protease is responsible for the primary cleavage in 
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hepatoviruses, but in all picornaviruses its role is the catalysis of a series of cleavages: 
the first between P2 and P3, then the release of precursors and mature proteins. Both 
3Cpro and 2Apro are active in the nascent polyprotein and catalyse themselves release by 
self-cleavage. The third cleavage occurs only during the final stages of virion 
morphogenesis and consists in the maturation of some structural proteins (VP4/VP2) 
(Figure 1.24) (Ehrenfeld et al., 2010; Fields et al., 2001) 
 
Figure 1.24. Genome organization of Picornavirus and processing of the polyprotein (from 
http://viralzone.expasy.org/all_by_species/33.html). 
 
1.5.2 Picornaviral 2A protein 
One of the major differences among picornaviruses is the nature of 2A protein 
that varies considerably in sequence, length and activity. Hepatovirus 2A protein does 
not have a cleavage function. Enterovirus 2A protein is a protease of about 17 kDa 
(2Apro), structurally similar to the trypsin-like serine proteases; 2Apro cleaves its 
polyprotein in cis at the P1/P2 junction. In the remaining viruses the 2A protein is 
different in size but shares a common mechanism of action: cardiovirus 2A is large 
(143-145 amino acids) while aptho-, thesco- 2A is very short, only about 20 amino 
acids in length. Despite this difference, the 13-18 C-terminal amino acids are common, 
and cause primary cleavage of the polyprotein via ribosome skipping. In particular the 
three C-terminal residues (NPG) of 2A, together with the N-terminal proline of the 2B 
protein are completely conserved (Figure 1.25) (Donnelly et al., 1997; Donnelly et al., 
2001b; Ryan and Flint, 1997; Ryan et al., 1991). 
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Figure 1.25. Activity of the 2A protein in different Picornaviruses (Donnelly et al., 2001b). 
 
1.5.3 Foot-and-Mouth Disease Virus 2A protein 
Foot-and-mouth disease virus (FMDV) is a picornavirus that belongs to the 
apthovirus genus; its 2A region is very short, only 18 amino acids in length 
(LNFDLLRLAGDVESNPG), and it is conserved among all the viruses of this genus. 
Several works have been done to clarify how a sequence so short and without 
proteolitic activity can mediate polyprotein cleavage. The common strategy of all these 
works was to put an irrelevant protein immediately upstream and downstream 2A, 
generally two different reporter genes, and evaluate the activity of the peptide in this 
foreign context. Some of the observations that have been made are: FMDV 2A peptide, 
together with N-terminal 2B proline (from now: 2A+P), retains its activity also when 
the upstream and downstream contexts are replaced. Changing the sequences, however, 
causes a reduction in the cleavage from 100% to 85% (Ryan et al., 1991). FMDV 2A+P 
is able to mediate cleavage at its C-terminal in a completely foreign context, as well as 
it does in the viral native context. This means that 2A does not require other domains 
within FMDV polyprotein to work properly, indeed it is an autonomous element (Ryan 
and Drew, 1994). Cleavage is co-translational, works only in cis, and it is resistant to a 
wide range of protease inhibitors. The small proportion of uncleaved product does not 
undergo subsequent cleavage (de Felipe et al., 2003; Ryan and Drew, 1994). Cleavage 
occurs in all the eukaryotic system tested, but not in the prokaryotic ones (Donnelly et 
al., 1997). FMDV 2A+P mediated cleavage is not due to the RNA sequence, because it 
varies a lot among the different viruses and does not cause the formation of particular 
RNA secondary structure (Donnelly et al., 2001b). In many of the artificial systems 
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analysed, an imbalance between the amount of the protein upstream and downstream 
the peptide has been highlighted; in particular, the N-terminal protein of 2A is produced 
2 to 5 times more than the C-terminal. This imbalance in the accumulation of the 
proteins is not due to different rate of protein degradation, nor to premature 
transcription or translation termination (Donnelly et al., 2001b) 
A translational model describing the activity of FMDV 2A peptide has been 
proposed, taking into account other experimental observations. First, despite the 
absence of a STOP codon the translational complex stalls or dissociates at the 2A C-
terminal. This effect can explain the imbalance in the amount of the two proteins. 
Second, upstream and downstream proteins are translated without the synthesis of the 
peptide bond between them. The proposed mechanism of action is the following: (I and 
II) synthesis of the peptide bond between Proline and Glycine, the C-terminal amino 
acids of 2A peptide; (III) translocation of the peptidyl(2A)-tRNAGly from the A to P site 
of the ribosome and entry of the prolyl-tRNA in the A site; (IV) 2A conformation 
inhibits the nucleophilic attack by the prolyl-tRNA amide nitrogen upon the 
peptidyl(2A)-tRNAGly carbonyl carbon, allowing the hydrolysis of peptidyl(2A)-
tRNAGly ester linkage; (V) release of the nascent peptide; (VI) translocation of the 
prolyl-tRNA to the P site, as if the synthesis of the peptide bond has occurred, and 
continuation of translation. To better understand this auto-processing activity of 2A 
peptide, it is important to note that the cleavage occurs only when the N-terminal amino 
acids of the downstream protein is a Pro (Figure 1.26) (Donnelly et al., 2001b). 
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Figure 1.26. Mechanism of action of 2A peptide (Donnelly et al., 2001b). 
 
1.5.4 Self-processing peptide or “CHYSEL” technology 
Usually within an expression vector it is possible to clone only one gene, in 
addition to those already present in its backbone (i.e. gene to confer antibiotic 
resistance). However sometimes it could be useful to co-express more than one gene 
using a single vector: for example a reporter gene to detect the expression of a 
therapeutic one, the two chains of an antibody, different chains of complex proteins. 
During the 1980s many strategies have been used to try to obtain the co-expression: 
insertion of splicing sites, usage of multiple promoters, fusions of proteins, insertion of 
sites for proteases, re-initiation of translation, insertion of IRES (Internal Ribosome 
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Entry Site) (de Felipe, 2002). All these strategies showed problems that in many cases 
prevented their utilization and, during the 1990s, they were abandoned in favour of the 
IRESs. 
IRES is a nucleotide sequence that binds ribosomes and allows a cap-independent 
translation initiation, with  a translation initiation starting inside a mRNA. Basically, in 
a single transcriptional unit there are two different sites of translation initiation: 
translation of the first ORF is cap-dependent, while translation of the second ORF 
depends on IRES. The main problem with this method is that the level of expression of 
the gene downstream of the IRES is often low and difficult to predict; moreover IRES 
sizes are quite large, similar to that of a promoter, and therefore is difficult to use in 
small viral vectors such as AAVs (de Felipe, 2002; Martinez-Salas, 1999). 
During the last 20 years 2A peptide derived from FMDV or from other 
picornaviruses (Equine rhinitis A virus, Porcine Teschovirus-1, Thosea asigna virus 
(Osborn et al., 2005)) has been used for a wide range of biotechnological applications, 
in which there is the need to co-express two or more proteins from a single ORF. For 
this purpose, it seems to work better than other methods used before because it allows 
the production of the proteins at similar levels, it does not cause interference in the 
expression, and moreover it is very short, taking up only a minimal part of the cloning 
capacity of the vector. The mechanism is simple: the sequence of 2A, together with the 
N-terminal proline of 2B FMDV protein, is cloned in frame between the two genes of 
interest; transcription produces a single mRNA while after translation the upstream 
protein remains fused to the 2A and the downstream protein has only an additional 
proline at its N-terminus (Figure 1.27). These peptides have been renamed self-
processing peptides or CHYSELs (Cis-acting Hydrolase ELement) (de Felipe, 2004). 
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Figure 1.27. Schematic representation of the activity of 2A peptide. 
 
During the last years several works have been published showing that 2A peptide 
can be successfully used to: co-express proteins from plasmid and from viral vectors 
such as retroviruses (Szymczak et al., 2004), adeno-associated viruses (Fang et al., 
2005), and adenovirus (Funston et al., 2008); produce proteins both in eukaryotic cell 
lines, plants (El Amrani et al., 2004) and animals such as mice (Szymczak et al., 2004; 
Trichas et al., 2008), chickens (Verrier et al., 2011), pig (Deng et al., 2011) and 
zebrafish (Kim et al., 2011); produce proteins that effectively reach the desired sub-
cellular localization (cytosol, nucleus, mitochondria, endoplasmic reticulum, Golgi 
apparatus, plasma membrane) or the extra-cellular compartment (de Felipe and Ryan, 
2004); produce proteins that fold properly, assemble into active complexes or dimerize. 
For example between the proteins expressed with this method there are the two subunits 
of IL-12 (Chaplin et al., 1999; Fang et al., 2005), the murine antihuman-EGFR 
(Epidermal Growth Factor Receptor) 14E1 (Ho et al., 2009). To date, the most complex 
2A-based construct is CD3&-2A-CD3'-2A-CD3%-2A-CD3( that allows the co-
expression of the four transmembrane proteins of the CD3 complex. This constructs was 
co-express with TCR!-2A-TCR#, encoding for the two chains of the T-cell receptor 
(TCR). Both the CD3 and the TCR subunits were properly expressed and assembled, 
producing a functional TCR-CD3 complex in mice (Szymczak et al., 2004). 
Upstream Protein 2A peptide Downstream Protein 
NPG/P 
One 
mRNA 
NPG 
 P 
Protein1 
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2. MATERIALS AND METHODS 
 
Constructs 
2A containing plasmids 
pr1-2A-P-pr2 plasmids were obtained starting by pr1 and pr2 encoding plasmids 
already presents in the laboratory; F2A-P and T2A-P sequences were inserted 
downstream of pr1 and then pr2 sequence was inserted downstream of pr1-F2A-P and 
pr1-T2A-P plasmids. 
L-2A-H encoding plasmid was obtained by amplification with the appropriate 
restriction sites of L and H sequences, then inserted in place of pr1 and pr2 sequences. 
L-fur-2A-H encoding plasmid was obtained by insertion of fur-2A sequence in 
place of 2A sequence. 
2A-P* plasmid was obtained by inserting an oligonucleotide encoding a STOP 
codon in place of pr2 sequence. 2A* plasmid was obtained deleting the Pro codon by 
PCR using the QuikChange Site-Directed Mutagenesis Kit (Stratagene), starting from 
2A-P* plasmid. 
2A-P-roTag* plasmid was obtained by inserting an oligonucleotide encoding 
roTag (SISSSIFKNEG)-STOP in place of STOP codon. 2A-roTag* plasmid was 
obtained deleting the Pro codon by PCR using the QuikChange Site-Directed 
Mutagenesis Kit, starting from 2A-P-roTag* plasmid. 
EGFP-2A-P* and EGFP-2A* plasmids were obtained by amplification with the 
appropriate restriction sited from a plasmid already present in the laboratory of EGFP, 
then inserted in place of pr1 in 2A-P* and 2A* plasmids. 
Cyt-2A-P* and cyt-2A* plasmids were obtained by inserting an oligonucleotide 
encoding Methionine in place of the secretion signal in 2A-P* and 2A* plasmids. 
2A*(UAA), 2A*(UGA), 2A()G)*, 2A()PG)*, 2A()NPG)*, 2A(G>A)*, 
2A(G>E)*, 2A(G>R)*, 2A(G>W)*, 2A(GGA)*, 2A(GGC)*, 2A(GGG)*, 2A(GGT)*, 
2A()P)*, 2A()NP)*, 2A()G)-P-roTag*, 2A(P>A)-P-roTag*, *2A-P*, *2A*, 
*2A()N6)*, *2A()N5)*, *2AMUT-P*, and *2AMUT* plasmids were obtained by PCR 
using the QuikChange Site-Directed Mutagenesis Kit. 
2A()N3)*, 2A()N4)*, 2A()N5)*, 2A()N6)*, 2A()N7)*, and 2A()N15)* 
plasmids were obtained by inserting oligonucleotides encoding the corresponding N-
terminal deletion versions of 2A in place of full length 2A in 2A* plasmid. 
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2AMUT-P* plasmid was obtained by inserting an oligonucleotide encoding 2A-P 
with the mutated codons in place of 2A-P wild type sequence in 2A-P* plasmid. 
2AMUT* was obtained by by PCR using the QuikChange Site-Directed Mutagenesis Kit 
starting from 2AMUT-P* plasmid. 
fur-2A-P* and fur-2A* plasmids were obtained by inserting an oligonucleotide 
encoding for the furin cleavage site before 2A sequence. 
glyc-2A-P* and glyc-2A* plasmids were obtained by inserting an oligonucleotide 
encoding for the N-glycosylation site and the biotin acceptor peptide BAP 
(GLNDIFEAQKIEWHE, (Beckett et al., 1999)) before 2A sequence. 
 
Null Hong Kong !1 anti-trypsin 
The cDNA for the human !1-antitrypsin (!1AT, accession number K01396) was 
PCR amplified from RNA extracted from anonymous healthy donors lymphocytes and 
inserted into pcDNA3 expression vectors (Invitrogen) between the coding sequences for 
a secretion signal at the N-terminus, and the SV5 tag (GKPIPNPLLGLD) and the BAP 
at the C-terminus (pcDNA-!1AT-BAP). The vector expressing the NHK mutant of 
!1AT (Sifers et al., 1988) was generated by substituting the wild type !1AT sequence 
in the pcDNA-!1AT-BAP vector with a sequence containing a two-base deletion after 
codon 318 of the mature protein resulting in the insertion of 14 frame-shifted codons 
(pcDNA-NHK-!1AT-BAP).  
 
Tetherin 
Human Tetherin was tagged with SV5 and BAP immediately upstream of the 
GPI-anchor signal (Tetherin-BAP) and cloned into pcDNA3. Tetherin with the 
membrane proximal BAP (12 amino acids from transmembrane domain, BAP-Tetherin) 
was obtained by inserting the BAP-tag after Ala48. 
 
NS1 
NS1-BAP and BAP-NS1 plasmid were generated amplifying NS1 sequence 
(kindly provided by Linda Hendershot) cloning it in pcDNA3 vector codifying an 
immunoglobulin leader peptide, upstream the coding sequence for the BAP and SV5 tag 
or in between the two tags. 
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Other plasmids 
OTU plasmid was provided by Adolfo Garcìa-Sastre (The Mount Sinai Hospital). 
ATF6DN and ATF6ACT plasmids were provided by Kazutishi Mori (Kyoto University). 
p97 and p97QQ plasmids were provided by Linda Hendershot (St. Jude Children's 
Research Hospital). YOD1 and YOD1 C160S plasmids were provided by Christian 
Schlieker (Yale University). 
 
Cell culture and transfection 
HEK293T cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (FCS). HEK293T cells were transfected or, 
where indicated, co-transfected in 6-well plates (about 5x105 cells/well) by standard 
calcium phosphate technique. 
For 2A experiments, 18 hours after transfection medium was discarded and 
replaced by 2 ml of serum free medium. When required, the autophagy inhibitor 
Chloroquine (Sigma) or the proteasomal inhibitor MG132 (Sigma) were added at a 
concentration of 50 *M for 4 hours, or at 5 *M for 16 hours. When required, the 
translation inhibitor Cycloheximide was added at a concentration of 100 *g/mL for the 
indicated period of time. 
For retrotranslocation experiments, 18 hours after transfection medium was 
discarded and replaced by 2 ml of medium supplemented with 0.1 mM biotin and 
further incubated for at least 8 hours. When required, after 4 hours incubation with 
biotin, the proteasome inhibitors MG132 was added at a concentration of 15 µM for 3 
hours. 
CHO cells were grown in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 10% FCS. CHO were transfected in 6-well plates (about 5x105 
cells/well) by lipofection with LipofectaminTM 2000. 
 
Cell extracts, gel retardation assays and Western blotting 
After medium collection HEK293T transfected cells were washed with PBS to 
remove free biotin, harvested, and lysed directly in Eppendorf tube with 100 µl/sample 
of SDS-lysis buffer (100 mM Tris-HCl, pH 6.8, 6% SDS) and subsequently sonicated to 
disrupt nuclear DNA. For retrotranslocation experiments, cells were washed with 30 
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mM N-ethylmaleimide (NEM) (Fluka) in PBS and lysed in SDS buffer containing 30 
mM NEM. 
Proteins were separated by standard SDS-PAGE in reducing (25 mM Tris-HCl, 
pH 6.8, 1% SDS, 10% glycerol and 175 mM b-mercaptoethanol) or non-reducing SDS-
gel-loading buffer (25 mM Tris-HCl, pH 6.8, 1% SDS, 10% glycerol), before to be 
transferred to PVDF membranes. 
For gel retardation assays, samples denatured in SDS-gel-loading buffer were 
boiled for 10 min, cooled to room temperature, and incubated with 1 µg of Streptavidin 
(StrAv, Sigma) for 20 minutes before separation on SDS-PAGE, and transfer to PVDF 
membranes. 
Gels were transferred to PVDF membranes for immunodetection with anti-SV5 
mAb or anti-roTag followed by incubation with HRP-labeled anti-mouse whole IgG 
(Jackson) and ECL reaction. Western Blot (WB) of rabbit anti-actin (Sigma) was used 
as loading control. WB of mouse anti-p97 (BD Bioscience) was used to verify 
overexpression of p97. Quantification of bands was performed with the image 
processing software Image-J 1.43u (National Institutes of Health, USA). 
 
ELISA 
Polystyrene microplates (Nunc Maxisorp C96) were coated with antigen in buffer 
NaHCO3-Na2CO3 50 mM, pH 9.5 (100 ml/well. After 1 hour incubation at 37°C, 
supernatants of transfected cells or mice sera were added and, after incubation, reacted 
with either HRP-labeled anti-mouse whole IgG. Reaction was developed with TMB 
reagent (Sigma); after blocking with H2SO4, the O.D. at 450 nm was read on a BioRad 
microplate reader 550. 
 
RNA isolation, RT-PCR, and qRT-PCR 
Total RNA from HEK293T cells was isolated with RNeasy mini Kit (Qiagen) 
following manufacturer’s instructions. DNA was removed from isolated RNA by 
treatment with RNAse-free DNAse I (Fermentas Inc, Massachusetts, USA). Total RNA 
was retro-transcribed to cDNA by Moloney murine leukaemia RT (M-MLV-RT) in the 
presence of random hexamers (IDT). qRT-PCR was based on SYBR Green Master Mix 
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(applied Biosystems) technology; the levels of target gene expression were normalized 
to GAPDH and !Globin expression levels. 
 
[35S]-Methionine labelling  
Cells were first starved for 30 minutes in Methionine/Cysteine free medium 
supplemented with 10% dialyzed FCS, then labeled for 15 minutes with 200 µCi/ml of 
[35S]-Methionine/Cysteine (Perkin Elmer). Cells were lysed in 100 µl of SDS-lysis 
buffer, diluted with 400 µl of TNN and digested with DNaseI (Promega) for 1 hour at 
37°C. SV5-tagged proteins were immunoprecipitated with anti-SV5 and Protein A-
agarose (Repligen), eluted by boiling in SDS-lysis buffer and samples were resolved on 
a reducing SDS-PAGE. Gels were fixed in 10% acetic acid and 10% methanol, 
incubated for 20 minutes in Amplify fluorographic enhancer (GE Healthcare), dried and 
exposed for autoradiography on Kodak BioMax XAR films. 
 
Silencing 
HEK293T cells were grown in 12-wells plates. Irrelevant anti-p97 siRNAs 
(Sigma) were transfected with Lipofectamine RNAiMAX reagent (Life Technologies) 
according to manifacturer’s instruction. 72 hours post siRNA transfection medium was 
discarded and replaced by 10% FCS supplemented medium, and DNA was transfected 
by standard calcium phosphate procedure. 24 hours post DNA transfection cells were 
lysed as already described. 
 
Sucrose gradient centrifugation 
107 HEK293T cells were harvested and dropped into a flask containing 30% of 
the cell suspension volume of medium frozen at -20ºC. Cells were washed and collected 
by centrifugation at 1000 rpm for 10 minutes at 4ºC. Cells were then resuspended in a 
hypotonic buffer (10mM Tris-HCl pH7.4, 10mM KCl, 1mM Mg Acetate, made up in 
DEPC treated water) and leaved at 4ºC for 10 minutes. An equal volume of a solution of 
70mM Tris-HCl pH 7.4, 150 mM KCl, 100 mM NH4Cl, 7mM Mg Acetate, 10 mM 
DTT and 0.5% NP40 was added to the cell suspension and leaved for 10 minutes at 4ºC. 
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Cells were centrifuged at 5000 rpm for 10 minutes at 4ºC and the supernatant was 
collected for analysis on sucrose gradients. 
Linear gradients of 15% to 40% sucrose were made in Tris-HCl 10 mM pH 7.4, 
KCl 50 mM, Mg Acetate 5mM buffer in 5 ml tubes of a SW 55 swinging rotor. 
Cell lysate was loaded on the top of the gradient and centrifuged for 45 minutes at 
45000 rpm at 4ºC. Gradient was then manually divided into 15 fractions. 
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3. RESULTS 
 
3.1 Analysis of 2A peptide activity 
A common strategy of some positive-strand RNA viruses is to encode their 
proteins in a single transcript, which upon translation produces a polyprotein, whose 
cleavage is often mediated by proteases included in the same polyprotein. In the case of 
Picornaviruses, however, the polyprotein encodes also for an alternative mechanism and 
undergoes a primary co-translational cleavage between domains containing the capsidic 
and the replicative proteins: this alternative primary cleavage is mediated by the so-
called 2A region of the polyprotein (Ryan and Flint, 1997). 
In some members of the Picornavirus family, such as the Foot-and-Mouth Disease 
Virus (FMDV), the 2A region consists in a short peptide of about 18-19 amino acids. 
This peptide, together with the N-terminal residue of the 2B protein (proline, Pro) 
immediately downstream, it is an autonomous element capable of mediating its self-
processing at the C-terminus during translation. Thus, there is release of the upstream 
peptide without a true termination of translation, in the sense that the ribosome does not 
dissociate and resumes translation from the Pro immediately downstream, the first 
amino acid of the 2B protein: we call this property “non-conventional translation 
termination”. For the activity of the 2A peptide, both the Asn-Pro-Gly residues at its C-
terminus and the Pro residue at the N-terminus of the downstream protein are essential 
(Donnelly et al., 2001a; Donnelly et al., 2001b). 
Several studies, describe in paragraph 1.5.3, were done in the 90s to elucidate the 
features of this peptide’s action. One of the main limitations of these studies is the usage 
of two different proteins as upstream and downstream reporters: in this way differences 
in the amount of the two proteins could not be ascribed only to the peptide action, but 
also to a different half-life or mRNA translatability. 
In this work we decided to overcome this limitation and to study 2A activity using 
a simple system. We built a basic bicistronic vector, in which the same reporter, a 
secretory protein therefore synthesized on membrane-bound ribosomes was put 
upstream (protein1, pr1) and downstream (protein2, pr2) of 2A peptide. The reporter 
protein was an SV5-tagged scFv. Because 2A remains fused to the upstream protein it is 
possible to discriminate the two proteins by their different molecular masses. Since in 
literature several 2A peptides, derived from different viruses, have been described we 
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decided to compare two different peptides, one derived from the Food-and-Mouth 
Disease Virus (FMDV – F2A peptide) and one from the Porcine Teschovirus (PT – 
T2A peptide) to look for possible differences in their activities. The F2A used contained 
the last 5 amino acids of VP1 (C-terminal part of P1) followed by the 18 amino acids of 
2A: this 23 amino acids-long oligopeptide was shown to be more efficient than F2A 
alone in driving expression of the two proteins upstream and downstream of 2A 
(Donnelly et al., 2001a) (Figure 3.1).  
Figure 3.1 Bicistronic vector. Scheme of the bicistronic vector and sequences of the 2A peptides 
used. 
 
We transfected the human cell line HEK293T with pr1-F2A-P-pr2 or pr1-T2A-P-
pr2, and we analysed by Western Blot (WB) the supernatants. As shown in figure 3.2A 
both 2A peptides performed a very efficient STOP-codon independent translation 
termination, as indicated by the absence of a pr1-2A-pr2 fusion product, while re-
initiation of translation from P was not completely efficient, as indicated by the lower 
amount of pr2 in relation to pr1. Quantification of the amount of pr2 relative to pr1 
showed that F2A was more efficient than T2A in resuming translation: while pr2 after 
F2A was around 60% compared to pr1, after T2A it was only 40%. Similar results were 
obtained by transfecting the hamster cell line CHO (Figure 3.2B): also in this case 
fusion product was undetectable and re-initiation of translation was more efficient by 
using F2A. In both cases the ratio protein1/protein2 was higher in CHO than in 
HEK293T: pr2 after F2A was around 85% compared to pr1, while after T2A was 50%. 
Taking into account these results we decided to adopt peptide F2A for all future 
experiments. 
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Figure 3.2 Analysis of 2A peptide activity. (A) WB of supernatants of HEK293T cells transfected 
with pr1-F2A-P-pr2 or pr1-T2A-P-pr2 and quantification. Three independent experiments are 
shown. (B) Same as (A) in CHO cells. 
 
3.1.1 2A peptide system: biotechnological application 
We decided to exploit the 2A peptide system to produce a full antibody (Ab) 
molecule, which consists of two identical light chains (L) and two identical heavy 
chains (H) linked by disulphide bridges (H2L2). We built a vector in which the L chain 
was placed upstream F2A, and the H chain downstream (Figure 3.3.A, construct 2). 
This design was chosen because the downstream protein, as shown in figure 3.2, is 
produced at a lower level that the upstream one. It is well known that H chains, when 
produced in excess of the L chains, cannot be secreted and become toxic to the cell, 
while excess L chains are secreted and do not produce toxicity (Kohler, 1980). 
Therefore it is desirable to have an excess of L instead of H chains. We also made an 
improvement on the vector by adding a furin cleavage site (fur) between the light chain 
and peptide 2A (Figure 3.3A, construct 3). Furin is an enzyme localized in the Golgi 
apparatus that cleaves proteins downstream of a four basic amino acid target sequence 
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(Arg-X-(Arg/Lys)-Arg) (Barr, 1991; Duckert et al., 2004). In this way, furin cleavage in 
the Golgi allowed expression of the L chain free of the 2A peptide. 
First, we checked the expression of L and H chains from construct 2 and 3, using 
as a control a co-transfection of two vectors (Figure 3.3A, construct 1), one encoding 
the L and one the H chain. As shown in figure 3.3B, L and H chains were very well 
produced, folded and secreted; however, furin was not able to completely cleave 2A 
from the L chain, resulting in two bands when samples were run in reducing condition 
(lane 3, reducing). Then, we analysed the capability of the antibodies produced with the 
three different systems to recognize its antigen by ELISA: all three of them were similar 
in their recognition ability (Figure 3.3C). 
 
Figure 3.3 Production of a full antibody in HEK293T cells. (A) Scheme of the vectors used in the 
study. (B) WB of supernatants of HEK293T cells transfected with the vector indicated in panel (A) 
and run in reducing or non-reducing conditions. (C) Graphic representation of antigen recognition 
by the antibody obtained by ELISA. 
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We then moved to analyse the expression of the antibody in vivo. We built an 
Adeno-Associated Viral Vector encoding for the full antibody that was then packaged 
into infective recombinant AAV (rAAV) particles. 
Adeno-Associated Virus (AAV) is a small, non-enveloped Parvovirus with a 
linear single-stranded DNA genome of 4700 nucleotides. It is a dependovirus, because 
it can cause a productive infection only in the presence of a helper virus. In the absence 
of a helper virus, it remains in an episomal form and only rarely can integrate site 
specifically into the human chromosome 19 establishing latency. AAV is an attractive 
viral vector fore several reasons: it can infect both dividing and non-dividing cells; it 
does not randomly integrate into the host cell genome and remains in an episomal form; 
it can transduce in vivo a wide range of tissues, depending on the serotype (brain, liver, 
muscle, lung, retina, cardiac muscle); it can initiate long-term gene expression in those 
tissues; it does not express any viral proteins, while the vector contains only the two 
ITRs (Inverted Terminal Repeat), cis-acting elements necessary for the packaging, 
therefore not immunogenic; and it do not cause inflammation. Furthermore, wild-type 
AAVs do not cause any known disease and do not stimulate cell-mediated immune 
response (Daya and Berns, 2008; Giacca, 2010; Li et al., 2005) 
CsCl purified rAAV was then injected into the tibial muscle of mice. Sera were 
collected for almost one year and, after having sacrificed mice, we collected the tibial 
muscle. As shown in figure 3.4A, the antibody was produced from the rAAV infected 
cells, was circulating in the sera and able to recognize its antigen for a long period of 
time; of course, after having sacrificed the mice, we still found the antibody in the 
injected muscle (Figure 3.4B) 
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Figure 3.4 Production of antibody in vivo. (A) Graphic representation of sera reactivity obtained 
by ELISA using antigen-coated plates. (B) Non-reducing WB of extracts prepared from the muscle of 
three different mice (1, 2, 3) injected with the rAAV encoding the full antibody. 
 
These experiments demonstrate that 2A peptide is a valid method to produce complex 
proteins through only one vector encoding a single mRNA. It represents a general 
strategy for passive gene-based immunisation with therapeutic antibody, as well as 
molecules composed by more that one protein. Administration through a rAAV, 
moreover, allows the expression of the protein for a long period of time. In the case of a 
therapeutic antibody, this strategy might be very useful to avoid a frequent 
administration of the antibody protein, which can be replaced by a single administration 
of the protein-encoding vector. 
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3.2 Imposing conventional termination on 2A heavily impairs expression of 
upstream protein. 
While comparing expression efficiency of proteins upstream and downstream of 
2A we designed a monocistronic genetic construct containing the reporter secretory 
protein (SV5-tagged scFv) followed by F2A and a STOP codon (UAG,*) immediately 
after the 2A terminal Gly-codon (construct 2A*. Figure 3.5A, left panel). In this 
construct translation termination of the reporter polypeptide was conventional, that is to 
say STOP codon-mediated. We also designed a second monocistronic construct with a 
Pro-codon (that is the first amino acid after 2A in the virus) after the 2A terminal Gly-
codon and the STOP (construct 2A-P*. Figure 3.5A, right panel). In this case translation 
termination was expected to be non-conventional, that is non-mediated by the STOP 
codon. We found, however, that termination in construct 2A-P* was not entirely non-
conventional. Mass spectrometry analysis of the secreted product showed that it 
terminated both in NPG (non-conventional termination) and in NPGP (conventional 
termination) in a ratio of around 1.5:1, thus indicating that although non completely, a 
substantial proportion underwent non-conventional termination. 
When the two constructs (2A* and 2A-P*) were transfected into HEK293T cells 
they performed, surprisingly, very differently in their ability to produce the pr-2A 
polypeptide. As shown in figure 3.5B, while the protein obtained from construct 2A-P* 
was produced in large amounts and very well secreted, extremely low levels (less than 
1%) were produced from construct 2A*. 
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Figure 3.5 Expression analysis of pr-2A-P* and pr-2A*. (A) Scheme of the monocistronic vectors 
used in the study. (B) WB of supernatants and cell extracts of HEK293T cells transfected with pr-2A-
P* and pr-2A*. 
 
This dramatic effect of 2A on the expression of the upstream protein was only 
apparent in the context of conventional termination (2A*) and not in non-conventional 
one (2A-P*), as the presence or absence of the Pro-codon was the only difference 
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presence of a STOP-codon immediately downstream of the 2A terminal Gly-codon that 
heavily compromised expression of the upstream protein, since high expression levels 
were obtained when the next codon after 2A was Pro or when it was a codon different 
from Pro, which caused no termination and fusion with the downstream roTag. 
 
 
 
 
 
 
 
Figure 3.6 Expression analysis of 2A-P-
roTag* and 2A-roTag*. WB of cell 
extracts of HEK293T cells transfected with 
2A-P-roTag* and 2A-roTag*. The same 
samples were developed with anti-SV5 mAb 
(left panel) and anti-roTag (right panel). 
 
The strong effect on the levels of pr-2A produced from conventional termination 
was not dependent on the sequence of the upstream protein, nor on being synthesised on 
membrane bound ribosomes. In fact the same effect was obtained by using as reporter 
cytosolic proteins (translated from free ribosomes), either EGFP (Figure 3.7A) or the 
same scFv lacking the secretory leader peptide (Figure 3.7B). Moreover, the effect was 
not the consequence of the STOP codon used, as the same expression impairment was 
obtained when UAG was changed to UAA or UGA (Figure 3.7C). 
These findings led us to the conclusion that this effect was exclusively dependent 
on 2A peptide. 
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Figure 3.7 Expression analysis of 2A-P* and 2A*. WB of cell extracts of HEK293T cells 
transfected with (A) EGFP-2A-P* and EGFP-2A*, (B) cyt-2A-P* and c-2A*, (C) 2A-P* and three 
different 2A* each one terminating with one of the STOP codons (UAG, UAA and UGA). 
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in conventional termination reflects properties also relevant for its activity in non-
conventional termination.  
 
 
 
 
 
 
Figure 3.8 Mapping the N-terminal 2A. WB 
of cell extracts of HEK293T cells transfected 
with the N-terminal deletion mutants 
2A($N3)*, 2A($N4)*, 2A($N5)*, 2A($N6)*, 
2A($N7)* and 2A($N15)*. 
 
We then investigated the role of the 2A C-terminal residues. In contrast to the 
strong effect observed with full-length 2A (ending in NPG*), C-terminal deletion 
mutants lacking the last three, two or one amino acids [2A(+NPG)*, 2A(+PG)* and 
2A(+G)*, respectively] allowed protein expression from 2A* (Figure 3.9A). Also 
mutation of the last Gly in a different amino acid (A, E, R, or W) fully restored protein 
expression (Figure 3.9B). Furthermore, the effect was due to the G residue itself rather 
than the G codon, since all four different ones (GGU, GGC, GGA and GGG) showed 
similar impaired protein expression (Figure 3.9C) suggesting that the effect was due to 
the amino acid itself rather than the mRNA sequence. In addition, deletion of only Asn-
Pro or Pro while maintaining the terminal Gly [2A(+NP)* and 2A(+P)*] also restored 
expression (Figure 3.9D). 
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Figure 3.9 Mapping the C-terminal 2A. WB of supernatants (A and B) and cell extracts (C and D) 
of HEK293T cells transfected with (A) 2A* and the C-terminal deletion mutants 2A($NPG)*, 
2A($PG)* and 2A($G)*, (B) 2A* and the C-terminal mutants 2A(G>A)*, 2A(G>E)*, 2A(G>R)* 
and 2A(G>W), (C) four different 2A* each one terminating with one of the Gly-encoding codons 
(GGA, GGC, GGG and GGT). (D) 2A* deletion of only NP or P while maintaining the terminal G 
[2A($NP)* and 2A($P)*] 
 
Interestingly, as previously mentioned, NPG C-terminal amino acids are essential 
for 2A activity on non-conventional termination. Indeed, deletion of G in construct 
2A("G)-P-roTag* or substitution of P (from NPG) with A in construct 2A(P>A)-P-
roTag, completely abrogated non-conventional termination, producing only the product 
fused to roTag, as demonstrated by the presence of a single band detected with anti-
SV5, of the same molecular mass than the one detected with anti-roTag (Figure 3.10). 
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Figure 3.10 Analysis of C-terminal 2A mutants 
activity in non-conventional termination. WB of 
cell extracts of HEK293T cells transfected with 
2A($G)-P-roTag* and 2A(P>A)-P-roTag*. 
 
Taken together these data indicated a key role for the terminal residues NPG both 
in non-conventional as well as in conventional termination yet with totally opposite 
effects. While NPG are absolutely required for 2A non-conventional termination, 
therefore allowing expression of protein1, their presence strongly inhibits protein1 
expression in the context of stop codon-mediated termination. 
 
3.2.2 Translationality of the mRNA is not compromised 
The possibility that the difference in expression of the upstream protein between 
constructs 2A* and 2A-P* was due to intrinsic instability or compromised translability 
of the 2A* mRNA was also investigated. First, differences in the relative mRNA levels 
was ruled out by real time quantitative RT/PCR: mRNA levels was almost the same 
both if normalized to the housekeeping gene GAPDH, or to a co-transfected control 
plasmid encoding !Globin (Figure 3.11A). 
Thus, compromised expression of upstream protein was most likely a direct 
consequence of impaired conventional termination of the newly synthesised peptide 2A 
at the Gly* site. Indeed, addition of a STOP-codon just upstream of the complete or 
partial 2A sequences (constructs *2A-P*, *2A*, *2A(+N6)*, and *2A(+N5)*), that is 
maintaining the same nucleotidic sequence but excluding 2A from translation, resulted 
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in all cases in normal and similar protein expression levels (Figure 3.11B and 3.11C), 
indicating that mRNA stability was not involved. To further exclude the involvement of 
the nucleotidic sequence in the impairment of expression, we built a construct encoding 
the same 2A peptide with all codons mutated (2AMUT*), which was as inhibitory as the 
one with wild type codons, while the construct containing 2AMUT followed by Pro 
(2AMUT-P*) was not (Figure 3.11D). As expected, also in this case a stop codon 
positioned upstream of 2AMUT (constructs *2AMUT* and *2AMUT*-P) abrogated 
inhibition (Figure 3.11E). The same conclusion was supported when using the Porcine 
Teschovirus 2A peptide (constructs T2A* and T2A-P*), that have only five residues 
different from FMDV; also in this case the effect was comparable to the one derived 
from FMDV (Figure 3.11F) 
Collectively, the data presented indicate that the cause of impaired protein 
expression from 2A* resides exclusively on imposing stop codon-mediated termination 
at the C-terminus of peptide 2A, on the length of the peptide, and on the NPG amino 
acids at the C-terminus.  
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Figure 3.11 Analysis of 2A nucleotidic sequence. (A) mRNA expression, normalized with the 
housekeeping gene GAPDH or with the co-transfected vector encoding aGlobin, of 2A-P* and 2A* 
as revealed by real-time PCR. WB of cell extracts of HEK293T cells transfected with (B) 2A-P* and 
2A* and their mutants carrying a STOP codon upstream 2A (*2A-P* and *2A*), (C) 2A($N5)* and 
2A($N6)* and their mutants carrying a STOP codon upstream 2A (2A*($N5)* and 2A*($N6)*), (D) 
2A-P* and 2A* with 2A encoded by the wild type (WT) or the mutated (MUT) nucleotidic sequence, 
(E) 2AMUT-P* and 2AMUT* and their mutants carrying a STOP codon upstream 2A (*2AMUT-P* and 
*2AMUT*), (F) T2A-P* and T2A* with 2A peptide derived from Porcine Teschovirus. 
 
3.2.3 Protein from 2A* is degraded by the proteasome 
Once produced, both proteins expressed from 2A-P* and from 2A* seems to have 
a similar intracellular half-life, as indicated by treatment with the translation inhibitor 
cycloheximide (CHX, figure 3.12). However, by analysing also the supernatants, it is 
evident that it is not true, because protein from 2A-P* is actively secreted, whereas 
protein from 2A* is not secreted and therefore degraded.  
 
Figure 3.12 Analysis of proteins half-life. WB of supernatants and cell extracts of HEK293T cells 
transfected with 2A-P* or 2A* in absence (-) or presence of CHX for the periods of time indicated. 
1% of cell extract was loaded for 2A-P* and 10% for 2A*. Cell extracts and supernatants at the 
point (-) represents the material accumulated after 1 day of transfection. 
 
We decided to investigate the fate of 2A* product, and in particular if it was 
degraded by the proteasome by using the proteasome inhibitor MG132, or by the 
autophagy pathway by using the autophagy inhibitor chloroquine (CQ). As shown in 
figure 3.13A and B, a strong accumulation of material was observed after MG132 but 
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not after CQ treatment, indicating that the small amount of protein released from the 
stalled ribosomes was degraded by the proteasome. 
To further confirm the involvement of the Ubiquitin-Proteasome System (UPS) in 
the degradation of protein from 2A*, we analysed the effect of co-expression of the 
viral cytosolic deubiquitinase-like protein OTU (derived from the Congo Hemorragic 
Fever Virus). OTU deubiquitinates cytosolic polyubiquitinated proteins targeted to 
degradation (including ERAD substrates), making them unable to be engaged by the 
proteasome. As shown in figure 3.13C, overexpression of OTU caused an accumulation 
of protein from 2A*. 
Notably, inhibition of proteasomal degradation both with MG132 and OTU did 
not restore the expression of protein from 2A* at the same level of that from 2A-P*. It 
was therefore concluded that degradation was not the only reason of the very small 
amount of protein from 2A* compared to 2A-P* 
 
Figure 3.13 Analysis of protein degradation. WB of cell extracts of HEK293T cells transfected with 
2A-P* or 2A* in absence (-) or presence of (A) autophagy inhibitor chloroquine (50%M for 4 hours); 
(B) proteasomal inhibitor MG132 (5%M for 16 hours); and (C) viral deubiquitinase OTU. 
 
3.2.4 Ribosomes stalling at the termination site 
It has been described that while performing its physiological activity, peptide 2A 
causes a transient stalling of ribosomes at the non-conventional termination site, to 
allow re-orientation and release of the nascent peptide and continuation of translation. 
We reasoned that a possible cause of the impaired expression of protein from 2A* could 
be an excessively prolonged stalling, that could not be “resolved” because of the 
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absence of a Pro-codon and, as a consequence, of the tRNAPro. To address this question 
we performed three different types of experiments. 
In one set of experiments we investigated the localization of protein produced 
from 2A* in comparison to that from 2A-P*. If the hypothesis of prolonged stalling was 
true, protein from 2A* should remain bound to ribosomes and therefore unable to be 
completely translocated to the Endoplasmic Reticulum (ER) lumen. To prove this, we 
modified our construct in two different ways to be able of determine its localization. In 
the first case, a furin (fur) cleavage site was inserted between the SV5 tag and the 2A 
peptide (constructs fur-2A-P* and fur-2A*, figure 3.14 left panel). Since furin is an 
enzyme located in the Golgi, cleavage indicates that the examined protein is following 
the secretory pathway. Cleaved and un-cleaved proteins could be discriminated by their 
different sizes. 
In the second case an N-glycosylation site (Asn-Gly-Ser, NGS) was inserted 45 
residues upstream of the stop codon (constructs glyc-2A-P* and glyc-2A*, figure 3.14 
right panel). Taking into account that Ribosomal Exit Tunnel (RET) comprises 30-35 
amino acids and the translocon around 20, and that the minimal length between the 
ribosomal Pepeptidil Transferase Centre and the N-glycosylation site needed to allow 
glycosylation is of around 70 amino acids, we expected the polypeptide to be 
glycosylated only upon release into the ER lumen following release from the ribosome. 
In contrast, if the ribosome gets stalled with the 2A peptide interacting with RET, the 
NGS sequence would not be available and the protein would not be glycosylated. 
  
Figure 3.14 Monocistronic vectors used to determine the localisation of the proteins produced 
from 2A-P* and 2A*. 
 
As shown in figure 3.15, the two protein products produced from constructs 2A* 
and 2A-P* had completely different localizations. Analysing the pattern revealed by 
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furin cleavage (3.15A), it was clear that protein from fur-2A-P* followed its 
physiological secretory pathway; indeed it was fully cleaved in the supernatant while in 
the cell extract also the non cleaved band was present, reflecting the material that had 
not yet moved through the Golgi. Protein from fur-2A*, instead, was almost completely 
not cleaved and absent in the supernatant, indicating that had not moved through the 
Golgi. 
Consistent with this finding are the results obtained analysing the status of the 
proteins with the glycosylation sites (3.15B). Protein from glyc-2A-P*, as expected 
since it was cleaved by furin, was almost completely glycosylated indicating its 
translocation to the ER lumen. Protein from glyc-2A*, instead, was found mostly un-
glycosylated indicating cytosolic localisation. This band, however, could be the 
consequence of two different processes: I) incomplete translocation into the ER, and 
therefore non-glycosylated, or II) retro-translocation after having entered the ER, as a 
consequence of activation of ER Associated Degradation (ERAD), that results in 
material de-glycosylated by the cytosolic PNGase. 
 
Figure 3.15 Analysis of protein localisation. WB of supernatants and cell extracts of HEK293T 
cells transfected with (A) fur-2A-P* and fur-2A*; and (B) glyc-2A-P* and glyc-2A*; sample loaded 
amount is indicated. 
 
This first set of results confirms our hypothesis of a different intracellular protein 
localization probably as a consequence of ribosome stalling. 
In a second experiment we checked if the proteins from 2A* and 2A-P* were 
produced at the same rate. Cells transfected with the two constructs were pulsed for 15 
minutes with [35S]-Methionine in presence of the proteasomal inhibitor MG132 to avoid 
possible protein degradation, and then the proteins were immunoprecipitated with anti-
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SV5. As shown in figure 3.16, protein from 2A* accumulated during the pulse at a 
lower level than from 2A-P* (7%), consistent with ribosome stalling. The reduction was 
not as much as what was observed by WB, confirming that the much stronger effect 
observed in steady state levels was the consequence of an increased degradation of the 
product. 
 
 
 
 
 
 
Figure 3.16 Pulse labelling of 2A-P* and 2A*. PAGE of [35S]-
Methionine/Cysteine 15 minutes pulse labelling of proteins from 
2A-P* and 2A* produced in HEK293T and immunoprecipitated 
with anti-SV5. 
 
To prove the presence of ribosome stalling at the termination site we produced 
two bicistronic constructs (schematically shown in Figure 3.17) in which protein1 (pr1) 
was produced in both cases following 2A non-conventional termination (2A followed 
by P), while protein2 (pr2, same as pr1 with an extra tag to allow discrimination by 
protein sizes) was produced from either conventional termination (pr2-2A*, construct 
A) or, as a control, from non-conventional termination (pr2-2A-P*, construct B). 
We reasoned that, if ribosomes stall at the stop codon downstream of pr2-2A* 
(construct A, case I), then expression of the upstream pr1 should also be affected. 
Indeed, ribosomes stalled at the stop codon on the mRNA would initially compromise 
production of pr2, but soon after also of pr1. The ribosome at the non-conventional 
termination site, in fact, after release of pr1 will not be able to translate the following 
codon, already occupied by a stalled ribosome. In the absence of ribosome stalling 
(construct A, case II), instead, pr1 would be equally expressed from constructs A and B, 
despite lack of expression of pr2 from construct A. 
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Figure 3.17 Bicistronic vectors used for the analysis of ribosome stalling.  
 
The results in figure 3.18 clearly show that expression of both pr2 and pr1 were 
highly compromised from construct A (lane 7) but not from control construct B (lane 6). 
Expression of protein from pr2-2A* does not interfere per se with the expression of pr1-
2A-P*, as shown in lane 5 where the two construct were co-transfected from two 
different vectors. In lane 6, it is noteworthy that, relative to pr1, pr2 was expressed at a 
lower level than the one shown in figure 3.2. This feature can be explained as the 
addition of two different effects: first, as already described pr2 is always produced at 
lower levels than pr1; and second, pr2 with the extended roTag (pr2-roTag-2A-P) is per 
se expressed (from a monocistronic construct) at a slightly lower lever than pr1 (see 
lane 4). In spite of this, comparison of lanes 6 and 7 clearly show that in construct A the 
decreased expression of pr2 did not have an effect on pr1 expression, while in construct 
B pr1 expression was heavily compromised, consistent with a prolonged ribosome 
stalling at the stop codon. 
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Figure 3.18 Ribosome stalling analysis. WB analysis of cell extracts of HEK293T cells transfected 
with the indicated single or combined constructs. 
 
3.2.5 Unfolded Protein Response (UPR) and 2A* 
One possibility to be considered was whether stalling of ribosomes would trigger 
the UPR. We analysed the possible activation of two of the three main pathway 
involved in this response, and in particular those involving the sensors ATF6 and IRE1. 
To test activation of the IRE1 pathway, we analysed the splicing pattern of its 
substrate XBP1 that is cleaved in response to UPR. As shown in figure 3.19A, the 
amount of spliced XBP1 was comparable in cells not transfected, transfected with the 
control 2A-P* or in those transfected with 2A*, thus ruling out activation of this 
pathway.  
To test involvement of the ATF6 pathway, we co-transfected cells with 2A* and a 
dominant negative ATF6 (ATF6dn) that blocks UPR once activated, or an ATF6 version 
that triggers UPR also in the absence of ER stress (ATF6act) (Haze et al., 1999; Yoshida 
et al., 2000). As shown in figure 3.19B, ATF6act caused a reduction in the expression 
levels regardless of the construct, as expected if UPR was activated, while ATFdn did 
not rescue protein expression from construct 2A*.  
These results indicate that UPR activation appears not to be involved in protein1 
compromised expression. 
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Figure 3.19 Analysis of UPR. (A) RT-PCR amplification of Xbp1 from RNA derived from HEK293T 
cell transfected with empty vector (-), 2A-P* and 2A. (B) WB of cell extracts of HEK293T cells co-
transfected with 2A-P* or 2A* and an empty vector (indicated as -), ATF6act or ATF6dn.  
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3.3 The role of the p97 ATPase activity in ERAD 
The following part has been done in collaboration with a former Ph.D. student in 
the lab, Gianluca Petris. The experiments reported here are those in which I have been 
directly involved, as part of a wider work. 
It is widely known that one of the main players in ER Associated Degradation is 
the AAA-ATPase VCP/p97. It is generally thought that p97 ATPase activity is required 
for retro-translocation and proteasomal degradation, and that its loss causes retention of 
ERAD substrates in the ER lumen. As a consequence, p97 ATPase activity is 
considered essential for extraction of proteins from the ER membranes. 
To study the role of p97 in ERAD, we used a method recently developed in our 
laboratory (Petris et al., 2011), which is based in the specific in vivo mono-biotinylation 
by the cytosolic biotin ligase BirA of protein substrates tagged with the 15 amino acids-
long Biotin Acceptor Peptide BAP (GLNDIFEAQKIEWH). The E. coli BirA is a 
35kDa well characterized protein, whose function is to activate biotin to form biotinyl-
5’-adenylare and transfer the biotin moiety to biotin-accepting proteins. BirA mono-
biotinylates proteins in a highly specific and almost irreversible way, and its location is 
cytosolic, allowing a precise discrimination between the proteins located in the 
Endoplasmic Reticulum (non biotinylated) or in the cytoplasm (biotinylated). To 
discriminate between the non-biotinylated and biotinylated isoforms a technique based 
on a Western Blotting retardation assay (WB-ra) was used: denatured samples are 
incubated with streptavidin (StrAv), a protein resistant to SDS-PAGE conditions and 
then run in PAGE. StrAv forms a molecular complex with biotinylated molecules that 
are retarded in relation to the non-biotinylated ones. This method, schematically shown 
in figure 3.20, allows to determine cytosolic localisation proteins regardless of its post-
translational modifications (i.e.: glycosylation, oxidation), solubility, and sensitivity to 
proteases (such as trypsin). 
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Figure 3.20 Scheme of in vivo biotinylation 
of retro-translocated proteins. Membrane or 
secretory proteins with the BAP-tag 
localized to the luminal side of the ER. Upon 
retro-translocation the cytosolic BirA 
covalently adds a biotin to the single 
acceptor lysine within BAP. 
 
We investigated the role of p97 during the retro-translocation step of ERAD in 
living cells by using the dominant negative mutant p97QQ, a p97 specific siRNA, and 
the chemical enzyme inhibitor DBeQ. 
 
3.3.1 Effect of p97QQ on different ERAD substrates 
The dominant negative p97QQ mutant, which has two residues (Glu 305 and 578) 
mutated into Gln (Ye et al., 2003), completely lacks ATPase activity and has been 
widely used in different experimental contexts. We tested its effect on retro-
translocation on three different model ERAD proteins: the immunoglobulin non 
secreted light chain NS1, the Null Hong Kong mutant of the secretory !1 anti-trypsin 
(NHK-!1AT), and the membrane-bound cellular glycoprotein Tetherin. These three 
proteins are actively retro-translocated from the ER lumen to the cytosol for 
proteasomal degradation. 
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3.3.1.1 Non secreted light chain NS1 
NS1 is an immunoglobulin , light chain, soluble and non-glycosylated, 
characterized as an ERAD model substrate when expressed without a heavy chain (H). 
In the presence of H, in fact, NS1 can fold and be secreted as part of a mature antibody 
molecule, while in the absence of H it is bound to the ER chaperone BiP, before being 
retro-translocated and degraded (Knittler and Haas, 1992; Leitzgen et al., 1997). 
Initially, an N-terminus BAP-tagged version of NS1 was co-transfected only with 
cyt-BirA, and its retro-translocation level was analysed before and after proteasomal 
inhibition. As shown in figure 3.21A, without MG132 we found a little amount of retro-
translocated (biotinylated) material, which accumulates in cells treated with MG132, 
while the non-biotinylated levels remained almost the same as in the DMSO-treated 
control. This indicates that, in presence of the proteasomal inhibitor, the rescued 
material was the one retro-translocated that becomes degraded by the proteasome, in the 
absence of MG132. 
We next co-expressed NS1 with cyt-BirA and p97QQ or, as controls, with an 
irrelevant protein or with p97 wild type. As shown in figure 3.21B, in presence of 
p97QQ NS1 levels increased, as expected in case of impaired targeting of the substrate 
to the proteasome. This rescued material has always been interpreted as ER localised, 
and unable to be retro-translocated to the cytosol due to the absence of the putative 
extraction activity of p97. Surprisingly, however, most of NS1 was biotinylated (around 
70%), indicating that this fraction corresponded to molecules accumulated in the cytosol 
after retro-translocation and not in the ER lumen. Also in this case, in fact, the amount 
of non-biotinylated material was almost the same as the one in cells expressed without 
the mutant. It is interesting to note that over-expression of wild type p97 also caused a 
mild increase in NS1 levels, but in this case the accumulated material was mostly not 
biotinylated. 
Finally, we evaluated retro-translocation of NS1 following co-expression with the 
viral cytosolic deubiquitinase-like protein OTU. As shown in figure 3.21C, biotinylated 
NS1 accumulated in the presence of OTU alone, and this accumulation was not 
impaired when co-expressed with p97QQ, further demonstrating that VCP/p97 activity 
is not required for effective retro-translocation of NS1. 
Furthermore, since NS1 has been proposed to accumulate in a complex not 
completely retro-translocated, with the VL domain exposed to the cytosol and the CL 
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domain in the lumen, we compared the biotinylation levels of NS1 BAP-tagged at the 
N-terminus and C-terminus. As shown in figure 3.21D, a similar level of retro-
translocation was observed for both versions co-expressed with p97QQ. Thus, both the 
N- and C-termini appear to be equally exposed to the cytosol. 
 
Figure 3.21 Analysis of p97QQ effect on NS1 retro-translocation. WB-ra of cell extracts from 
HEK293T cells co-transfected with (A) BAP-NS1 and BirA, in absence (DMSO) or presence of 
MG132 (15%M for 3 hours); (B) BAP-NS1, BirA and empty control vector (-) or either wild type or 
dominant negative p97 mutant (p97QQ); (C) BAP-NS1, BirA and empty control vector, or OTU, or 
p97QQ, or both OTU and p97QQ; (D) p97QQ and NS1 BAP-tagged at the N-terminus or at the C-
terminus. NS1 was detected by means of the SV5-tag fused to its C-terminus. Lower panels in (A), 
(B) and (C) show actin and p97 as control of loading and overexpression. 
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3.3.1.2 Null Hong Kong !1 antitripsin (NHK-!1AT) 
NHK-!1AT is a natural occurring mutant of the secretory !1 antitripsin. It is 
characterized by a frame-shift mutation and a consequent premature STOP codon that 
produces a truncated protein of 45kDa containing three N-glycosylation sites. NHK-
!1AT lacks protease inhibitory activity, is retained within the ER and degraded through 
the proteasomal pathway (Sifers et al., 1988); because of these features is has been 
widely used as ERAD model. 
The results obtained with NS1 were surprising. So, we moved to test the effect of 
p97QQ on NHK-!1AT, a different model of soluble ERAD substrate. As shown in 
figure 3.22A (compare lanes 1-2 and 7-8), while in absence of proteasomal inhibition 
biotinylated material is undetectable, after the addition of MG132 a band corresponding 
to de-glycosylated protein accumulated; this material, as expected because of its 
cytosolic localisation, is fully biotinylated. Also a fraction of glycosylated molecules 
was biotinylated (a ratio or around 1:1 between glycosylated and de-glycosylated). 
In the presence of p97QQ (lanes 5-6), also NHK-!1AT showed impaired 
degradation with a large accumulation of biotinylated material (around 60% of the 
total). The non-biotinylated fraction, representing non-retrotranslocated molecules, were 
present at the same level as in control cells (lanes 2 and 6). As for NS1, despite the 
increased expression induced by p97 wt, the accumulated NHK-!1AT was not 
biotinylated. Upon proteasome inhibition with MG132, as mentioned before, de-
glycosylated NHK-!1AT was detected, both in the control and p97 wt samples. 
Surprisingly, when co-expressed with p97QQ, the large proportion of the accumulated 
biotinylated molecules corresponded to glycosylated material and a very low amount to 
de-glycosylated ones. Thus, while p97 ATPase activity is not required for retro-
translocation, it is needed for effective de-glycosylation and consequent proteasome 
degradation, suggesting a role for p97 as a segregase on the dislocation complex 
rendering the ERAD substrate accessible to both PNGase and the proteasome. 
Further evidence that p97QQ was not blocking retro-translocation of NHK-!1AT 
was obtained by co-expression with the cytosolic de-ubiquitinase OTU (Figure 3.22B). 
As expected, co-expression with OTU alone largely stabilised de-glycosylated NHK-
!1AT, which was totally biotinylated; moreover, also a partially degraded biotinylated 
fragment was apparent. Notably, upon co-expression with both p97QQ and OTU, the 
profile of biotinylated material was similar to the one obtained with OTU alone, 
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indicating that p97QQ did not impair retro-translocation and, in addition, that PNGase 
recruitment to the dislocated complex was facilitated by OTU activity. 
These results indicated that for NHK-!1AT as well, p97QQ largely affects de-
glycosylation and proteasomal degradation but not the actual retro-translocation step.  
 
Figure 3.22 Analysis of p97QQ effect on NHK-!1AT retro-translocation. WB-ra of cell extracts 
from HEK293T cells co-transfected with (A) BAP-tagged NHK-!1AT, BirA, and empty control 
vector (-), wild type p97, or p97QQ, in absence or presence of MG132 (15%M for 3 hours); (B) 
BAP-tagged NHK-!1AT, BirA and empty control vector, OTU, p97QQ, or both OTU and p97QQ. 
Open and filled arrowheads indicate de-glycosylated non-shifted and shifted material, respectively. 
Open and filled arrows indicate degradation fragment non-shifted and shifted, respectively. NHK-
!1AT was detected by means of the SV5-tag fused to its C-terminus. Lower panels in (A) and (B) 
show actin and p97 as control of loading and overexpression. 
 
3.3.1.3 BST-2/Tetherin 
As a third model protein of ERAD we chose Tetherin, a type-II membrane-bound 
glycoprotein with two glycosylation sites. Tetherin has a short cytosolic N-terminal 
domain, an ectodomain of around 120 amino acids, and a GPI anchor at its C-terminus 
(schematically shown in Figure 3.23). It forms covalent dimers between two parallel 
monomers by three inter-chain disulphide bonds located in the ectodomain. Tetherin is 
targeted to proteasomal degradation either alone or induced by the HIV-1 accessory 
protein Vpu (Strebel, 2014). 
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Figure 3.23 Schematic representation of Tetherin structure, with the site of insertions of the BAP 
tag. 
 
We used a version of Tetherin BAP-tagged in an ER luminal position at the C-terminal 
part, just upstream of the GPI anchor signal (Tetherin-BAP, figure 3.23). As shown in 
figure 3.24A, in non-treated cells a small fraction of Tetherin was found biotinylated 
(lanes 1-2); after the addition of MG132, as already shown for NHK- !1AT, a de-
glycosylated biotinylated band accumulated, and also a fraction of glycosylated 
molecules were found to be retro-translocated. 
In presence of p97QQ (lanes 5-6), Tetherin was stabilised, with almost all the 
accumulated material exposed to cytosolic biotinylation. Upon proteasome inhibition 
with MG132, the effect of p97QQ in impairing de-glycosylation was also apparent, with 
the ratio glycosylated/de-glycosylated protein strongly increasing (lanes 11-12). p97 wt 
did not have any effect of Tetherin expression. 
Again, co-expression with OTU, alone or in combination with p97QQ produced 
large accumulation of biotinylated Tetherin, further demonstrating ongoing retro-
translocation in conditions of impaired p97 activity (Figure 3.24B). The phenotype of 
OTU was dominant over the one with p97QQ. 
Finally, we compared the biotinylation of Tetherin-BAP with a version BAP-
tagged at the N-terminal part, proximal to the trans-membrane domain (BAP-Tetherin, 
figure 2.23). Upon co-expression with p97QQ biotinylation levels were comparable 
(Figure 3.24C), indicating that impaired p97 activity does not preclude full exposure to 
the cytosolic side of the luminal domains of dislocating molecules. 
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Figure 3.24 Analysis of p97QQ effect on Tetherin retro-translocation. WB-ra of cell extracts from 
HEK293T cell co-transfected with (A) Tetherin-BAP, BirA, and empty control vector (-),wild type 
p97, or p97QQ, in absence or presence of MG132 (15%M for 3 hours); (B) Tetherin-BAP, BirA and 
empty control vector, or OTU, or p97QQ, or both OTU and p97QQ; (C) BAP-Tetherin, BirA and 
empty control vector, or p97, or p97QQ. Tetherin-BAP is shown as a control. Open and filled 
arrowheads indicate de-glycosylated non-shifted and shifted material, respectively. Tetherin was 
detected by means of the SV5-tag fused to its C-terminus. Lower panels in (A) and (B) show actin 
and p97 as control of loading and overexpression. 
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3.3.2 Effect of silencing and inhibition of p97 
To further confirm the results obtained with the dominant negative p97QQ 
mutant, we performed experiments of p97 silencing with a specific siRNA and p97 
chemical inhibition. 
As shown in figure 3.25A and 3.25B, silencing of p97 caused an accumulation of 
biotinylated protein both in the case of NS1 and NHK-!1AT, consistent with the 
requirement of p97 for targeting to the proteasome, but not for effective retro-
translocation. As observed upon co-expression with p97QQ, p97 silencing impaired de-
glycosylation of cytosolic NHK-!1AT. 
 
 
Figure 3.25 Analysis of p97 silencing on ERAD model proteins. WB-ra of cell extracts from 
HEK293T transfected with an irrelevant siRNA (si-IRR) or a siRNA specific for p97 (si-p97), and 
after 3 days with BAP-NS1 (A) or NHK-!1AT (B), and BirA. Blots were developed with anti-SV5. 
Lower panels in (A) and (B) show actin and p97 as control of loading and silencing. 
 
Experiments were also performed in cells treated with DBeQ, a chemical inhibitor 
of p97 ATPase activity (Chou et al., 2011). DBeQ treatment produced phenotypes 
similar, but not as strong, to p97QQ. As shown in figure 3.26A, DBeQ alone or in 
combination with MG132 caused stabilisation of biotinylated NS1, although lower than 
MG132. When tested on glycoproteins NHK-!1AT (figure 3.26B) and Tetherin (figure 
3.26C) the effect of DBeQ was mostly evident on the impaired de-glycosylation. The 
relative level of de-glycosylated biotinylated NHK-!1AT changed from 50% in the 
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presence of MG132 to 10% in the presence of DBeQ, while for Tetherin from 80% with 
MG132 to 50% with DBeQ. Again, p97 chemical inhibition did not prevent retro-
translocation but rather engagement of the substrate by PNGase. 
 
Figure 3.26 Analysis of p97 chemical inhibition on ERAD model proteins. WB-ra of cell extracts 
from HEK293T transfected with BAP-NS1 (A), NHK-!1AT (B), or Tetherin-BAP (C) and BirA, and 
treated with MG132 (15%M for 4h), DBeQ (15%M for 4h), or both, or DMSO as a control. Blots 
were developed with anti-SV5. Lower panels in (A) and (B) visualize actin as control of loading. 
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3.3.3 The p97 associated YOD1 deubiquitinase 
YOD is a deubiquitinase belonging to the OTU family, so it possesses an OTU 
domain, but also a N-terminal ubiquitin-like domain, with which it interacts with p97, 
and a C-terminal Zing finger motif. It has recently been shown that YOD1 is one of the 
main players in the p97-dependent deubiquitinase activity associated to ERAD, and it is 
believed to favour degradation. A dominant negative mutant of YOD1 (C160S) was 
shown to stabilise mostly ubiquitinated and glycosylated ERAD substrates (Ernst et al., 
2011; Ernst et al., 2009). As for p97, these results have been interpreted as an 
accumulation of the substrate in the ER lumen, as a consequence of stalling of 
molecules on the putative exit channels. It was also concluded that the deubiquitinase 
activity is required for retro-translocation. We thus investigated, also because of the 
dependence of YOD1 activity with that of 97, the extent of dislocation of the ERAD 
substrates NS1, NHK-!1AT and Tetherin upon co-expression with the dominant 
negative YOD1 C160S. 
As shown in figure 3.27A, wild type YOD1 does not significantly affect the 
endogenous levels of NS1, while the C160S mutant induced strong accumulation of 
biotinylated molecules, indicating that the stabilised fraction was cytosolic and not 
luminal, and that YOD1 catalytic activity was required for NS1 degradation but not for 
dislocation. As expected, since YOD1 activity is p97-dependent, in the presence of 
p97QQ, YOD1 C160S did not show any additional effect. 
When co-expressed with YOD C160S, also NHK-!1AT (figure 3.27B) and 
Tetherin (figure 3.27C) accumulated in the biotinylated form. In presence of MG132, as 
already seen with p97QQ, they accumulate only in the glycosylated biotinylated form, 
indicating impairment in the de-glycosylation step. 
Unsurprisingly, the p97-independent activity of the viral de-ubiquitinase OTU 
caused accumulation of de-glycosylated NHK-!1AT and Tetherin, bypassing the block 
induced by the YOD1 mutant, further demonstrating that retro-translocation of these 
two glycoproteins was not affected in the absence of the p97-associated de-ubiquitinase. 
Instead, the results demonstrate that YOD1 de-ubiquitinase activity is required for 
degradation.  
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Figure 3.27 Analysis of YOD(C160S) on ERAD model proteins. WB-ra of cell extracts from 
HEK293T transfected with BAP-NS1 (A), NHK-!1AT (B), or Tetherin-BAP (C) and BirA, and empty 
control vector, YOD wild type or mutated C160S. Blots were developed with anti-SV5. Lower panels 
in (A) and (B) show actin as control of loading. 
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3.4 2A-mediated ribosome stalling triggers ERAD 
The protein produced from 2A* is a secretory protein that, if it follows its normal 
pathway should have entered the ER. However, we found it mostly in the cytosolic 
compartment. In addition, we partially recovered its expression after proteasomal 
inhibition with MG132 or after overexpression of the viral deubiquitinating enzyme 
OTU: these features are shared with ERAD substrates as presented in the previous 
paragraphs.  
In the presence of p97QQ (figure 3.28A), protein from 2A* showed impaired 
degradation with a large accumulation of biotinylated material. The non-biotinylated 
fraction, representing non-retrotranslocated molecules, was present at almost the same 
level as in control cells transfected with an irrelevant vector or with wild type p97. In 
this case, not only the glycosylated band accumulated but, unlike to what was observed 
with the other ERAD models, also the de-glycosylated one accumulated and, as 
previously noted, a very large proportion of the accumulated glycosylated material was 
biotinylated. We have previously concluded that p97 ATPase activity was needed for 
effective de-glycosylation and proteasome degradation. In addition, as already 
mentioned in paragraph 3.2.4, the fraction of molecules with no sugars could 
correspond to molecules de-glycosylated (i.e: entered in the ER and then retro-
translocated) or non-glycosylated (never entered the ER). The results obtained with 
p97QQ suggested that the biotinylated fraction of the upper band corresponded to 
material retro-translocated from ER to cytosol and not de-glycosylated because of the 
impaired PNGase activity, while the material of the lower band corresponded to 
material non-glycosylated since it never entered the ER. 
A very similar result was obtained following co-expression with the dominant 
negative YOD C160S. Also in this case both, the upper and lower bands accumulated, 
and almost all the protein was biotinylated (Figure 3.28B). 
From these results it can be concluded that ribosomes stalled at the 2A/stop-codon 
site trigger activation of the ERAD pathway on the product from the stalled ribosomes.  
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Figure 3.28 Analysis of p97QQ and YOD C160S effects on protein from construct glyc-2A*. (A) 
WB of cell extracts of HEK293T transfected with glyc-2A* and BirA, and empty control vector (-), 
wild type p97, or p97QQ. (B) WB of cell extracts of HEK293T transfected with glyc-2A* and BirA, 
and empty control vector (-), wild type YOD1, or mutant YOD1 C160S. 
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3.5 Translation by free ribosomes 
As shown in figures 3.7A and 3.7B, impaired expression at the 2A/STOP-codon 
site was not an exclusive feature of translation from translocon-associated membrane-
bound ribosomes producing the protein into the ER lumen, but also of free ribosomes 
translating the same reporter (without the signal leader peptide). 
We decided to investigate the fate of the cytosolic protein by means of a set of 
experiments as previously described: treatment with MG132, co-expression with OTU 
and   with p97QQ. As shown in figure 3.29, MG132 treatment and OTU caused 
accumulation of the protein, thus indicating that it is degraded by the proteasome. 
Surprisingly, also p97QQ caused accumulation; in this case, however, since the protein 
was cytosolic the effect could not be due to impaired ERAD. Instead, the result suggests 
that the product from stalled ribosomes can not be engaged by the proteasome in the 
absence of p97 activity. Indeed, it has been recently demonstrated that p97 is involved 
in rescue of stalled ribosomes and consequent degradation of stalled nascent peptide. 
Therefore, accumulation of cytosolic pr1 could reflect an impaired recognition of 
peptides produced from stalled ribosomes, further confirming our previous finding. 
 
Figure 3.29 Degradation of cytosolic 2A*. WB of cell extracts of HEK293T cells transfected with 
2A-P* or 2A*, and empty control vector, or OTU, or p97QQ, in absence or presence of MG132 
(5%M for 16 hours). 
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sucrose gradient ultracentrifugation. As shown in Figure 3.30A, the protein produced 
from construct 2A*, that was targeted to proteasomal degradation, was found in the 
bottom fractions of the gradient. This fraction did not correspond to polyribosomes-
associated protein, because treatment with micrococcal nuclease did not recover the 
protein in the upper part of the gradient. In contrast, the same pr1 produced from 
construct 2A-P* was found in the top fractions. These results suggest that the protein 
destined to proteasomal degradation forms large aggregates, which are not observed in 
cells expressing the protein from construct 2A-P*, where degradation is not relevant. 
Moreover, sucrose gradient ultracentrifugation of extracts from cell transfected with the 
cytosolic reporter protein, showed the same distribution of the reporter in the top 
fractions for both constructs 2A* and 2A-P* (Fig. 3.30B). We concluded that the 
formation of large complexes or aggregates is a peculiar characteristic of the protein 
from 2A* that had entered into the ERAD pathway; large aggregates could represent the 
dislocation complex. 
Figure 3.30. Analysis by sucrose gradient ultracentrifugation. WB of fractions from sucrose 
gradients (15%-40%) after ultracentrifugation. Gradients were loaded with cell extracts from 
HEK293T transfected with the indicated constructs, divided into 15 fractions and analysed by WB 
with anti-SV5. 
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4. DISCUSSION 
 
4.1 Analysis of 2A peptide activity 
The possibility to co-express two or more proteins in the same cell with a single 
vector, and even from a single mRNA, is of particular interest in the therapeutic field; it 
allows, for example, to co-express a therapeutic gene together with a reporter gene for 
its traceability, or to co-express several subunits of a protein. Of immunologic interest, 
for example, it’s the possibility to co-express the light and the heavy chain of an 
antibody, or the chains of the T cell receptor, or the chains of cytokines such as IL-12. 
The classical approaches for the productions of bi- or multi-cistronic vectors 
consist in the usage of IRES (Internal Ribosomal Entry Site) or internal promoters. 
However these methods show some limitations, for example the fact the expression 
levels of the different proteins could be highly variable and not predictable, or the fact 
that they consist of long sequence, a problem for the usage of vectors with a limited 
cloning capacity (i.e. Adeno Associated Viral Vector) (de Felipe, 2002). 
An alternative approach consists in the usage of the viral 2A peptide. Translation 
termination is the final step of protein synthesis and occurs when a STOP codon enters 
the ribosomal A site, is recognized and bound by the release factors, that in turn trigger 
the hydrolysis of the ester bond between the nascent peptide and the tRNA in the P site, 
causing the release of the newly synthetized polyprotein and the recycling of the 
ribosomal subunits (Alkalaeva et al., 2006). We called this kind of termination 
“conventional”, to distinguish it from an alternative mechanism of termination 
occurring in some members of the picornavirus family. These viruses, in fact, encode 
their proteins in a single transcript, which upon translation produces a polyprotein, 
whose primary cleavage occurs co-translationally and is mediated by the so-called 2A 
region of the polyprotein (Donnelly et al., 1997). 2A peptide is able of mediating its 
self-processing at the C-terminus, and we call this property “non conventional 
termination”: in contrast with the conventional one, in fact, it does not need the 
presence of a STOP codon to cause the release of the protein, and the ribosome is not 
dissociated but continues translation. In literature are present several studies, described 
in paragraph 1.5.3 (Donnelly et al., 1997; Donnelly et al., 2001a; Donnelly et al., 2001b; 
Ryan and Drew, 1994; Ryan et al., 1991), that try to clarify the activity of these 
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peptides, the most studied of which is that derived from the Foot-and-Mouth Disease 
Virus (FMDV). 
The reasons why we decided to analyse again the activity of the 2A peptide were: 
1) in most studies published, analysis of 2A activity was carried out with in vitro 
transcription/translation reactions; 2) the reporters proteins used upstream and 
downstream of 2A were different; 3) a work that compares the activity of different 2A 
peptides in vivo is missing. 
We decided to analyse 2A peptide activity by building a basic bicistronic vector in 
which the same reporter, a secretory protein therefore synthesized on membrane-bound 
ribosomes, was put upstream (protein1) and downstream (protein2) of 2A. Moreover, 
we decided to test two different 2A peptides, derived from the Food-and-Mouth Disease 
Virus (FMDV – F2A peptide) and from the Porcine Teschovirus (PT – T2A peptide) to 
look for possible differences in their activities. The F2A used contained the last 5 amino 
acids of VP1 (C-terminal part of P1) followed by the 18 amino acids of 2A: this 23 
amino acids-long oligopeptide was shown to be more efficient in driving expression of 
the two proteins upstream and downstream of 2A. 
2A peptide-mediated non-conventional termination consists in two step: ability of 
releasing the upstream protein, highlighted by the absence of fusion product with the 
downstream protein, and ability to reinitiate translation from the Pro immediately 
downstream of 2A after releasing the upstream protein. What emerged from our study 
was that both F2A and T2A were able to efficiently release the upstream protein with 
the mechanism of non-conventional termination; this was partially in contrast with 
studies reported in literature where a small amount of fusion product was found 
(Donnelly et al., 2001a; Ryan and Drew, 1994). It is possible, however, that sequences 
upstream or downstream the peptide influence this ability. The second finding was that 
both F2A and T2A were not able to reinitiate translation of the downstream protein with 
100% efficiency; this is in agreement with what previously reported, with protein2 
always reported to be present at a smaller amount than protein1 (Donnelly et al., 2001a; 
Donnelly et al., 2001b; Ryan and Drew, 1994). Finally, we found that F2A is more 
efficient than T2A in resuming translation from Pro, as indicated by the higher ratio 
between protein2 and protein1. For these reasons F2A was chosen to continue the 
studies. 
To test the possibility of using this system in vivo we decided to produce a full 
antibody (Ab) molecule. We built a vector in which the L chain was placed upstream 
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F2A, and the H chain downstream: this design was chosen because the downstream 
protein is produced at a lower level that the upstream one, and the H chains produced in 
excess of the L chains cannot be secreted and become toxic to the cell. We also made an 
improvement on the vector by adding a furin cleavage site between the light chain and 
peptide 2A. Furin is an enzyme localized in the Golgi that cleaves at a specific 
consensus sequence allowing, in our case, expression of the L chain free of the 2A 
peptide. By expressing these vectors in cells, we found that 2A peptide activity can be 
exploited to produce L and H from a single mRNA that assembled correctly to produce 
a full antibody able to recognize its antigen. This finding has also been confirmed in 
vivo, by administering the vector as an Adeno-Associated Viral Vector through 
injection in mice tibial muscles. The antibody produced from the rAAV-infected cells 
was circulating in the sera and able to recognize its antigen for a long period of time. 
 
4.2 Imposing conventional termination on 2A impairs expression of upstream 
protein 
While we were analysing the expression efficiency of proteins upstream and 
downstream peptide 2A in the context of a bicistronic vector, we made two 
monocistronic vectors to be used as controls. In one of these monocistronic vectors we 
maintained the 2A peptide termination site complete with the Pro (first amino acid of 
the downstream protein) that can be consider a bicistronic vector in which the 
downstream protein is constituted only by one amino acid (construct 2A-P*); in this 
case, translation termination is expected to be non-conventional. The second construct, 
with the Pro removed, is a true monocistronic one (construct 2A*). By removing the Pro 
codon, we changed a non-conventional termination site into a conventional one. 
Actually, when we analysed by mass spectrometry the product of construct 2A-P*, we 
found that around 60% of material was terminating with a non conventional termination 
(that is, ending with Gly), while the remaining 40% was terminating with a 
conventional termination, thus “skipping” the 2A peptide termination site. This product 
can be considered a fusion protein, and so this result suggest that, at least in the case in 
which the downstream protein is constituted by a single amino acids, non conventional 
termination is not as efficient as shown before. 
Despite this aspect, protein from construct 2A-P* was expressed and secreted in a 
very high amount. Surprisingly, protein from construct 2A* was almost undetectable. 
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Constructs 2A-P* and 2A* differ only on a single amino acids, and mainly in the way 
they terminate protein synthesis. The involvement of termination in this phenotype was 
proved also by another finding: when we added a further tag not beginning with Pro 
immediately after 2A (construct 2A-roTag*) we restored protein expression. The 
protein produced was, because of Pro absence, a fusion product indicating that the 
elongation step was not affected by the sequence. In this experiment, we used as a 
control a construct with Pro followed by the additional tag; in this case non-
conventional termination was very efficient, as demonstrated by the absence of a 
detectable signal with anti-roTag. Keeping in mind the mass spectrometry results, this 
data indicated that the absence of a stop codon (replaced with the 11 amino acids of the 
roTag after Pro) is sufficient to allow a full efficient termination reaction by 2A. In the 
future we will further study this aspect, trying to find a possible correlation between the 
length of downstream protein and the non-conventional termination efficiency. 
The first question we tried to answer was whether this phenotype was 
reproducible also with other upstream proteins. We modified our construct in two ways: 
by removing the secretion signal, maintaining the same protein in a different cellular 
context, or by substituting the single chain with EGFP, removing also the SV5 tag. We 
obtained the same result, providing some additional information: first, the reason of 
impaired expression was ascribable only to the 2A peptide, as it was the only element 
that the three different constructs had in common; second, the effect was not dependent 
on the ribosomal population translating the protein, as it occurred both with ER 
membrane-bound and cytosolic free ribosomes; third, taking into account the two 
previous considerations, the problem resides either in the 2A nucleotidic sequence or in 
the amino acidic one, in the latter case as a consequence of interaction between the 
peptide and the ribosomal exit tunnel. 
We started analysing the 2A sequence, and in particular the role of the amino 
acids at the N-terminus. 
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Figure 4.1 FMDV 2A peptide sequence with indicated amino acid position. 
 
To do this, we decided to “map” the 2A sequence by deleting progressively the N-
terminus amino acids, until we recovered protein expression. As for the presence or 
absence of the Pro codon, also in this case the effect was “black or white”: at a specific 
point in fact, corresponding to a sequence length of 12 amino acids from the C-terminus 
[2A()N6)], we almost completely recovered expression. Thus, 13 amino acids is the 
length necessary to impair protein expression [2A()N6)], and this length is particularly 
interesting because the minimal length necessary for peptide 2A to perform non-
conventional translation termination has been mapped to 12 amino acids (Ryan and 
Drew, 1994). This finding establishes a relationship between the effect of expression 
impairment and the physiological 2A peptide activity, suggesting that the inhibitory 
effect of 2A in conventional termination reflects properties relevant for its activity in 
non-conventional termination. Moreover, the lower importance of 2A N-terminal region 
respect to the C-terminal one is suggested also by its sequence variability among the 
different 2A sequences, whereas the C-terminal one is more conserved. Analysing the 
2A C-terminal part, we found that the presence of the three terminal Asn-Pro-Gly amino 
acids is essential for the impaired expression effect. Anticipating the STOP codon to the 
position normally occupied by Gly18, Pro17, and Asn16, in fact, completely restored 
protein expression, as well as maintaining the STOP after the Gly18 but removing the 
previous Pro17 and Asn16-Pro17. Also changing Gly18 with a different amino acid 
completely restored expression, further proving the essentiality of Gly for the inhibitory 
effect. 
While this work was in progress, a work was published (Sharma et al., 2012) in 
which the authors analysed in yeast and in in vitro transcription/translation the 
importance of the identity of amino acids at nearly all positions of FMDV 2A peptide. 
They found, as we did, that the presence of a STOP codon in place of Pro19 impaired 
upstream protein expression. In this case, they were able to see the peptidyl-tRNA and 
so they interpreted this result as an impediment of the eRF1/3 complex to release the 
1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 
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nascent chain. We never detected bands corresponding to peptidyl-tRNA, this could be 
due to the method used to detect protein (western blot versus radioactive labelling) or to 
the system used (cell transfection versus in vitro transcription/translation). Another 
difference between our finding and that reported in the paper, is that they saw an 
impairment of expression also when STOP was in place of Gly18, while we saw 
restoration of the expression.  
After having analysed the role of amino acids on this effect, we moved to consider 
the nucleotidic sequence. It was possible, in fact, that altering the coding sequence, even 
if only for one codon, could affect the stability of the mRNA. This was not the case, as 
demonstrated by quantitative real-time PCR, in which the amount of the two mRNAs 
was almost the same. We confirmed this finding in other different ways: first we added 
a STOP codon immediately before the 2A nucleotidic sequence, in such a way we 
maintained the same mRNA but excluding the peptide from translation; in this way we 
recovered the expression in constructs carrying the 2A* and 2A()N6)* nucleotidic 
sequences after the STOP codon, indicating that the 2A amino acids, rather than the 
mRNA, were responsible for the effect. Second, we built a construct encoding the same 
2A peptide with all the codons mutated (2AMUT): this mutagenized 2A peptide was as 
inhibitory as the one with the wild type codons, further confirming the involvement of 
the amino acidic and not of the nucleotidic sequence in the impairment of expression. 
Finally, we replace Pro19 with a STOP codon in the 2A peptide derived from the 
Porcine Teschovirus, and also in this case placing a STOP immediately after Gly 
impaired the expression. This finding, in addition to definitely exclude nucleotidic 
sequence and so mRNA stability as the cause of the expression impairment, confirms 
that the deleterious effect of 2A in conventional termination reflects properties relevant 
for its activity in non-conventional termination, as we obtained the same result with 
peptide with different sequences, derived from different viruses, but performing the 
same activity in their natural context. 
We then decided to investigate the possible reason of this effect. When we 
checked protein half-life through an experiment in which protein synthesis was blocked 
with cycloheximide, it was immediately clear how the proteins from 2A* and 2A-P* 
were having different behaviours: while intracellularly they seemed to have a similar 
half-life, considering the supernatants it was evident that this interpretation was wrong. 
Product form 2A-P*, in fact, was actively secreted, while that from 2A* was 
undetectable in the supernatant. The progressive decrease of the amount from 2A* 
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without a “recovery” in the supernatant, suggested the protein was degraded. 
Considering the two major degradation pathways in the cell, autophagy and proteasomal 
degradation, we found that the protein from 2A* was degraded by the proteasome, since 
we recovered its expression by adding the proteasomal inhibitor MG132. However, 
proteasomal inhibition did not restored the expression of protein from 2A* at the same 
level of that of protein from 2A-P*, and this finding suggested that protein degradation 
was not the only one cause of the different expression between the two constructs. 
It has been widely described that, to perform its activity as non-conventional 
translation terminator, 2A peptide causes a short and transient stalling of ribosomes 
when Gly is in the P site and Pro in the A site (Donnelly et al., 2001b; Sharma et al., 
2012). 2A forms an amphipathic !-helix over most of its length, with a reverse turn at 
its C-terminus. Transient ribosome stalling is thought to occur because of a re-
orientation of the peptidyl-tRNAGly in the ribosomal exit tunnel (RET), such as to 
disfavour peptide bond formation to prolyl-tRNAPro and instead to promote the 
hydrolysis of the peptidyl-tRNAGly ester bond (Donnelly et al., 2001b; Ryan, 1999). 
Moreover Pro has been described as the poorest nucleophile of the amino acids and the 
only one able to allow 2A activity: in fact, mutations of Pro cause the production of a 
fusion protein instead of two separated ones. These findings suggest that the 
conformational re-orientation of the peptidyl-tRNAGly is in some way able to 
discriminate between prolyl-tRNAPro from other aminoacyl-tRNA. Our data suggests 
also that in presence of any aminoacyl-tRNA except for tRNAPro, 2A peptide 
conformation inside the RET allows a continuation of translation, while in presence of a 
STOP codon it assumes a conformation that completely disfavour translation 
termination and nascent peptide release. Since the product we find, albeit at very low 
levels, is already hydrolysed from the tRNA,,it is likely that the peptide remains 
blocked within the RET when the ribosomal P site is occupied by eRF1 instead of a 
tRNA.  
Because of the transient stalling in peptide 2A in its physiologic context we 
decided to investigate if, in presence of a STOP codon instead of Pro19, there could be 
an excessively prolonged stalling. In one set of experiments we investigated the 
localization of protein produced from 2A* in comparison to that from 2A-P*. If the 
hypothesis of prolonged stalling was true, protein from 2A* should remain bound to 
ribosomes and therefore unable to be completely translocated to the ER lumen. We 
found that the two proteins had a completely different cellular localization, as attested 
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by two different criteria. First, we inserted in our construct a cleavage site for furin, an 
enzyme located in the Golgi, just upstream of 2A. Since the protein has a secretion 
signal, if it enters the secretory pathway it encounters furin that cleaves at its consensus 
sequence, generating a cleaved protein discriminable from the non-cleaved one by its 
different size. Protein from 2A-P* behaved as a “normal” secretory protein, with a high 
amount of cleaved protein in the supernatant and two bands in the cellular extract, one 
cleaved reflecting the protein that has reached the Golgi, and one non cleaved reflecting 
the protein still in the ER or in the cytosol. Protein from 2A* was undetectable in the 
supernatant, and the small fraction present in the cell extract had a size corresponding to 
the non-cleaved protein. This finding restricted the possible localization to the ER 
and/or the cytosol. It was therefore clear that the protein does not entirely follow the 
secretory pathway. Second, to discriminate between the ER luminal and the cytosolic 
localization, we inserted in our protein an N-glycosylation site: the protein should 
become glycosylated if inserted into the ER, not glycosylated if did not enter the ER, or 
de-glycosylated if it entered the ER and then was retrotranslocated to the cytosol for 
degradation. We selected a precise point for the insertion of the glycosylation site, 45 
amino acids upstream the STOP codon. Since the ribosome exit tunnel accommodates 
30-35 amino acids and the translocon around 20 amino acids, the site for N-
glycosylation would be available only if the peptide is released from the ribosome and 
completely translocated into the ER, while if the peptide remains associated to the RET 
and does not reach the ER lumen, it would be free of sugars. The control protein 
produced from 2A-P* behaved as a secretory glycoprotein, resulting almost fully 
glycosylated; this was already expected, as it is efficiently secreted. Instead, the protein 
produced from 2A* was found for the great part without sugars. With this data alone, 
however, we could not discriminate between a protein non-glycosylated and de-
glycosylated. The sugar free protein, in fact, can be derived from two different 
processes: 1) lack of complete translocation into the ER and therefore non-
glycosylation, because of the interaction between the nascent peptide and the ribosomal 
exit tunnel, and 2) total translocation and glycosylation followed by retrotranslocation 
to the cytosol and de-glycosylation by the cytosolic PNGase. Despite this data did not 
gave us a definitive answer, further experiments, discussed below in paragraph 4.4 gave 
us the indication that the sugar free band is composed both by non-glycosylated and de-
glycosylated material. 
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To prove more directly the involvement of ribosome stalling we labelled with 
[35S]-methionine the protein produced in 15 minutes, in cells treated with MG132 to 
avoid degradation. If stalling occurred, the protein from 2A*, produced in a relatively 
short period of time, was expected to be translated at lower levels. This was exactly 
what happened: a strong reduction in the amount of protein translated when compared 
to the one from construct 2A-P*, confirming compromised termination. 
A further confirmation of the role of stalling was obtained exploiting the 
physiological 2A activity; we built a classical bicistronic vector, with a protein1 
followed by 2A-P and protein2, which ended with 2A*. We reasoned that if ribosomes 
were stalled at the stop codon after 2A, after a first round of protein1 translation, there 
would be compromised expression of protein1 because stalled ribosomes would prevent 
continuation of translation from codon Pro19. The proof that the absence of protein1 
was the consequence of ribosome stalling and not of an intrinsic problem of the 
construct was provided by the control bicistronic vector with protein2 ending in 2A-P*, 
which allowed high level expression of protein1.  
The data presented suggests a model in which 1) ribosome stalling at the Gly-
STOP site causes low expression of the upstream protein, and 2) the very little amount 
of protein finally released from the ribosome is degraded (eventually after 
retrotranslocation from ER to cytosol) by the proteasome. 
At present we have several questions still unanswered. One regards the role of 
Release Factors in expression impairment: one possibility is that eRFs enter in the 
ribosomal A site, hydrolyse the linkage between the tRNA and the nascent chain, which 
will not be released due to its interaction with RET probably influenced precisely by the 
eRFs; another possibility is that the eRFs enter the A site but the nascent chain 
conformation does not allow the hydrolysis, although this is quite unlikely since 
peptidyl-tRNA was no detected; the last possibility is that the nascent chain 
conformation does not allow eRF entrance into the A site. In this latter case remains the 
problem of how the peptidyl-tRNA is hydrolysed. As mentioned above, we never 
detected peptidyl-tRNA and, in addition, we could not immunoprecipitate the ribosome 
with the nascent chain. This is probably due to the intervention of mechanisms that 
sense the presence of a ribosome stalled complex (RSC) and work to resolve the 
situation. These mechanisms have been described (Brandman et al., 2012; Defenouillere 
et al., 2013; Verma et al., 2013) and consist in the rescue of the RSC by allowing 
ubiquitination and consequent extraction and degradation of the nascent peptide blocked 
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in the RET and dissociation and recycling of ribosomal subunits, not necessarily in this 
order. These mechanisms have been proved for the rescue of ribosomes stalling in the 
non-stop and non-go decay (NSD and NGD) pathways. We can hypothesize a similar 
mechanism also in our case despite the fact that, unlike to what happens in those two 
decay mechanisms, we did not detect differences in the mRNA levels of 2A* compared 
to the control 2A-P*, indicating absence of a higher mRNA degradation rate. 
 
4.3 The role of p97 ATPase in ERAD 
p97 is a cytosolic enzyme that can be found soluble or, when involved in ERAD, 
associated to the cytosolic side of the ER membrane. p97 has been found interacting 
both with ubiquitinated and non-ubiquitinated proteins. The role of p97 in ERAD has 
been extensively studied during the past years, and the common view is that p97, 
together with its co-factors Ufd1 and Npl4, is necessary for the extraction of 
polyubiquitinated substrates from the ER to the cytosol during the dislocation step. 
Extraction is thought to occur after a first round of ubiquitination that serves to tag the 
protein addressed to degradation, but prior to proteasomal engagement. p97 ATPase 
activity is believed to provide the force required for substrates extraction from the ER 
compartment, and in particular to active pull substrates through a hypothetical 
retrotranslocon or to segregate the polypeptide already liberated from the ER 
membrane, but enclosed in large protein complexes (Ernst et al., 2011; Jarosch et al., 
2002; Nakatsukasa et al., 2008; Ye et al., 2001, 2003). A similar role has been proposed 
for p97 mediated protein extraction from chromatin (Dantuma and Hoppe, 2012) and 
segregation of polypeptides from large protein complexes and aggregates. After 
retrotranslocation p97 might deliver ERAD substrates to the proteasome through one or 
more of its interactors containing ubiquitin-binding and ubiquitin-like domains. 
The majority of the retrotranslocation models predict that, if p97 is absent or 
inactive ERAD substrates are retained in the ER lumen (not dislocated) or remain 
partially dislocated associated to the ER membrane (Claessen et al., 2010; Okuda-
Shimizu and Hendershot, 2007; Rabinovich et al., 2002; Ye et al., 2001, 2003). The 
partial dislocation model has been postulated to justify the presence of ERAD 
substrates, “tagged” with cytosolic localization markers such as ubiquitination and 
deglycosylation, in the pellet following ultracentrifugation in cell fractionation 
experiments (corresponding also to the microsomal/ER containing fraction). However 
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during this procedure several particles, other that ER-derived and other small vesicles, 
might sediment in the pellet: mitochondria (Tang et al., 2011), ribosomes (Ackerman et 
al., 2006), proteasomes, and large protein aggregates. It is widely accepted that during 
ERAD one or more large protein complexes are formed, usually found in the cytosolic 
side of the ER and anchored to the ER membrane through trans-membrane proteins 
such as the translocon sec61, derlin, or the E3 ligases Hrd1 and gp78 (Christianson et 
al., 2012; Lilley and Ploegh, 2004, 2005). It is possible that ERAD substrates totally 
exposed to the cytosol are found in the pellet fraction because in part form aggregates or 
because they are indirectly bound to the ER membrane through one or some of the 
proteins in the complex. From this perspective, the reported requirement of ATP and 
p97 ATPase activity (Ye et al., 2001, 2003) might not be for protein dislocation from 
the ER to cytosol, but simply for releasing the substrate from the p97-containing large 
complex. 
An observation in favour of the accumulation of ERAD substrates in the ER 
lumen and not in the cytosol is that down regulation of p97 ATPase activity triggers 
UPR (Jarosch et al., 2002; Rabinovich et al., 2002; Ye et al., 2001), which initiates by 
activation of the ER-resident transmembrane sensors from the luminal side. However, it 
is known that p97 has an important role in many cellular processes, and it is possible 
that perturbation of one of them, instead of the accumulation of substrates in the ER, 
triggers UPR. Moreover, the UPR sensors are transmembrane proteins with their active 
sites in the cytosol, as well as cytosolic are the effectors of this response. It can not be 
excluded that events in the cytosol can give a UPR-like phenotype. Indeed, 
accumulation of protein aggregates in the cytosol can strongly trigger ER stress 
(Leitman et al., 2013). Finally, affecting p97 activity for a long period of time might 
cause a bottleneck, and therefore possible that at a certain point the ERAD substrate 
starts to accumulate in the ER. 
Two are the main problems in the determination of p97 exact role in ERAD: the 
first one regards the precise localisation of the ERAD substrate in the ER lumen or in 
the cytosol, and the second resides in the general semantic definition of what is meant 
by “retrotranslocation step”. 
The methods currently used to establish whether a protein is in the ER lumen or in 
the cytosol are cell fractionation, protease sensitivity assays and analysis of 
glycosylation and oxidation status. The issue regarding the cell fractionation has been 
already discussed. The protease sensitivity assays, considered a marker of ER retention 
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upon resistance to protease activity presents an interpretation problem. The control used 
to verify that a protein resistant to protease activity is effectively localised in a 
membrane compartment is to treat the sample with a non ionic-detergent that dissolves 
the membranes thus allowing a complete degradation. However, polypeptides in large 
complexes associated to membranes can be resistant to proteases, not because they are 
in the ER but because they are masked by the other interacting components. These 
complexes could be sensitive to mild detergents, allowing protease degradation. 
Notably, ERAD complexes resistant to non-ionic detergent solubilisation have been 
described known (Ernst et al., 2011; Greenblatt et al., 2011). Regarding the 
glycosylation and the oxidation status, it is in general widely accepted that glycosylated 
and/or oxidised proteins are ER resident, while un-glycosylated and/or reduced proteins 
are in the cytosol. When a glycoprotein is exposed to the cytosol can be substrate of the 
cytosolic cellular PNGase (also called N-glycanase), the only eukaryotic enzyme 
deputed to completely remove N-linked sugar moieties from polypeptides, leaving an 
Asp residue in place of the original glycosylated Asn. From routine biochemical 
analysis (i.e. WB) un-glycosylated and de-glycosylated proteins are often 
indistinguishable. If it is true that a de-glycosylated glycoprotein is in the cytosol, a 
glycosylated one can be both in the ER and in the cytosol: de-glycosylation, in fact, 
occurs only after ER to cytosol dislocation and it has been found not to be essential for 
proteasomal degradation. Moreover, we have recently demonstrated that glycosylated 
and oxidised proteins can be found in the cytosol (Petris et al., 2014). Interestingly, the 
main criteria to assign glycosylated proteins to the ER and de-glycosylated ones to the 
cytosol and therefore to monitor dislocation is frequently used by the same group that 
has found how de-glycosylation is dispensable for protein degradation (Ernst et al., 
2011; Ernst et al., 2009; Kario et al., 2008; Misaghi et al., 2004). Thus a cytosolically 
localised protein after retrotranslocation from the ER lumen can remain glycosylated, 
for instance when PNGase is downregulated and not recruited to the substrate or when 
the N-glycosylation site is protected by protein folding (Byun et al., 2010; Petris et al., 
2014).  
We decided to use our method based on the specific in vivo biotinylation of 
proteins that have retrotranslocated to the cytosol (Petris et al., 2011) to study the effect 
of p97 ATPase activity impairment in ERAD. This highly efficient system (BirA 
catalyses a biotinylation reaction in 5 second) allows us to overcome the problem of 
protein localisation posed by the methods described above. Notably, in the biotinylation 
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method, there is no manipulation of the samples, as cells are directly lysed in strong 
SDS denaturing conditions and then subjected to analysis by WB. 
Regarding the meaning to be given to the process of retrotranslocation, according 
to the literature it is frequently considered as the dislocation (translocation through the 
membrane) and solubilisation of the substrate in the cytosolic fraction prior to 
proteasomal degradation (Hampton and Sommer, 2012). However, this definition can 
not be applied to all ERAD substrates, some of them in fact never appear soluble before 
proteasomal degradation (Okuda-Shimizu and Hendershot, 2007). Moreover, in most 
cases protein solubilisation is observed only after proteasomal inhibition (Ernst et al., 
2011; Ernst et al., 2009): solubilisation, in this case, might be an artefact due to the 
escape from degradation after disassembly of the ERAD complex. A proteasomal 
population has been found associated with the ER membrane whose role could be 
substrate degradation during or immediately after membrane crossing. In some 
circumstances, however, the proteasome was also proposed to participate in the 
dislocation step (Kalies et al., 2005; Okuda-Shimizu and Hendershot, 2007; Romisch, 
2005). It is clear, therefore, that a common view of what “retrotranslocation” means is 
important to discriminate if ERAD players, as p97, are actually necessary for crossing 
the membrane, or to render the substrate soluble. 
Our results clearly challenge the predominant view of p97 as energy provider for 
the extraction of unfolded proteins from a putative retrotranslocon in an ATP-dependent 
manner. Co-expression of the dominant negative p97QQ together with the ERAD 
model substrate NS1 BAP-tagged at the N-terminus (BAP-NS1), in fact, produced a 
large accumulation of biotinylated NS1, indicating exposure of the protein to the cytosol 
(Figure 3.22B). However, it is possible that in agreement with the model proposed by 
Okuda-Shimizu et al. (Okuda-Shimizu and Hendershot, 2007), biotinylated BAP-NS1 
still represents a partial dislocation intermediate. This possibility was eliminated by 
tagging NS1 at the C-terminus and showing the same biotinylation pattern (Figure 
3.22D). Moreover, in the partial dislocation model NS1 was proposed to be 
ubiquitinated, while we found it mostly non-ubiquitinated. p97 has been proposed to 
extract proteins from the retrotranslocon by using polyubiquitin as a recognition signal. 
However, finding NS1 biotinylated and non-ubiquitinated upon p97QQ co-expression 
indicates that p97 is not the protein responsible for the extraction of the ERAD 
substrates and suggests that its ATPase dependent DUB-associated activity is not 
responsible of the deubiquitination after retrotranslocation. 
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These surprising results were also confirmed with other two ERAD model 
substrates: NHK-!1AT (Figure 3.23A) and Tetherin (Figure 3.24A). Both these proteins 
have glycosylation sites, giving us another parameter to interpret our data. When co-
expressed with p97QQ, NHK-!1AT accumulated as a biotinylated and glycosylated 
protein; Tetherin accumulated mainly in the biotinylated and glycosylated form, but 
also a very small amount of deglycosylated and biotinylated material was present. 
Following proteasomal inhibition, both NHK-!1AT and Tetherin accumulated in de-
glycosylated form, but this fraction was very poorly detectable when p97QQ was co-
expressed. The interaction between p97 and the cytosolic de-glycosylating enzyme 
PNGase is well established. It is possible that, by blocking p97 ATPase activity, the link 
between the substrate recognition performed by p97 co-factors (bound to p97 N-
terminus), and the effector function of proteins such as PNGase (bound to p97 C-
terminus), results impaired. ATP hydrolysis causes deep conformational changes in p97 
structure (Davies et al., 2008; Rouiller et al., 2002), and it is therefore possible that by 
blocking this function and the consequent structure rearrangement also the recruitment 
of downstream effectors is affected; from this point of view, it can be envisaged that 
PNGase action occurs downstream of p97 activity. The small amount of de-
glycosylated protein found with p97QQ can be explained by the interaction between 
PNGase and derlin-1 (Greenblatt et al., 2011) that might provide a more direct link 
between the de-glycosylating enzyme and the glycoprotein. Regarding this finding, the 
accumulation of glycosylated material with p97QQ co-expression is well documented, 
but it has been always interpreted as accumulation on the ER luminal side. Our results, 
obtained with our biotinylation method indicates, in contrast, that the protein 
accumulates in the cytosolic side, and therefore that the impairment arising from the 
inhibition of p97 activity is after the retrotranslocation step. 
These results were also confirmed by inhibiting p97 ATPase activity in two other 
alternative ways: silencing of p97 with a specific siRNA, and using DBeQ, a chemical 
inhibitor of p97 activity. Also with these methods, in fact, we observed accumulation of 
biotinylated protein and a reduction in the relative level of de-glycosylated biotinylated 
material upon p97 downregulation (siRNA) or inhibition (DBeQ). 
An additional interesting data emerged from the co-expression of p97QQ and the 
p97-independent CHFV-derived deubiquitinase OTU (a well-known cytosolic enzyme): 
the effect of the co-expression, in fact, resembles that of the over-expression of OTU 
alone. In both cases we found an accumulation of biotinylated de-glycosylated and 
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glycosylated NHK-!1AT (Figure 3.23B) and Tetherin (Figure 3.24B); with NHK-
!1AT, moreover, also a biotinylated degradation fragment appeared. This data indicates 
that p97QQ was not blocking retrotranslocation, as the effect of OTU is similar to the 
inhibition of proteasomal degradation. It also indicates that removal of ubiquitin 
molecules by this viral DUB overcomes the necessity of an active p97 for PNGase 
activity. Its effect is similar to that already reported for the DUB protease domain of the 
Epstein-Barr Virus (EBV) large tegument protein (BPLF1); EBV-DUB, as well as 
CHFV OTU, hydrolyses K48- and K63 ubiquitin linkages (Ernst et al., 2011). 
Interestingly, however, different results to those with CHFV OTU were obtained 
with the p97-dependent deubiquitinase YOD1. Up to now, more than 30 DUBs able to 
associate with p97 are known; for some of them, such as ataxin-3, the proposed role is 
to remove ubiquitin from ERAD substrates preventing their degradation while for 
others, such as USP13 and YOD1, it is believed play a role to favour degradation. 
YOD1 deubiquitinating activity, in particular, is thought to be essential for 
retrotranslocation (Ernst et al., 2011; Ernst et al., 2009). As discussed above, the 
methods used to determine the localization of the accumulated substrate is the main 
problem in the interpretation of the data. By using a dominant negative version of 
YOD1, named YOD1 C160S, and the in vivo biotinylation method, we obtained almost 
the same phenotype as with p97QQ alone (Figure 3.27) that is, accumulation of the 
biotinylated ERAD substrates. The de-glycosylated fraction of NHK-!1AT and 
Tetherin, accumulated after proteasomal inhibition with MG132, disappeared upon co-
expression with YOD C160S, indicating again an impairment of the de-glycosylation 
step. It is possible, thus, that a deubiquitination step in the ERAD complex is required 
prior to protein de-glycosylation. As already observed with p97QQ, co-expression of 
YOD C160S and viral OTU overcomes this effect allowing the de-glycosylating 
reaction. Accumulation of de-glycosylated protein with co-expression of YOD C160S 
and EBV-DUB has already been reported; the interpretation given was that EBV-DUB, 
by de-ubiquitinating the ERAD substrate blocked in the retrotranslocon, allowed its 
engagement by p97 overcoming the inactivity of YOD1 C160S (Ernst et al., 2009). Our 
interpretation, based on our biotinylation results is quite different: because with YOD1 
C160S overexpression the accumulated glycosylated material is mostly biotinylated and 
therefore cytosolic, the appearance of de-glycosylated material with CHFV OTU is not 
due to substrate retrotranslocation (already happened) but to the possibility to render the 
substrate available for PNGase deglycosylation.  
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Consistent with our interpretation, in a work recently published (Wang et al., 
2013), the authors found the ERAD substrate MHC-I! retrotranslocated (using our BirA 
biotinylation method) after cell treatment with DUBs inhibitors. More importantly, the 
dislocated material was mainly glycosylated and associated with the pellet/microsomal 
fraction, leading the authors to conclude that MHC-I! dislocation is dependent of DUB 
activity; the data, instead, in agreement with our observations, indicate that DUB 
activity is required for solubilisation and efficient deglycosylation, as the material was 
already retrotranslocated (biotinylated). 
The current view on the role of ubiquitination in ERAD is that at least two rounds 
of ubiquitination/deubiquitination are necessary for proteasomal degradation: a first 
round of ubiquitination would be responsible for the proper assembly and regulation of 
the dislocation complex, and a second would target the dislocated cytosolic protein to 
the proteasome. An issue particularly debated is if the first ubiquitination that precede 
substrate extraction from the ER membrane occurs on the substrate or on one or more of 
the ERAD participating proteins. Our results suggest the second hypothesis. In fact, we 
did not find relevant levels of biotinylated and ubiquitinated ERAD substrate protein. 
Two recent reports (Bernardi et al., 2013; Wang et al., 2013) share this conclusion. 
Wang et al. draw this conclusion by using an ERAD substrate devoid of potential 
ubiquitination sites and found that the molecule was still dislocated. Bernardi et al. 
propose that the catalytically inactive YOD mutant binds and traps an ubiquitinated 
ERAD component making it inactive, and propose as potential candidate the E3 
ubiquitin ligase Hrd1; however, their point of view is that trapping ubiquitinated Hrd1 
avoids substrate retrotranslocation. In a previous work in 2009, instead, (Ernst et al., 
2009) found an increased amount of ubiquitinated ERAD substrate with YOD1 C160S 
co-expression. They concluded that YOD1 activity was required for p97-driven 
dislocation of ERAD substrates, and that the inhibitory effect exerted by YOD1 C160S 
is due to a failure in deubiquitination of p97-associated dislocation intermediates. In our 
model, as mentioned before, substrate dislocation occurs without p97 involvement; the 
first ubiquitination may occur on one or more ERAD components of he dislocation 
complex on the ER membrane cytosolic side; ubiquitination by Ub ligases recruits p97, 
which in turn for its activity needs deubiquitination by its associated DUB. The result 
obtained by Ernst et al. is consistent with our model: immunoprecipitating the ERAD 
substrate in presence of YOD C160S (and so in presence of an “indirectly” inactive 
p97) co-immunoprecipitated also ubiquitinated ERAD components, detected by 
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immunoblotting with the anti-ubiquitin antibody. This also led us to expand the already 
proposed p97 role as a “segregase” that separates polypeptides from relatively large 
complex structures. This p97 segregase function on large multiprotein complexes is in 
agreement with our interpretation of a post dislocation role of p97 in ERAD. 
 
Figure 4.2 Proposed retrotranslocation model, according to our result. 
 
4.4 2A-mediated ribosome stalling triggers ERAD 
The protein produced from 2A* is a secretory protein that, if it follows its normal 
pathway should have entered the ER. However, we found it mostly in the cytosolic 
compartment. In addition, we partially recovered its expression after proteasomal 
inhibition with MG132 or after overexpression of the viral deubiquitinating enzyme 
OTU: these features are shared with ERAD substrates as presented in the previous 
paragraphs.  
Therefore, we decided to test the role of the two ERAD players p97 and YOD1 on 
our protein. The results of co-expression of p97QQ with the ERAD model substrates 
NHK-!1AT and Tetherin, showed that p97 plays a role upstream of the de-
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glycosylation step: in fact, while blocking protein degradation at the proteasomal level 
(by MG132) leads to accumulation of de-glycosylated material, the presence of p97QQ 
caused accumulation of biotinylated but glycosylated molecules. In contrast, 
overexpression of p97QQ with protein from 2A*, caused accumulation of both, 
glycosylated and sugar free biotinylated material. This finding helped us to clarify an 
aspect already discusses in paragraph 4.2: whether the sugar-free material was non-
glycosylated (never entered the ER) or de-glycosylated (entered the ER, 
retrotranslocated to the cytosol, and PNGase de-glycosylated). Since active p97 is 
essential for de-glycosylation, then the accumulated glycosylated biotinylated protein 
corresponds to material entered in the ER, where it was glycosylated, and then 
retrotranslocated to the cytosol, but not de-glycosylated because of p97QQ, whereas the 
accumulated sugar-free biotinylated material, instead, corresponds to molecules that 
never entered into the ER, and therefore de facto non-glycosylated. In conclusion, the 
sugar-free band found after glyc-2A* transfection corresponds to both de-glycosylated 
and non-glycosylated protein. Further confirmation derived from the overexpression of 
YOD1 C160S that reproduced the phenotype already obtained with p97QQ. 
This finding lead us to propose a model in which stalling of ribosomes associated 
to the ER membrane is sensed by a cytosolic or ER-bound factor that signal to the ER, 
where the nascent protein is almost fully localized, activating targeting of the nascent 
peptide to the ERAD pathway with the consequent retrotranslocation to the cytosol and 
proteasomal degradation. For the fraction of the sugar-free protein that never 
completely entered the ER, we can hypothesize that it remains attached to the ribosomal 
exit tunnel and, after subunits dissociation directly released in the cytosol. It is possible 
that the factor that sense ribosome stalling is a transmembrane protein with a cytosolic 
domain able to interact with the ribosome, and a luminal luminal domain interacting 
with the nascent peptide. 
 
 
4.5 Translation by free ribosomes 
The last aspect to be considered is that the impaired expression of protein from 
2A* takes place also when the translated protein is cytosolic. Unlike proteins with a 
secretory signal that are translated by ER membrane-bound ribosomes, cytosolic 
proteins are translated by ribosomes free in the cytosol. To investigate the fate of 
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proteins from cytosolic 2A* we used the same tools already used for secretory 2A*: 
proteasomal inhibition with MG132, overexpression of the deubiquitinase OTU, and 
overexpression of p97QQ. Treatment with MG132 and overexpression of OTU caused 
accumulation of cytosolic protein, indicating that it is normally degraded by the 
proteasome. While this result was expected, the phenotype obtained with p97QQ 
instead was more surprising. Overexpression of p97QQ, in fact, caused accumulation at 
a level comparable to that obtain with MG132 treatment. However, being the protein 
cytosolic the reason of the accumulation can not be linked to retrotranslocation. 
Recently, it has been demonstrated that p97 is part of a complex, called ribosome-bound 
quality control complex (RQC), that recognizes stalled ribosomes in NSD and NGD, 
ubiquitinates and extract the nascent peptide from the RET, and sends it to degradation 
(Brandman et al., 2012; Defenouillere et al., 2013; Verma et al., 2013). Thus, the result 
obtained, suggests that in absence of p97 ATPase activity (i.e: with p97QQ) the nascent 
peptide from cytosolic 2A* remains in the RQC in line with the role of p97 as 
segregase. This finding, moreover, strengthens our hypothesis that ribosome stalling is 
the primary cause of impaired expression that in turn triggers proteasomal degradation. 
Notably, despite the fact that the protein produced from secretory and cytosolic 2A* 
share the same phenotype, the pathway for the recognition of stalled ribosomes and the 
degradation of the nascent protein can not be exactly the same. For instance, some of 
the factors responsible for sensing stalling may be the same, since membrane-bound and 
free ribosomes are both in the cytosolic compartment; ubiquitin ligase responsible for 
the nascent protein ubiquitination would most likely not be the same: secretory proteins, 
in fact, should follow the retrotranslocation pathway, while the cytosolic proteins should 
be ubiquitinated probably by a ribosome-associated ubiquitin ligase. In NSD and NGD 
the pathway that recognizes stalled ribosomes, ubiquitinates the nascent peptide and 
dissociates the ribosomal subunits (RQC complex), comprises the proteins Tae2, Rqc1, 
the ribosome associated ubiquitin ligase Ltn1 (Bengtson and Joazeiro, 2010) or Not4, 
and p97: these mediators could have a role also in our case. That the proteins from 
cytosolic and secretory 2A* follow different pathways was also suggested by their 
distribution on sucrose gradients. Protein from cytosolic 2A*, in fact, remained in the 
upper part of the gradient, corresponding to soluble proteins. Protein from secretory 
2A*, instead, was found mainly in the bottom of the gradient, corresponding to large 
aggregates most likely composed by members of the dislocation complex. 
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Figure 4.3 Ribosome stalling activated ERAD model. ER-SRS, Sensor of Stalled Ribosomes 
associated to ER. 
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